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INTRODUCTION 
Infertility is referred to by the World Health Organisation (WHO) as the inability of a couple 
to achieve pregnancy within one year of regular unprotected intercourse[l]. About 15o/o of 
couples who do not achieve pregnancy within 1 year seek medical treatment for infertility. 
Eventually, So/o of them remain childless against their wishes. 
Infertility affects both men and women. In 50% of involuntarily childless couples, a male 
infertility associated factor is identified together with abnormal semen parameters. Several 
factors can be responsible for impaired male fertility: congenital or acquired urogenital abnor-
malities, urogenital tract infections, increased scrotal temperature (such as that caused by vari-
cocele), endocrine disturbances, genetic abnormalities, immunological factors and testicular 
deficiency (1 ). Nonetheless, in 30-40% of men with abnormal semen parameters no cause can 
be found, which is then named idiopathic male infertility. 
Testicular development and its bearing on the development of testicular cancer 
To permit normal spermatogenesis later in life, it is important for the male gonads that testicu-
lar development is not hampered by internal or external factors. To ensure the transmission of 
genetic information through the spermatozoa, specific germ cell precursors are set aside during 
early embryogenesis. Known as primordial germ cells, these cells have unique characteristics, 
such as an capacity to suppress the induction of differentiation, a commitment to either the 
male or the female lineage, and a capacity to generate the highly specialized daughter cells 
that, after fertilization, regain an activated differentiation program. The latter means that they 
can form all embryonic and extra-embryonic tissues, including the germ-cell population [2]. 
In other words, they are in fact really the totipotent stem-cell population of the body, and 
represent the circle of life. 
The development of the testes starts in the fifth week of life, when the primordial germ 
cells migrate to the genital ridge; once there, they are termed gonocytes. Eventually, these 
gonocytes differentiate to type A spermatogonia, which will form spermatozoa after puberty 
(spermatogenesis). During this differentiation, the germ cells are characterized by several mark-
ers, including alkaline phosphatase, c-KIT, OCT3/4, VASA, and NANOG. 
If gonadal development is disturbed, it can lead to the so-called testicular dysgenes·ls 
syndrome. This was first described by Skakkebaek eta!., who states that the development of 
the testis is disturbed by several internal and external factors [3] that may cause Leydig-cel! 
and Sertoli-cell dysfunction, and may thereby disturb the differentiation of the gonocytes and 
derivatives. This can create various problems, such as minor spermatogenic disorders, cryptor-
chidism, hypospadia, infertility and even testicular germ cell cancer. 
Testicular cancer, i.e. germ-cell tumors, is the most common cancer in men in their 20s and 
30s. Unfortunately, its incidence is rising [4]. In the Netherlands, about 600 patients per year 
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(2007) are diagnosed with a testicular germ-cell tumor (TGCT), a number that is expected to be 
more than 700 patients in 2010 (KWF data 2005). 
The first sign of such a testicular cancer is often a painless enlargement of the testicle, In 
about 60% of the patients the tumour has already metastasized to the lymph nodes and some-
times to other organs when first diagnosed. Carcinoma In Situ (CIS) is currently accepted as the 
precursor of all TGCTs, i.e. the seminomas and nonseminomas, in adolescent and young adult 
males [5, 6]. In many respects, CIS cells resemble PGCs/gonocytes: both have erased genomic 
imprinting and a similar morphology, and both express the same immunohistochemical 
markers, such as OCT3/4, PLAP, AP-2y, and c-KIT [7, 8]. CIS cells probably result from delayed or 
blocked differentiation of embryonic germ cells. Patients harbour these pluripotent CIS cells in 
their testicle, which, after puberty, eventually progress into a TGCT [3]. 
In its pre-invasive stage, CIS can be detected by testicular biopsy, but its inconsistent pre-
sentation, which is characterized by a heterogeneous distribution, can result in false-negative 
diagnosis in some cases [9]. Because a testicular biopsy is also an invasive procedure that brings 
additional risks, it cannot be used as a screening tool in large populations. One alternative 
method of detecting CIS is by detecting exfoliated tumor cells in semen, but so far this has not 
been very successful [10]. 
Because the detection and treatment of CIS can prevent the development of an invasive 
cancer, it clearly has major advantages, not least because it spares patients from treatment 
protocols which are potentially detrimental to the gonads. 
Cancer and fertility 
Before gonadotoxic treatment is initiated, adult male cancer patients are often referred for 
semen cryopreservation of a semen sample. Sometimes, the pre-treatment semen quality is 
impaired due to disease related factors hampering semen cryopreservation. Sperm banking 
can be a difficult issue to discuss with patients who have recently been diagnosed with cancer, 
especially in adolescents and pre-pubertal boys, who might not be able to produce a semen 
sample. Sometimes, in pubertal boys spermatogenesis may not yet have started and it is dif-
ficult to predict this based on clinical parameters. This poses a difficult problem for clinicians 
who encounter pediatric cancer patients. 
The recovery of spermatogenesis after gonadotoxic treatments can take several years, and 
still no serum markers are available to predict whether this will happen.lf azoospermia persists 
after cancer treatment it may be possible to induce pregnancy with cryopreserved semen 
and assisted-reproduction techniques. The value of sperm banking before cancer treatment 
is expressed by the total number of men who remain infertile after treatment and the number 
of live births using this cryopreserved semen after surviving cancer. There is a definite need to 
discuss semen cryopreservation with all male cancer patients prior to cancer treatment. 
As this introduction shows, fertility and cancer are intertwined in many ways. Both are the 
subject of this thesis. 
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AIM OF THE THESIS 
The general aim of the work presented in this thesis is to illustrate the relationship between 
gonadal function and cancer. In doing so, we first concentrate on the increased risk of develop-
ing testicular germ cell tumours (TGCT) in infertile men. Next we discuss the best method to 
evaluate testicular biopsies for detecting Carcinoma in Situ (CIS) of the testis, the precursor of 
testicular cancer. Furthermore, we elaborate on a non-invasive detection of testicular cancer 
using immunohistochemistry to detect exfoliated CIS cells in semen. We end this thesis with 
evaluating the detrimental effects of childhood cancer treatment on gonadal function and 
present the significance of performing pre-treatment semen cryopreservation in all cancer 
patients. 
OUTLINE OF THE THESIS 
Chapter 3 describes a specific subgroup encountered in the subfertile population. It is shown 
by several large studies that patients who have an impaired fertility are at risk for developping 
testicular cancer [8]. The risk of developing TGCT in male patients who visit an andrologic clinic 
is approximately 1%. This is one of the reasons why a scrotal ultrasound is mandatory in the 
evaluation oft he infertile male. Subgroups in the infertile patient population have a higher risk 
on TGCT. Recently, De gouveia de Brazoa eta/. found that infertile men with bilateral testicular 
microliths on scrotal sonopgrahy had 20% risk of CIS[9]. Infertile men, especially those with 
additional signs of testicular dysgenesis such as testicular microlithiasis (TM), might therefore 
be a group that might benefit from a screening protocol designed to detect testicular cancer or 
the precursor lesion. However, standard follow-up schedules for this group are lacking making it 
difficult to clearly investigate the role of these microliths in the testicular dysgenesis syndrome 
and the risk forTGCT. We propose an active approach including performing testicular biopsies 
to detect CIS in the testes for men diagnosed with TM. 
In chapter 4 we present the pitfalls encountered in CIS diagnostics due to the random 
distribution in the testis. CIS is virtually always found in the parenchyma adjacent to TGCTs 
in orchidectomy specimens, and it is reported that in testicular biopsies, without an invasive 
tumour, CIS is missed in approximately 0.5 percent [6, 10]. Dieckmann et al. proposed to take a 
two-sited surgical biopsies from a single testis which improves the diagnostic yield with 18% 
[11 ]. Application of immunohistochemistry using specific antibodies can furthermore increase 
the overall sensitivity and specificity of diagnosing CIS in testicular biopsies. Currently, OCT3/4 
is in our opinion the best marker in TGCT diagnostics. One of the biggest advantages is that 
100% of the cells of CIS, seminoma and embryonal carcinoma show a nuclear staining [12-14]. 
In chapter 5 we evaluated the additional diagnostic value of OCT3/4 immunohistochemistry 
in detecting CIS in testicular biopsies. In chapter 6 we describe an other method to detect 
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CIS using a non-inavsive method. We describe a pilot study in which we evaluate if OCT3/4 
immunohistochemistry could be used to detect exfoliated CIS cells in semen. 
In the second part of the thesis we focuss on cancer related infertility. In chapter 7 we 
describe the semen quality of cancer patients who were referred for semen cryopreservation. 
In our study we evaluate which patients are at risk for decreased pre-treatment semen quality. 
In young pre-pubertal or pubertal boys, semen cryopreservation is a difficult issue to discuss. 
Not all boys have masturbated at this age or feel comfortable talking about masturbation and 
in some spermatogenesis is still absent. In chapter 8 we describe a group of pubertal cancer 
patients who are referred for semen cryopreservation. We evaluate which markers could be 
useful to predict a successful semen cryopreservation attempt. Successful semen cryopreserva-
tion offers these young boys a change for offspring later in life. To assess the value of banking 
sperm the number of men who use their banked semen should be assessed as well as the 
number of life births after IVF. In chapter 9 we describe a large cohort of cancer patients who 
banked their semen and evaluate which of them used their semen. We furthermore evaluated 
the outcome of the fertility treatments in which the banked semen was used.ln the last two 
chapters 10 + 11 we elaborate on the detrimental effects of chemotherapy and radiotherapy 
given during childhood cancer treatment. We describe a large cohort of patients who were 
treated for childhood cancer with a very long follow-up. These data give more insight into 
which patients are at increased risk for post-treatment gonadotoxicity. 
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SUMMARY 
Testicular microlithiasis (TM) has been associated with testicular germ cell tumors (TGCTs} in 
adolescents and adults and with its precursor carcinoma in situ (CIS). A clear definition ofTM 
and the need for further diagnostics and follow-up is lacking. We reviewed the literature ofTM 
and its association with TGCT/CIS and current follow-up advises and propose a management 
approach based on associated risk factors for TGCT. In the literature, a wide variance of TM 
incidence is reported in different patient populations. A consensus concerning the malignant 
potential ofTM has not been reached. In addition, a cleardefin.lflon on TM is lacking. Although 
a correlation between TM and TGCT or CIS is found, precise management and follow-up sched-
ules are absent. We suggest that all hyperechogenicfoci smaller than 3 mm without shadowing 
should be named TM irrespective of their number. In addition, we suggest a management 
scheme for physicians encountering TM in daily practice. Our algorithm suggests taking a tes-
ticular biopsy in a selected patient population with at least one additional risk factor for TGCT. 
A long-term active follow-up schedule, including ultrasonography and physical examinations, 
is not indicated in the remaining patients with TM. 
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INTRODUCTION 
Testicular microlithiasis {TM) is an incidental finding during ultrasonographic investigation of 
the testis. These TM appear as 1- to 3-mm-sized multiple foci within the parenchyma of the 
testis [15, 16] (Figure 1). This observation is infrequent but it has generated interest as an 
informative parameter to identify males at increased risk for Carcinoma fn Situ (CIS) of the testis 
and testicular germ eel! tumors (TGCT) during adolescence and adulthood, i.e. seminomas and 
nonseminomas. Although most clinicians classify hyperechogenic lesions detected on scrotal 
ultrasound investigation as TM, a precise definition has not been accepted yet. In essence TM 
is a benign condition and has been found together with several urological conditions, such 
as infertilty [17-19], cryptorchidism [20-22], testicular torsion [23, 24], testicular atrophy [25], 
Fig 1: landscape testicular microlithiasis in a small atrophic inhomogeneous testis. 
Klinefelter's syndrome [25, 26] and and disorders of sex development [25]. The association with 
CIS [9, 15, 27, 28] andTGCTs [27, 29, 30] is also well documented;TM is found in 74% of men with 
a TGCT [31].1n contrast, it can also be observed in 1.5 to 5.6% of the general population and can 
therefore be regarded as not testicular cancer specific [18, 32]. The observation and its potential 
association with TGCT raise concerns among urologists and radiologists but a consensus on 
follow-up schedules and interventions to rule out malignancy in these patients is lacking. With 
this overview, we propose a clear definition ofTM and give a guideline for clinicians on how to 
manage these patients. 
Incidence 
TM is being recognized with increasing frequency because of high resolution of modern ultra-
sound machines. With transducer frequencies of 7-13 MHz., scrotal ultrasonography is able to 
identify structures smaller than 1 mm, which leads to a more accurate view of the testicular 
parenchyma and a higher detection rate of intrascrotal abnormalities. The prevalence numbers 
of TM in studies of large cohorts of men show a wide range. This may be explained by the 
difference in the selection of men in these studies. In healthy men, for example, the prevalence 
varies between 1.5 to 5.6%, compared to 0.8 o/o to 20.0% in infertile populations (Table 1 ). TM 
! 
6 
18 
Table 1: TM prevalence in general populations and subfertile populations 
Authors Total TGCT TM Prevalence Criteria MHZ Malignancies 
Patients Risk (n} % (%ofmen 
factor withTM) 
Von Eckardstein et al., 198 None 3 1.5 >5 7.5 
2001 (33%) 
Peterson et al., 2001 1504 None 84 5.6 >5 7-10 0 
Total general 1702 None 87 5.1% 1 (1%} 
Population 
Kessaris et al., 1994 150 5 2 1.3 10 0 
Aizenstein et al., 1998 180 5 5 2.8 >5 7 0 
Pierik et al., 1999 1372 5 12 0.9 7-10 7 (58%} 
Von Eckardstein et al., 1399 5 32 2.3 >5 7-10 3 CIS (9%} 
2001 
Schrey et al., 2001 1030 5 8 0.8 >10 
Turchi et al., 2001 250 s 2 0.8 0 
Thomas et al., 2001 159 5 10 6.1 >5 7 0 
de Gouveia Brazao et 263 5 53 20 7.5-12 6(15 (11%) 
al., 2004 (30 (BTM) 
Sakamoto et al., 2006 545 5 30 5.5 5-7.5 0 
Mazzilli et al., 2005 283 s 13 4.6 5.5-12 0 
Total subfertile 5899 5 139 2.4 17(4%) 
population 
5: subfertile population, TM: testicular microlithiasis, BTM: Bilateral testicular microlithiasis. 
was found in 139 out of 5899 infertile men indicating an average prevalence of around 2.4% 
in these patients (Table 1 ). In populations referred for scrotal complaints, a variety in incidence 
is reported ranging from 0.6 to 4.1% (Table 2). A comparison among most studies is difficult 
because of the absence of a clear definition of TM as well as the use of different ultrasound 
frequencies. In addition, the populations used vary widely and for the largest part describe 
the presence ofTM in men with palpable abnormalities ofthe testis suggestive for testicular 
cancer. Furthermore, most studies are retrospective and therefore suffer from biases inherent 
to retrospective studies. A clear incidence number is therefore difficult to give and mainly 
depends on the population screened. 
Definition and Etiology 
The exact etiology ofTM is unclear. It is suggested that these calcified concretions within the 
lumen of seminiferous tubules originate from sloughing of degenerated intra-tubular cells and 
failure of the Sertoli cells to phagocyte the debris [33-35]. Raman spectroscopic mapping dem-
onstrated that testicular microliths were located within the seminiferous tubule and consisted 
of hydroxyapetite [36]. Although calcifications in a tumor containing testis also revealed high 
levels of hydroxy a petite, caution should be taken to name these microlithiasis since their origin 
and pathogenesis are not completely clear [36, 37]. 
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Table 2: Prevalence ofTM and association with malignancy in referred patients. 
Authors Total TM Prevalence Frequency Malignancy in Odds 
Patients % MHZ menwithTM ratio 
Ganem et al., 1999 1100 22 2.0 5-10 8/22 (36.4%) 
Hobart et al., 1992 1710 11 0.6 5-10 5/11 (54.4%) 
Otite et al., 2001 3026 54 1.8 7 16/54 (29.6%) 13.2x 
(criteria>5) 
Derogee et al., 2001 1535 63 4.1 7 and 10 30/63 (47.6) 
(criteria >3) 
Skyrme et al., 2000 2215 34 1.4 7.5 5/34 (14.7%) 
Cast et al., 2000 4819 33 0.68 7.7 and 7/33 (21.2%) 21.6x 
(crlteria>5) 5-10 
Middleton et al., 2002 1079 195 18.1 >7.5 12/195 (6.1 %) 
Miller et al., 2007 3279 67 2.0 -or>10 5/67 (7.5%) 
Bach et al., 2001 528 48 9.0 7 13/48{27.1%) 
(criteria >5) 
Sakamoto et al., 2006 969 46 4.7 5 + 7.5 8/46(17.4%) 
Ringdahl et al., 2004 160 12 7.5 4/12 {33.3%) 
Bach et al., 2003 156 23 14.7 7 5/23 (21.7%) 
Pourbagher et al. 2004 5263 40 0.76 7.5 4/40 (10%) 
(BTM) 
Kosan et al. 2008 179 21 10.6 10 3/21 (14.3%) 
Total 26018 669 2.5 125 (18.7%) 
BTM- bilateral testicular microlithiasis 
TM is classified by testicular ultrasonography as hyper-echogenic lesions between 1 and 3 
mm in diameter without shadowing. TM usually has a diffuse pattern but number and distribu-
tion are variable [38]. A sub-classification in Classic or Limited TM has been suggested accord-
ing to the presence of respectively more or less than five microliths per view. A recent study 
in 1079 patients by Middleton eta/. showed that this classification is arbitrary in the context 
of malignant transformation. Their study showed no difference in risk of a co-existing tumor 
between patient with a classic TM pattern and patients with only few microliths per testis [30]. 
Sanli et al. recently also demonstrated that a grading of classic TM according to the number of 
microliths is not mandatory as this does not predictTGCT development [39]. 
In our opinion, all hyperechogenic foci on testicular ultrasound smaller than 3 mm without 
shadowing should be named TM, independent of the number of TM per view or in the total 
testis. These microliths should be located in the testicular parenchyma and not in a TGCT. 
Furthermore, factors potentially disturbing the normal testicular parenchyma such as testicular 
tumors, testicular trauma or surgical procedures should also be clearly noted as these might 
indicate a different etiology. 
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Risk of CIS of the testis in men with TM 
The incidence of TGCTs, i.e. seminomas and nonseminomas, has increased during the last 
decades [40]. It is currently accepted that CIS is the precursor, which represents a primordial 
germ cell or gonocyte [2, 41]. Early detection of CIS or organ confined TGCT improves prognosis 
and prevents the need for orchidectomy and chemotherapy and/or radiotherapy [42]. It is 
relevant to realize that CIS is in fact an asymptomatic condition and TM might be the only due 
to its presence. Kang et at. found that the microscopic prevalence ofTM among 463 testicular 
biopsies was higher in biopsies with CIS 39% compared to 2% in biopsies without CIS [43]. 
Therefore, TM might indeed be useful to define a high risk group in whom CIS is more frequent 
[44]. TM is commonly associated with CIS in case reports and small studies [9, 1S, 27, 4S, 46]. 
Linke eta/. performed a post mortem study on presumably healthy males with no known 
testicular complaints and found a prevalence of CIS in 6 out of 1388 patients (0.43%), of whom 
two (33.3%) had TM [47]. Poubargher eta/. studied 36 patients with bilateral TM and did not 
detect any newly formed tumors during the median 34 months follow-up. Follow-up included 
ultrasound and physical examinations at 6-month intervals. Although no tumors developed, 
these examinations do not exclude CIS and the follow-up pe(1od of this study might be too 
short as only 50% of the patients with CIS will develop a TGCT in 5 year [48]. In a more recent 
study of De Gouveia-Brazoa et at. the risk of CIS in a infertile population was 20% in the pres-
ence of bilateral TM compared to 0.5% in the patients withoutTM[9]. A recent article by Sanli et 
al. also suggested a higher risk of developing a TGCT in men with bilateral TM [39]. 
In patients with a TGCT the risk of CIS or tumor in the contralateral testis is reported to be 
around S percent. If the contralateral testis contains TM, this risk will increase to 22-78% (odds 
ratio 12.0 to 16.8) [49, SO]. Bach eta!. performed a retrospective study in 156 patients with a 
TGCT.In this population, 23 patients were diagnosed with contralateral TM of whom 4 patients 
(17.3%) were diagnosed with testicular malignancy in that testis compared to only 2 in the 
remaining 133 patients without TM (1.5%)[50]. Holms eta/. showed the presence of contralat-
eral tumor in seven out of nine men (77.7%) with contralateral TM compared to only three out 
30 (1 Oo/o) patients when the contralateral testis appeared normal on ultrasound evaluation[49]. 
However, the absence ofTM does not safeguards patients from CIS as nine out of the 25 patients 
with CIS (36%) from these two studies had no sonographic abnormalities [49, 50]. Based on 
these studies, it is clear thatTM and CIS can be associated but CIS can occur withoutTM. Most 
likely, TM is a sign of the testicular dysgenesis syndrome (TDS), a condition that is associated 
with CIS [51]. Therefore, patients with TM should be examined for other criteria forTDS such as 
testicular atrophy, testicular maldescent, history of contralateral tumor, hypospadias, low or 
absent sperm count or inhomogeneous ultrasound appearance [52, 53]. These findings might 
provide additional evidence for the presence of CIS and therefore the need for testicular biopsy. 
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Risk ofTGCT in men with TM 
Although, the association between TM and TGCTs is well documented, there is no convincing 
evidence to suggest thatTM is solely a pre-malignant condition. In the literature, the association 
between TM and TGCTs ranges from 6.1 %to 54.4% in a referred population (Table 2). These 
patients were referred for scrotal ultrasound for a variety of scrotal complaints including tes-
ticular torsion, painless lumps, hydrocele, testicular pain, epididymitis and subfertility. lkinger 
eta!. found calcifications in 74% of the testis containing malignancies, using a mammography 
technique. In that study, there was a slightly higher incidence ofTM in non-seminoma patients 
(87%) than in seminoma patients (60%). Only few case studies report on the actual develop-
ment of a TGCT afterTM was identified [54-56]. The tumor in those studies developed between 
6 months and 11 years after discovering the TM. The relative increase in risk of developing a 
tumor in men with TM in a referred population varied from 13.2 to 21.6 fold (Table 2) [57, 58]. 
These two studies describe the presence ofTM besides an invasive TGCT and not just the pre-
malignant CIS stage. These calcifications might be secondary to the presence of the tumor [37]. 
Treatment of these patients is directed towards treating the suspected tumor and not influ-
enced by the TM. DeCastro eta!. recently published a 5 year follow-up study of asymptomatic 
men with TM and found a odds ratio of developing a testicular tumor of 317 compared to men 
with no TM [56]. Coffey et al recently demonstrated that TM is more frequent in male relatives 
of men with TGCT, which suggests a familial risk factor forTGCT [59]. 
FOLLOW-UP 
A large survey under British Urologists showed that one-third of them performed follow-up of 
men with TM [60]. Follow-up should result in early detection of testicular malignancies. In gen-
eral, most authors describe a follow-up scheme consisting of self-examination in combination 
with regular physical examination by an urologist and scrotal ultrasound especially if additional 
risk factors are present. The regimes used differ widely in interval and method of follow-up and 
are not conclusive about length of follow-up (Table 3). 
The corner stone of any follow-up scheme for patients with TM should be self-examination 
of the testis. Self-examination wi!! aid in early detection ofTGCT. Huyghe eta!. showed that in 
nonseminoma patients diagnostic delay is associated with worse stage and survival [61]. The 
physician should therefore raise the patient's awareness so that clinical delay is minimal. 
We provide a follow-up schedule with suggestions for men diagnosed with TM, without a 
testicular lesion, based on the current literature (Figure 2). lfTM is diagnosed in combination 
with other intra-testicular abnormalities suspicious for a TGCT the physician should make his 
treatment decision on the suspicious lesion. The presence of TM adjacent to the lesion only 
increases the change of malignancy [62]. 
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Table 3: Overview of studies describing a follow-up schedule for men with TM 
Study Follow- Self Physical 
up examination examination 
Ultrasound 
(Interval) 
Serum 
markers 
Biopsy Length of 
follow-up 
indicated (Interval) physkiOn (Interval) 
+ Zastrow et al 
ell + 2005 patients Regular 
Dagash et aL 
+ +/-B 2007 +f-B Monthly (Annual) 
Sakamoto et 
+f-C + 
al2006 (Regular) 
Rashid et al. +/-D 
+ Annual 2004 + Yearly by 
+ Monthly +Physical primary care 
examination 
taker 
urologist 
Leenen eta I + + + 
2002 Children Annual 
Bennet et al. 
2001 +f-E +I- Periodic E 
Otiteetal. + 
+ 2001 + 12-18 Months +P 
Ganem eta I. 
+' 
+ 
+ + Annual 2000 
Milleretal. +~ + + + 1996 6-12 Months 
Skyrmeet + + 
+ + 
al.2000 Biannually Biannually 
Pourbagher + + 
eta I. 2005 Annual + Annual 
+I- Done if risk factors are there,- Not suggested,+ Suggested, ? Not precisely described 
a: Additional pathological ultrasound or clinical findings, focal or unilateral TM, existence of a 
contralateral tumor or infertility with cryptorchisme and atrophic testes 
Until peak 
incidence 
20-45 year 
B: cryptorchidism, infertility, testicular atrophy, testicular asymmetry or previous history of testicular 
cancer 
C: infertile men with bilateral TM or men with unilateral TGCT and TM in the contralateral testis 
d: Cryptorchidism, Atrophy, Infertility, lntratubular germ cell neoplasia, Gonadal dysgenesis, 
Contralateral testicular tumor, Exogenous estrogen administration 
e:Only ·m case of a contralateral tumor 
F:Previous history of testicular malignancy or the presence of equivocal findings 
G:Recommends extensive evaluation including chest X-ray, computerized tomography and testicular 
biopsy especially in men with a history of testicular cancer and testicular microlithiasis. 
H:lnitial CT abdomen+ thorax if no testicular tumor is present 
Regular scrotal ultrasonography is often advocated. Using ultrasonography the physician 
is able to detect non-palpable masses. This might lead to early diagnosis but will mostly not 
prevent orchidectomy. Furthermore, it remains to be proven that screening testicles forTGCTs 
with ultrasonography results in better survival rates. In addition, CIS itself is not detectable with 
Testicu1ar 
Microlithiasis 
Risk factors 
Infertility 
BilateraiTM 
Cryptouchid~sm 
Atrophic testic1es 
Conlralateral tumour 
Age youn-ger 
than 50 years 
Treatment 
orchDdectomy 
or 
rad~otherapy 
Afterfertil~ty preservation 
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Self Exam~nation 
Setf Examination 
Self Exam~nation 
Fig 2. Follow-up scheme for patients with TM without a concomitant testicular tumor. 
ultrasonography. Finding the precursor CIS lesion is the only way to improve patient outcome, 
especially related to retention of hormonal function and thereby quality of life. It is debatable 
if annual testicular ultrasonography plays a role in the follow-up ofTM as a survival benefit has 
not yet been proven. It might be an alternative for patients with TM with a relative high risk who 
refuse or are unable to undergo a testicular biopsy. However, until the role of regular scrotal 
ultrasound in patients with TM regarding survival and cost-effectiveness is investigated this 
should not be regarded as standard care. 
WHEN IS A TESTICULAR BIOPSY INDICATED? 
A testicular biopsy is currently the gold standard in CIS diagnosis. However, it is not neces-
sary to perform this invasive procedure in all males with TM. The majority of men with TM will 
never develop a TGCT [32, 56]. Some patients with TM are at a higher risk for CIS or testicular 
malignancy, thus follow-up schedules should be focused on this group. Performing a tes-
ticular biopsy will accurately diagnose CIS with a false-negative risk of O.So/o [61]. We propose 
a follow-up protocol in which testicular biopsies should be considered in patients with TM 
with an increased risk of CIS or TGCT (Fig 2). These include men with infertility and bilateral 
TM, atrophic testes, undescended testes and men with a history of TGCT and contralateral 
TM. In adult men with a history of undescended testis the risk of CIS is approximately 2 to 
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4o/o [63]. If in these testicles TM is present the risk increases to approximately 1 0 percent [21 ]. 
Men with infertility or abnormal semen analysis have a increased risk on developing a TGCT 
and this should be taken into account when managing TM in this patient population [8, 64]. 
In infertile men, the prevalence ofTM varies from 0.8 to 20 percent (Table 1). The number of 
reported malignancies (n=16, 0.3o/o) in the infertility group might be too low as active follow-
up has not been performed and none ofthe paf1ents had testicular biopsies performed. This 
could lead to an underestimation of the CIS prevalence in this selected population. Raman 
eta/. compared the incidence of TGCTs in 3800 infertile males and compared this with the 
general population. They found a 20-fold greater incidence of tumors in subfertile males [64]. 
In men with a TGCT, the risk of CIS or cancer in the contralateral testis is also increased. Har-
land eta/ performed a retrospective study in 186 testis cancer patients in whom contralateral 
biopsies were performed [52]. They found that patients with small contralateral testis had a 
20% prevalence of CIS in the contralateral testis. Furthermore, they found that men presenting 
before the age of 30 had a 34% prevalence of CIS. Dieckmann et at found a 18% risk of CIS in 
men under the age of forty whom have a TGCT and a contralateral atrophic testicle [65]. If a 
testicular biopsy is performed, 'it should contain at least 30 tubules to allow the pathologist to 
evaluate a representative part of the testicle. Berthelsen et at. proposed a 3x3x3mm biopsy as 
an accurate biopsy size to detect CIS with considerable security if at least 10% of the tubules 
contain CIS [66]. Dieckmann eta!. proposed to take a two-sided biopsy which increased the 
diagnostic yield with 18% [65]. The discordant result in this study predominantly occurred in 
normal sized testis and not in the atrophic testis. Performing a two-sided biopsy in the latter 
group should therefore be done reluctantly as this might lead to severe testicular damage and 
dysfunction. We strongly recommend the use of immunohistochemistry for the evaluation of 
testicular biopsies [67]. It is well known that CIS is difficult to identify in testicular biopsies. 
Immunohistochemistry will provide an extra diagnostic yield in diagnosing CIS. In a recent 
study, we confirmed earlier reports and found an extra diagnostic yield of 20% in identifying 
CIS in biopsies form infertile males with immunohistochemistry using OCT3/4, PLAP and c-KIT 
[68, 69]. OCT3/4 is currently the best marker for CIS, seminomas and embryonal carcinomas 
[13]. If a testicular biopsy is performed and CIS or TGCT is not present, no active follow-up 
by an urologist is recommended, because the change of a false-negative result is minimal if 
performed and evaluated correctly. 
DISCUSSION 
TM is associated with an increased risk of CIS and TGCT. However, this condition should not 
be considered premalignant, but it is rather a representation of rapid cell turnover resulting in 
microlithiasis as shown in a study with 131 specimens collected after orchiedectomy [17, 19]. 
The overall incidence in subfertile populations lies around the 2.4 o/o (Table 1), this underscores 
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that not all patients with TM will develop a TGCT as the risk for TGCT in subfertile males lies 
around the 1 o/o. This fits well in the testicular dysgenesis syndrome theory (TDS), as the pheno-
type of this syndrome ranges from infertility to TGCT, and although TM is a sign ofTDS not all 
will develop a TGCT. The relative higher prevalence number in the general population might be 
explained by the study design of the mentioned studies. In contrast to most studies, Peterson 
eta/. conducted a prospective study in which the detection ofTM was one of their main goals. 
The other studies are mostly retrospective studies based on reports, which can lead to lower 
prevalence numbers. 
Although TM is associated with testicular dysfunction the amount of microliths is not a reli-
able indicator for the risk of tumor development [30, 39]. A difficult clinical situation occurs if 
only one microlith is found. However, if other risk factors are present a testicular biopsy can be 
performed. Because prospective data about the risk of CIS orTGCT in this specific subgroup is 
lacking we cannot make evidence based recommendation. The clinician should therefore make 
a decision based on the risk factors present. At least the patient should be informed about the 
risks and self-examination should be taught. 
The role ofTM in patients with testicular masses is in our opinion not of major importance as 
this will not aid in making a diagnosis of the tumor. However, it plays a crucial role in predicting 
formation ofTGCTs and the presence of CIS in the contralateral testis [49, 50]. Unilateral TM in 
contralateral testis after orchidectomy must be considered as a significant signal to consider 
contralateral biopsy. It is clear that men with TM have an increased risk of developing a TGCT. 
However, most men with isolated TM will not develop a TGCT [9, 70]. 
The corner stone of any follow-up scheme should be self-examination of the testicle. 
Although the benefit of self-examination remains unclear, it at least makes the patient aware of 
potential symptoms of a TGCT. Hug he eta/. recently showed a correlation between diagnostic 
delay and stage and survival [61 ]. Ninety-one percent of these patients had scrotal complaints 
of painless swelling, a change in testicular consistency or scrotal pain. This means that al! TM 
patients should be made aware of the symptoms accompanying testicular cancer and advised 
to perform self-examination. Doing so men wHI discover testicular lumps earlier and potential 
diagnostic delay may be brought down. 
Many follow-up schedules are described using scrotal ultrasonography. It is calculated that 
the costs of performing follow-up with ultrasound evaluation in all men with TM lies around 
the 18-billion dollars per year [32]. Furthermore, it is debatable that performing regular scrotal 
ultrasound will have any positive effect on mortality from TGCT as this reaches almost 90 per-
cent with the current treatment modalities. Therefore, routine scrotal US should not be used 
for follow-up in men with TM until prospective studies have proven a significant benefit. We 
believe that in patients with TM and signs ofTDS a testicular biopsy should be considered. We 
are aware of the limitations of an open testicular biopsy, as false negative biopsies could occur 
due to the non-uniform distribution of CIS [37, 67]. We strongly advocate the use of OCT3/4 
immunohistochemistry in all testicular biopsies. 
26 
CONCLUSION 
A wide variety in prevalence ofTM is described in different populations due to different sample 
size, composition, US and screening criteria. TM consists of a large heterogeneous group and 
must be considered a benign condition. It is seen in various benign and malignant processes. 
Still, its association with TGCT is remarkably, and may be a very useful tool when screening 
for TGCTs, especially in its pre-invasive stage, in specific risk groups. In view of its association 
with cancer, regular self-examination in all patients and testicular biopsy in a selected high-risk 
group is advocated. Testicular biopsies should be considered if multiple factors representing 
TDS, such as infertility, atrophic testes, undescended testes, are present. 
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ABSTRACT 
Carcinoma in Situ (CIS) ofthe testis, also referred to as lntratubular Germ Cell Neoplasia Unclas-
sified (ITGCNU) is currently accepted as the common precursor for all malignant germ cell 
tumors of adolescents and adults that is, the seminomatous and nonseminoma cancers. These 
pre-invasive cells have specific cellular characteristics, which can be used for early diagnosis, 
routinely done by morphological analysis, sometimes supported by immunohistochemistry, of 
tissue obtained by an open surgical biopsy. False-negative biopsy results can occur mostly due 
to either non-random distribution of ITGCNU within the testis, misdiagnosis or suboptimal tis-
sue treatment and analysis. In this article, we demonstrate the potential pitfalls in the diagnosis 
of !TGCNU. The results support the use of the highly specific and sensitive immunohistochemi-
cal marker OCT3/4 for the diagnosis of ITGCNU and provide evidence for the non-random dis-
tribution of !TGCNU, which is a significant limitation in the diagnosis of this preinvasive lesion. 
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INTRODUCTION 
Testicular germ cell tumors (TGCTs) of adolescents and adults are the most frequent malignan-
cies in Caucasian males aged 20 to 34 years [42]. The disease specific survival ofTGCTs of men 
diagnosed in Europe from 1990-1994was 97o/o at 1 year and 93o/o at 5 years, the highest survival 
rate for any malignant tumor in men [71]. Despite this high cure rate, the annual increase in 
incidence of 2-So/o is a major concern [72]. Twenty-three percent of the men presenting with a 
TGCT have metastases and need radio- or chemotherapy with potentially serious side effects, 
such as infertility [73]. 
TGCTs, including seminomas and non-seminomas, have carcinoma in situ (CIS), also known 
as intratubular germ cell neoplasia unclassified (lTGCNU), as common precursor. !TGCNU 
develops into invasive malignancy in 70o/o of the cases in 7 years and presumably in all patients 
over a longer period of time [4]. ITGCNU can be successfully treated with local radiotherapy 
or orchidectomy. Early treatment prevents progression from this lesion to an invasive TGCT 
and thereby cures the patient [4]. This avoids adjuvant chemotherapy or radiotherapy to the 
retroperitoneum, and the risk of development of refractory disease. Therefore, efforts should 
be made to diagnose TGCT at the pre-invasive stage. !TGCNU is routinely diagnosed by his-
tological analysis of tissue obtained by a surgical biopsy [66]. The identification of ITGCNU in 
these testicular biopsies is based on morphology aided by immunohistochemical staining for 
a number of specific markers, of which OCT3/4 [13, 74] is highly sensitive and specific [13]. The 
percentage offalse-negative biopsies is estimated as low as O.So/o. This is supposedly due to the 
equal distribution of ITGCNU throughout the testis in the majority of patients [6]. However, a 
growing number of studies and case reports show that ITGCNU may also be present as a focal 
lesion in the testis and therefore might result in a false-negative conclusion [6]. 
In this article, we report a patient with infertility and bilateral testicular microlithiasis, 
in whom ITGCNU and intratubular seminoma was initially missed in a surgical biopsy speci-
men fixed in buffered formalin, based on morphological criteria alone. However, histological 
review, and application of immunohistochemistry for OCT3/4 showed the presence in the 
original biopsy sample. Remarkably, subsequent bilateral open surgical biopsies were devoid 
of ITGCNU. Based on the original observation based on OCT3/4 immunohistochemistry orchi-
dectomy was performed. A careful pathological investigation of the removed testis confirmed 
the heterogeneous distribution of ITGCNU. 
CASE REPORT 
A 30-year-old patient with primary infertility was referred to the Erasmus University Medical 
Center Rotterdam (Erasmus MC). The referring urologist had 6 months earlier performed 
bilateral open surgical testicular biopsies, which were originally both classified as disorganized 
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spermatogenesis with a Johnson score of 8 and no signs of malignancy. Endocrinological 
and clinical evaluation at the Erasmus MC revealed hypergonadotrophic hypogonadism with 
atrophic testes, with a FSH level of 64.1 U/L (ref 2.0-7.0), LH of 27.2 U/L (ref 1.5-8.0), testosterone 
of 7.6 nmol/1 (ref 1 0-30) and inhibin-B level of 0 ng/1 (ref 150-400). Semen analysis showed 
azoospermia with a pH of 7.7 and a seminal volume of 6 mi. 
Scrotal ultrasound was performed to measure testicular size, signs of epididymal obstruc-
tion and of testicular dysgenesis. It revealed bilateral small testes with a volume of only 4 
cm3 and several clustered microliths on both sides. No signs of obstruction were noticed. The 
patient had no history of cryptorchidism. The levels of the serum tumor markers 13-human cho-
rion gonadothropin, a-fetoprotein and lactate dehydrogenase were normal. Because bilateral 
microlithiasis is a risk factor for ITGCNU in males visit ing the fertility clinic, as demonstrated by 
us previously [9], the slides of the original testicular biopsies were revised, and immunohisto-
logical staining for OCT3/4 was done. The biopsy of the right testicle showed few tubules with 
the typical histology of ITGCNU: a string of large cells with clear cytoplasm and a round nucleus 
with conspicuous nucleoli located on the basement membrane and bordered by Sertoli cells at 
the luminal side. In some tubules similar tumor ce lls completely filled the lumen accompanied 
by few lymphocytes, thus rendering the picture typical for intratubular seminoma. In the sur-
rounding stromal tissue a mild lymphocyte infi ltrate was present. The diagnosis of ITGCNU and 
intratubular seminoma was confirmed by nuclear staining of the tumor cells for OCT3/4 (Figure 
1 ). The quality of the biopsy from the left testis was insufficient for diagnosis. 
1 
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Figure 1. Histology of the open surgical biopsy of the right testis stained immunohistochemically 
for OCT3/4, demonstrating nuclear staining intra tubular seminoma (1 .25 x). (Inset) Higher power of 
intratubular seminoma (40 x). 
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Seven month after the initial biopsy repeated ult rasonography at our Hospital, one month 
after the first consultation, showed a new hypo-echoic lesion with a diameter of 3.0 mm x 1.5 
mm in the left testicle. Because of the insufficient material of the first biopsy and the newly 
observed hypo-echoic lesion it was decided to perform a second bilateral open surgical testicu-
lar biopsy. Both biopsies showed strongly impaired spermatogenesis but no signs of ITGCNU, 
intratubular seminoma or an invasive TGCT, neither by morphological criteria nor by immuno-
histochemistry for OCT3/4. Because of the presence of ITGCNU and intratubular seminoma as 
demonstrated in the first biopsy, it was decided to perform an inguinal orchidectomy of the 
right testicle. Because no signs of malignancy were noted in the left testicle in the last biopsy 
while the first was not informative, it was left in situ. The orchidectomy specimen showed an 
atrophic testicle w ith fibrosed tubules. In seven out of the 11 sections taken from different parts 
of the testis (see Figure 2), ITGCNU was present and some tubules showed intact spermato-
genesis. In one section indeed a small invasive seminoma was identified. The focal distribution 
of ITGCNU is this patient explains the negative finding in the second random open surgical 
biopsy. After orchidectomy the ITGCNU cells were microdissected for evaluation of the pres-
ence of the codon 816 c-KIT mutation, known to be associated with bilateral tumors [75]. No 
mutation was detected. Computer tomographic scanning of the thorax and abdomen showed 
no metastases. Because the tumor is therefore a clinical stage I seminoma, the patient was 
treated with retroperitoneal irradiation. The left testicle will be checked with regular interval 
using ultrasonography. 
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Figure 20 A) Testis parenchyma with normal aspect with 11 marked areas which represent the formalin 
fixed (*) and snap frozen tissue samples. B) area 1 *;Oct 3/4 staining (2.5x). lnset (40 x). C) area 4. Direct 
alkaline phosphatase staining (1.25x). Inset (40x). Both sections demonstrate the presence of CIS/ITGCNU. 
DISCUSSION 
This case report illustrates a number of clinically relevant issues. First, it shows that the diagnosis 
of ITGCNU (and intratubular seminoma) can be missed by a general pathologist on a testicular 
biopsy fixed in buffered forma lin by morphological criteria alone. Second, the re-analysis based 
on immunohistochemistry is informative to prevent underdiagnosis of ITGCNU. At our institute, 
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OCT3/4 has proven to be the most robust marker for this purpose. The availability of mono-
clonal antibodies, proven to be specific and giving reproducible results, allows application of 
this analysis in daily pathological clinical practke. Third, and possibly most important from 
a clinical perspective, ITGCNU can be very unevenly distributed in a testis, which may result 
in a negative finding using a randomly taken testicular open biopsy. Last, this article again 
underscores our earlier observation that bilateral microlithiasis in infertile males is informative 
in selecting males with an increased risk for the presence of ITGCNU. In contrast to our initial 
study, this patient had no history of cryptorchidism, indicating that bilateral microlithiasis is of 
value in this context even without the clinical observation of undescended testis. Because it is 
not yet possible to detect ITGCNU with imaging techniques or serological methods, an open 
surgical biopsy of 3 mm is currently the standard approach for diagnosis, reported with a small 
risk of false-negative sampling. As demonstrated here, diagnosis of ITGCNU or intratubular 
seminoma, may be difficult on standard (formalin-fixed, Hematoxyline-Eosine stained) histo-
logical slides for a general pathologist not experienced with the possible false negative findings 
on biopsies. Based on these observations, we recommend that when a testicular biopsy is taken 
from subfertile men to screen for the presence of ITGCNU, immunohistochemistry for OCT3/4 
must be performed. This is even more highly recommended if the patient presents with bilat-
eral microlithiasis. In the literature it is claimed that a small number of ITGCNU cases are missed 
due to technical or judgment errors, while the majority are due to focal, uneven distribution 
of ITGCNU within the testicle [6]. Both reasons were combined in the patient presented here. 
ITGCNU was missed in the second random biopsy of an atrophic testicle measuring a volume of 
only4 cm3 because it may be focal even in the presence of an invasive tumor, in particular in the 
case of seminoma. A plausible explanation is that the host response elicited by the seminoma 
may eventually eradicate most of the ITGCNU in the adjacent parenchyma. This is supported 
by the observation that testicular parenchyma adjacent to a non-seminoma usually shows a 
more evenly distribution of ITGCNU [1 0]. Kliesch et al showed that in one quarter of the men 
who underwent two biopsies of the same testisiTGCNU was found in only one biopsy and thus 
could easily have been missed if only one biopsy had been performed [76]. A number of condi-
t'lons are known to predispose to ITGCNU, which are summarized in Table l.ln this perspective 
it might be useful to take more than one biopsy from each testicle in patients with specific 
Table 1: Risk factors (6,9) 
Contralateral tumor RR 24.8-27.6 
History of undescended testes RR 3.5-17.1 
Family history ofTGCT RR 2.15-12.3 
Subfertility RR 1.6-10.0 
Bilateral microlithiasis RR 2.0-20.0 
Atrophic testes RR 2.7-12.7 
Ambiquous genitals CR 25 o/o 
RR= relative risk CR= cumulative risk 
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risk factors for ITGCNU to improve diagnostic accuracy. If however, no ITGCNU is diagnosed, all 
patients should at least be advised to perform self-investigation. 
CONCLUSION 
The case reported is a further example of the non-random distribution of ITGCNU. It further 
emphasizes the need for specific immunohistochemical staining, using the OCT3/4 marker, on 
testicular biopsies to improve ITGCNU diagnostics. 
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ABSTRACT 
Carcinoma in situ (CIS) is the common precursor of all type II testicular germ cell tumors (TGCTs), 
i.e. seminomas and non-seminomas, which can be diagnosed using a surgical biopsy. The 
objective of this study was to investigate the additional value of immunohistochemistry for 
the diagnosis of CIS in assessing testicular biopsies taken in the context of infertility. A series 
of 21 infertile patients were retrieved from the Dutch pathological database (PALGA), being 
diagnosed with an invasive TGCT, while a matched previously obtained testicular biopsy was 
diagnosed as non-malignant. From 20 patients, both the invasive tumors as well as the biopsies 
were revised using morphology and immunohistochemistry for OCT314, placental-like alkaline 
phosphatase and c-KIT, all known established markers for CIS. The presence of CIS or invasive 
malignancies was scored. There are no interventions. Morphological criteria alone allowed an 
experienced patholog'1st in TGCTs to diagnose CIS ·m five and an invasive tumor in two cases 
(total n == 7, 35%). Application of immunohistochemistry resulted in the identification of an 
additional four cases of CIS (total n == 11, 55%, additional value of 20%). The initial correct diag-
nosis of CIS could have prevented a second gonadectomy in four patients {20%). This study, 
for the first time, really shows that time of progression from CIS to seminoma is longer than to 
non-seminoma. Our study demonstrates that immunohistochemistry should be performed for 
the diagnosis of CIS of the testis on single biopsies obtained because of infertility, resulting in 
an extra diagnostic yield of at least 20%. Application of this protocol will allow early diagnosis, 
and therefore prevent any adverse anti-cancer treatment sequelae including gonadectomy, 
and requiring life long androgen supplementation in some patients. 
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INTRODUCTION 
Carcinoma In Situ (CIS), also referred to as lntratubular Germ Cell Neoplasia Unclassified 
(ITGCNU) is currently accepted as the precursor of all testicular germ cell tumors in adolescents 
and young adults (TGCTs) , i.e., the seminomas and non-seminomas, which are also referred 
to as type II TGCTs [5]. CIS represents the malignant counterpart of a primordial germ cell/ 
gonocyte, which develops during intra-uterine development. In spite of this early initiation, 
the invasive TGCT manifests itself only after puberty. This means that there is a time window for 
early diagnosis of this precursor of type II TGCTs. Patients diagnosed with CIS can be cured by 
orchidectomy or by a low dose of testicular irradiation [79, 80] In the majority of cases testicular 
irradiation does not interfere with testicular hormonal function [81]. 
Individuals at risk for type II TGCTs, like those with infertility, may undergo testicular biopsies 
performed for determination of spermatogenic status. Patients also have biopsy performed 
specifically for the diagnosis of CIS, including patients with a contralateral TGCT, bilateral 
testicular microlithiasis, hypoechoic lesions found on testicular ultrasound and cryptorchidism 
[79, 82]. Although CIS is nearly always found in testicular parenchyma adjacent to an invasive 
TGCT in orchidectomy specimens, it is reported that in testicular biopsies that do not contain 
an invasive tumor, CIS is missed in about 0.5 percent [1 0, 65]. 
Besides false negative diagnosis due to a heterogeneous distribution [83, 84], CIS can be 
missed using standard haematoxy!in and eosin (H & E) stained sections. The recent identifica-
tion of highly specific and sensitive markers has significantly increased the detection rate of 
CIS. OCT3/4 (as known as POUSFl) is a good example in this context [12, 13]. OCT3/4 is present 
in CIS, seminoma and embryonal carcinoma, showing a consistent and strong nuclear staining. 
In contrast, no OCT3/4 staining is found in normal adult testis, which makes it specific for the 
diagnosis of the pre-invasive stage of all TGCTs and false positive results do not occur. [1 0]. 
To investigate if immunohistochemistry has additional value over standard morphological 
examination to diagnose CIS in testicular biopsies, even for an experienced pathologist, we 
performed a unique study in patients with a type IITGCT, who previously had a testicular biopsy 
performed in the same testis for infertility or testicular microlithiasis. These biopsies were 
initially diagnosed as not malignant, and re-evaluated by an expert pathologist and comple-
mented with immunohistochemical staining. We also explored the economical benefits of the 
implementation of OCT3/4 immunohistochemistry. 
MATERIAL AND METHODS 
Patient selection 
Since 1971 a national pathology database (PALGA) has covered all (n = 70) academic and 
non-academic pathology departments in the Netherlands, registering histopathology and 
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cytopathology results. We performed a PALGA database search to identify patients who under-
went a testicular biopsy and developed a TGCT later in life. This initial screening resulted in 121 
patients: pathology reports of the biopsies revealed twelve cases with CIS (1 0%), 88 invasive 
TGCTs (73%; 55 seminomas and 33 nonseminomas) and 21 cases without malignancy fulfilling 
our criteria. From the ten pathology departments ·Involved, we were able to collect the orig·mal 
paraffin blocks from 20 of these 21 patients (95%), and the original slides from 13 (65%). One 
patient for whom no pathological samples could be retrieved was excluded from the calcula-
tions. The indications for performing a testicular biopsy were recorded if this had been entered 
in the pathological evaluation. Because of ethical restrictions related to privacy protection to 
the use of data derived from PALGA, it was not possible to obtain additional patient informa-
tion, other than that mentioned in the pathology report. 
Immunohistochemistry & evaluation 
Three micron thick tissue sections were cut of all the retrieved blocks and stained with Hae-
matoxylin and Eosin (H & E) and evaluated by a pathologist experienced in germ cell tumor 
pathology (J.W.O.). In addition, parallel sections were stained using immunohistochemistry 
for OCT3/4, as well as c-KIT and placental-like alkaline phosphatase (PLAP), other established 
markers for CIS, as previously described [1 0]. To assess if differences in staining pattern of 
these markers we compared the immunohistochemically stained slides. The biopsy samples 
were blinded prior to evaluation, and the presence of CIS was scored first on the H & E stained 
sections and subsequently on the stained slides. CIS was morphologically defined as the pres-
ence of large atypical intratubular cells with large hyperchromatic nuclei containing several 
prominent nucleoli. Moreover, CIS containing seminiferous tubules mostly show thickened 
basal laminae and reduced luminal size. 
According to the recommendations of Holstein and Lauke, who stated that a reliable diag-
nosis could be made if more than 30 tubules were present in the biopsy, we counted the total 
number of seminiferous tubules to determine whether a reliable diagnosis could be made [85]. 
The orchidectomy specimens were diagnosed according to the 2004 WHO classification for 
Testicular Germ Cell Tumors [86]. 
Costs 
An exploratory cost-effectiveness analysis was performed to assess the costs and effects of 
performing immunohistochemistry (i.e., OCT3/4) on testicular biopsies in daily practice. The 
diagnosis of CIS based on a testicular biopsy obtained in the context of infertility and subse-
quent treatment will prevent development of an invasive type II TGCT, potentially leading to 
cost reductions regarding testicular cancer treatment. The costs of the three main scenarios 
involved in the treatment of patients with type II TGCTs were included. The first consists of 
orchidectomy with an additional S-yearfollow-up; the second of orchidectomy combined with 
abdominal irradiation, and the third of orchidectomy followed by cisplatin-based standard 
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chemotherapy. Literature analyses revealed that these treatment modalities are equally divided 
among the type II TGCT patients [87]. The related costs were obtained from our university hos-
pital. These costs were compared with the costs related to treatment of CIS by local testicular 
irradiation. The number of preventable invasive type II TGCTs was calculated based on identi-
fied CIS on biopsies performed for infertility in our institution during the last five years. From 
this cohort the number of preventable cancers was estimated from the extra diagnostic yield 
of immunohistochemistry. 
RESULTS 
In 21 patients, initial morphological investigation of an H & E stained histological section of the 
testicular biopsy performed in a routine pathology department revealed no CIS or an invasive 
type I! TGCT. However, all 21 individuals developed an invasive testicular cancer later in life, 
as confirmed by orchidectomy specimen evaluation. The biopsies were performed between 
1981 and 2003, of which the clinical indication is summarized in Table 1. The mean age at time 
of biopsy was 29.1 years (range 16 to 36 years), 33.2 years (range 19 to 44 years) at time of 
orchidectomy, and the mean timespan between the original biopsy and the orchidectomy was 
52.4 months (range 9.3 to 156.5 months). Orchidectomy analysis demonstrated 13 seminomas, 
six nonseminomas and two CIS only. The time to clinical presentation from CIS to an invasive 
tumor was 26 months in nonseminomas (median, range 9-78), 47 months for seminomas 
(median, range 15-157), and 54 months for the patients with CIS-only in the orchidectomy 
specimen (range 47-61, ).In spite of the limited number of cases the difference in time from CIS 
to clinical presentation is of interest (Fig.1 A, B). 
The original slides used for initial diagnosis were obtained from 13 cases and the original 
paraffin blocks from20 patients (for one patient no pathological material was available and was 
therefore not included in the study). Because one block lacked residual material, the original 
slides were obtained and one was immunohistochemically re-stained for OCT314. In line with 
the original diagnosis of the orchidectomy specimen, re-evaluation showed 13 seminomas, six 
nonseminomas, one CIS-only and one burned out tumor with CIS in the adjacent parenchyma 
(Table 1). Four patients had a history of unilatera!TGCT, and in three of them, a biopsy has been 
performed because of infertility. 
Re-evaluation on the basis of morphological examination using well defined chracateristics 
(see materials and methods section) of the original slides or newly cut slides showed that 
malignant cells were present in seven out of the 20 patients (35%), that is., five CIS (one oft hem 
with a previous TGCT), and two invasive seminomas. Two other biopsies, were recognized as 
suspicious for the presence of CIS, although it could not be diagnosed with certainty. Immu-
nohistochemistry was performed before coming to a definitive diagnosis (Fig. 2). In addition 
to the seven cases diagnosed on H & E morphology alone, immunohistochemistry for OCT3/4, 
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Table 1: Patient characteristics with primarily pathological evaluation and revision results. 
Case Age at History Fixative Age at 151 biopsy result Revision H&E Discordahces OCT3/4 Discordances Orchidectomy 
no. biopsy orchidectomy on H&E between H&E result 
(years) and OCT3/4 at 
revision 
36 azoospermia F 38 bilateral JS 8-9 no CIS* not discordant negative not discordant left, seminoma 
2 32 bilateral B 39 right no CIS not discordant negative not discordant right, 
orchidopexy hypospermatogenesis, embryonal 
azoospermia some SCOS tubules, carcinoma with 
Leydig cell hyperplasia teratoma 
3 31 orchidopexy, B 32 right CIS discordant positive not right, 
Infertility, SCOS with some discordant seminoma 
oligospennia tubules containing 
hypospermatogenesis 
JS 2-3 
4 35 azoospermia B 44 bilateral no CIS not discordant negative not discordant right, 
hypospermatogenesis seminoma 
5 28 right orchidopexy, B 39 bilateral JS 9-10 no CIS not discordant negative not discordant right, 
azoospermia seminoma 
6 27 infertility F 39 bilateral JS 3 CIS left+ right discordant bilateral not discordant right, 
positive seminoma 
7 30 orchidectomy right, B+F 33 3 biopsies performed First: no CIS first negative, discordant left, seminoma 
chemotherapy all three showed a Second: no CIS Second +third second 
BEP + RPLKD, maturation arrest Third: no CIS discordant positive, 
azoospermia third positive 
8 33 F 34 bilateral JS 9-10 no CIS* not discordant Left positive discordant left: seminoma 
9 28 azoospermia F 34 bilateral SCOS, severe Right, micro discordant Right positive not discordant right, 
spermatogenesis arrest invasive seminoma 
seminoma 
10 34 orchidopexy, B 37 bilateral oligospermia, no CIS not discordant negative not discordant right, immature 
azoospermia atrophy, Leydig cell teratoma 
hypoplasia 
11 29 bilateral testicular B 29 bilateral JS 10 no CIS* not discordant negative not discordant left, seminoma 
microlithiasis 
12 28 orchidectomy right F 31 leh, CIS discordant positive not discordant left, seminoma 
TGCT, infertility hypospermatogenesis, 
Ieydig cell hyperplasia 
13 24 TGCT F 28 left: 30% SCOS, suspect not discordant positive discordant left, seminoma 
nonseminoma hypospermatogenesis, 
right 4 year earlier, some tubules contain 
azoospermia spermatozoa 
14 34 azoospermia F 38 left JS 9 no CIS not discordant negative not discordant left, seminoma 
15 28 F 29 right, fibrosis, necrosis no CIS* not discordant negative not discordant right, mixed 
GCT EC+ yolk 
sac tumor 
16 31 infertility F 34 bilateral JS 7 CIS discordant left negative, not discordant right, 
right positive seminoma. 
17 31 azoospermia, F 36 left, Maturation arrest CIS discordant positive not discordant left, CIS only 
noma I 
gonadotrophins 
18 29 Infection 30 right, infection, suspicious no material right, 
for sarcoidosis obtained nonseminoma 
19 29 -No remaining B 33 right, JS2 areas with JS no Cis not negative not right, burned 3 
material in paraffin 6-7 discordant discordant out seminoma 3 
block. +CIS c 0 
0 
20 16 rightTGCT, F 19 leftJSlO suspect not discordant positive discordant left, J 
teratoma, nonseminoma 
~-
J 
21 21 F 21 Left, reactive connective nonseminoma discordant positive not discordant left, ro 3 
tissue, no testis in this non seminoma ~-
biopsy +embryonal 
~ 
0 
carcinoma ~ 
JS= Johnsen score; SCOS= Sertoli cell only syndrome; BEP= Bleomydn/Etoposide/Cisplatin; RPLND=Retroperitoneal Lymph Node Dissection; F=formalin, B= Bouin's " c 
" fixative;* No sufficient biopsy material, i.e., at least 30 seminiferous tubules present, was available. ~ 0 
" 3\" 
-
~ 
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Figure 1: Kaplan Meier curves showing t ime from biopsy to clinical presentation. A) Time to clinica l 
presentat ion in the complete group (n=21 ). B) Time to progression in the patient in whom during the 
re-evaluat ion malignancy was found (n=11 ).In one patient the o rchidectomy specimen showed CIS only, 
and this patient was included in the seminoma group. 
.. 
D 
Figure 2. A) H istology of an open su rgical biopsy of the test is stained w ith H & E (2SX) (patient no. 7, Ta ble 
1 ). It was identified as suspected, b ut not proven to contain CIS; B) Higher power of suspected lesion (H & 
E 1 OOx); C) Higher power of suspected lesion (H & E 400x). 
D) Histology of the same biopsy sta ined im m unohistochemica lly posit ive for OCT3/4 (2SX). The region 
wit h positive cell is indicted in the square; E) Higher power image of suspected lesion (OCT3/4, 200x); 
Only three tubules contained OCT3/4 positive cells (Brown); F) PLAP immunohistochemistry (200x) of the 
same region, confirming the presence of CIS cells (Red). 
PLAP and c-KIT identified four more cases of CIS (in tota l: 11 out of 20, 55%). These included 
the two cases identified as suspect ed for CIS (Figure 3). Four men had a hist ory ofTGCT in the 
contralateral testicle. In all 13 cases, no discrepancies were seen between the diagnoses made 
on the original slides and the diagnoses made based on the newly cut slides from the matched 
paraffin block. 
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biopsies form 20 patients re-evaluated 
lmmunoh is tochem i stry 
Figure 3: Flowdiagram showing biopsy outcome according to type of evaluation. 
For unknown reasons one patient (no. 7, Table 1) had undergone three successive biopsies 
within a period of 18 months. On the basis of the H & E stained sections no CIS was identified, 
both originally and upon review, but immunohistochemistry demonstrated CIS in the last two 
biopsies, although not recognized before. In four cases (patients no. 1, 8, 11, and 15, Table 1} 
who all underwent bilateral biopsies, the biopsy samples were negative for CIS on H & E evalu-
ation and contained less than 30 tubules. Therefore, these biopsies are in principle not eligible 
for diagnosis, because of the risk of false negative findings. However, immunohistochemical 
staining revealed CIS in one patient (no. 8). Immunohistochemistry was thus able to correctly 
diagnose CIS in 10 out of the 16 biopsies in which a reliable diagnosis could be made. 
Overall, Bouin fixed biopsy specimen showed a weaker nuclear OCT3/4 staining than 
formalin-fixated specimens, which was not found for c-KIT and PLAP. In spite of this weaker 
staining intensity, no CIS was missed as compared to the c-KIT and PLAP staining. 
During the last 5 years within our institute a total of 158 testicular biopsies in the context 
of infertility were taken, of which 10 (6.3%) contained CIS using immunohistochemistry for 
OCT3/4. Based on the additional value of OCT3/4 immunohistochemistry for the diagnosis of 
CIS (see above, i.e., 20%), evaluation of only H & E stained tissue sections would have under 
diagnosed two cases. The costs for the three treatment regimens for type II TGCTs and follow-
up are summarized in table 2. The extra costs of performing OCT3/4 immunohistochemistry on 
a single section was estimated as Euro 13, resulting in Euro 2.054 for all158 biopsies. Therefore, 
Table 2: Estimated cost ofTGCT treatment including 5-year followup, not including long-term effects 
Orchidectomy 
Orchidectomy with radiotherapy 
Orchidectomy with chemotherapy 
Average costs TGCTtreatment 
CIS treatment (local irradiation) 
Costs immunohistochemistry 
Average dst CIS diagnosis+ treatment 
TGCT, testicular germ cell tumor; CIS, carcinoma in situ 
Costs (Euro) 
4683 
9639 
15244 
9855 
7149 
1027 
8176 
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the average extra cost per OCT3/4~based screened CIS diagnosed patient was Euro 1.027. The 
costs per patient for early diagnosis and treatment of CIS is than Euro 8.176, which is still Euro 
1.679lower than the average costs related to treatment of invasive cancer. 
DISCUSSION 
This study describes the additional value of immunohistochemistry for diagnosis of CIS in 
testicular biopsies in a specific cohort of men with infertility. The findings support the earlier 
epidemiologically based conclusion that CIS will always progress to an invasive tumor, and that 
no spontaneous regression occurs [41]. Diagnosis of CIS is therefore an absolute indication 
for treatment. This study demonstrates that evaluation of standard H & E stained sections of 
testicular biopsy material results in underdiagnosis of CIS, even by a specialized pathologist, 
and that the additional use of immunohistochemistry is mandatory. 
In 1983, placental-like alkaline phosphatase (PLAP) was the first marker used in the detection 
of seminomas. Since then, other markers such as c-KIT, AP2-gamma and OCT3/4 have followed 
[1 0, 88-90]. Currently, OCT3/4 is the most robust marker in TGCT diagnostics and 100% of the 
CIS, seminoma and embryonal carcinoma cells show a strong nuclear staining. No false posit"1ve 
results have been reported, and based on the biological function of OCT3/4 this is unlikely to 
occur [12, 13]. This is in contrast to the application of PLAP, which is positive in 93-98%, and the 
finding of only focal c-KIT positive staining patterns in CIS [14, 91 ]. 
Our study is based on a revision of testicular biopsies of 20 patients who developed a TGCT 
after an initial CIS-negative biopsy. Because the development of a clinically manifest tumor is 
the only method to prove that a biopsy is false-negative, follow-up data are crucial to accurately 
define the extra diagnostic yield of immunohistochemistry of biopsy specimens. We have 
shown that immunohistochemistry has at least a 20 percent extra diagnostic yield in this popu-
lation and therefore seems mandatory for any pathological laboratory. This percentage might 
even be higher when biopsies are adequately taken as in 1 0 out of 16 of the biopsies with more 
than 30 seminiferous tubules malignancy was found. It is known that the peak incidence in age 
of nonseminomas is lower than that of seminomas. We describe, although in a small patient 
population, a trend in difference in time to clinical presentation from CIS to seminomas and CIS 
to nonseminomas, which is seen in daily practice but is difficult to prospectively demonstrate 
(Figure 2). 
Immunohistochemical staining results are dependent on tissue fixation and standardized 
protocols. Our study found a weaker signal using the OCT3/4 marker in Bouin-fixated tissue 
than in the specimens fixed in formalin. This is in contrast to a previous study, in which no effect 
of the fixative on OCT3/4 immunohistochemistry was found, in case of limited fixation time 
[13]. Although the time affixation could not be retrieved from the PALGA database, the weaker 
signal is most likely explained by the long Bouin's fixation of the samples included in the study 
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described in this paper. Guidelines on the use of fixatives for testicular biopsies are contradic-
tory on the use of Bouin's fixative or formalin [79, 92]. Stieve's fixation might be an alternative, 
although no such samples were included in this study. However, we observed previously no 
significant changes with standardized fixatives of different origin for the detection of OCT3/4 
by immunohistochemistry [10]. 
CIS was thought to be evenly distributed throughout the testis: a one single open surgi-
cal biopsy of at least 3 mm in diameter (with more than 30 tubules), would be sufficient for 
diagnosis [85]. However, CIS can also be non-randomly distributed throughout the testis or 
the parenchyma can be damaged during surgery which might result in false negative biopsy 
results (83, 93], possibly limited by the use of two-sided biopsies [65]. In our cohort biopsies 
from four patients contained fewer than 30 tubules and a reliable diagnosis could not be made. 
However, OCT3/4 immunohistochemistry showed the presence of CIS in one of these biopsies. 
The reasons for the 5 remaining negative biopsies out of the series of 20 cases (25%) are unclear. 
This percentage is higher that in published series (0·5%) [65] showing the representative value 
of a testicular biopsy to diagnose CIS. Potential explanations might be the selected group of 
patients for this study (selection bias), or indeed a heterogeneous distribution of CIS. The cases 
in which the biopsies lacked CIS were not the same patients who had undergone therapy for 
a previous TGCT. Furthermore we show here that an experienced pathologist is able to find 
more abnormalities, which advocates a centralized evaluation of testicular biopsies. This might 
be explained by the low incidence ofTGCTs, which might result in a reduction of pathologist 
awareness. 
Disseminated TGCTs need treatment containing irradiation or chemotherapy, which may 
have severe long-term consequences. Moreover, chemotherapy will not always eradicate CIS 
in the contra-lateral testis, resulting is possible development of a contralateral cancer, leading 
to complete castration [94]. CIS is curable in almost 100% of the patients using a low dose of 
irradiation of the testis, although rare exceptions are reported [79]. Testicular irradiation eradi-
cates all germ cells, both normal and malignant, but the effect on Leydig cell function is limited 
[95]. The choice between irradiation and orchidectomy for the treatment of CIS depends on 
the patient's choice and concomitant factors as fertility preservation and pre-treatment hypo-
gonadism. In our study, four patients with a history ofTGCT developed a contralateral tumor 
after a false-negative biopsy. In all cases, review of the initial biopsy showed the presence 
of CIS. Treatment of CIS in these four patients with local radiation could have prevented the 
second orchidectomy, definitive infertility and life-long treatment with androgens. At least one 
of these four patients was also treated with chemotherapy, confirming that receiving chemo-
therapy (bleomycin/etoposide/cisplatin) does not always prevent against the development of 
a contralateral cancer. 
Recent studies have shown a prevalence of CIS in infertile men of 1- 5% [4, 96, 97]. We there-
fore believe that for infertile men who are subjected to testicular biopsies for the evaluation 
of spermatogenesis not only the quality and quantity of spermatogenesis should be routinely 
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checked but the presence of CIS should also be investigated. It is the responsibility of the refer-
ring physician to accurately judge the risk for CIS, and to inform the pathologist of the risk 
factors in a particular patient. Subsequently, it is the responsibility of the pathologist to apply 
the best diagnostic procedure, preferentially including immunohistochemical staining. 
The cost-effectiveness analysis suggested a cost reduction from the use of OCT3/4 immu-
nohistochemistry of approximately Euro 1.500 per additionally found patient. Although not at 
all complete, it illustrates the potential health care profit when OCT3/4 is used routinely on all 
testicular biopsies in daily practice, especially in the context of infertility. 
The design of this study has some limitations, including absence of clinical data related to 
treatment modality, survival and quality of life. This prevents a firm conclusion on the benefit of 
diagnosing CIS in the initial biopsy. However, it can be concluded that the implementation of 
immunohistochemistry is most-likely cost effective, and improves quality of patient care, and 
should therefore be used as standard diagnostic practice. 
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ABSTRACT 
Objective: Carcinoma in situ (CIS) is accepted as the precursor of the germ cell tumors of the 
adult testis. CIS cells are located within the seminiferous tubules and can be exfoliated into 
semen. We performed a study to detect CIS cells in semen using the highly specific immunohis-
tochemical marker OCT3/4, potentially a method for noninvasive diagnosis. 
Material and methods: In 2006,41 men at risk for CIS of the testis were found eligible for this 
study. Indications for inclusions were a suspicious lesion on scrotal ultrasound investigation (n 
= 14), patients on surveil-lance after a history of a testicular tumor (n = 14), and 13 patients with 
bilateral testicular microlithiasis (TM). 
Results: Three of the13 men (23%)whounderwenttesticularbiopsiesfor bilateral TM were 
histologically diagnosed with CIS (two bHateral), and their semen showed OCT3/4-positive cells 
in all cases. Twelve of the 14 patients (86%) with a solid mass were diagnosed with a TGCTwith 
adjacent CIS in the parenchyma, and in 9 cases {75%) OCT3/4-positive cells were present in the 
semen. No OCT3/4-positive cells were found in patients with biopsies who did not show any 
evidence of malignancy. 
Conclusion: This study demonstrates that OCT3/4-positive cells can be found in semen 
from the majority of patients with CIS. The observations indicate that there is probably a time 
window in which the CIS cells are exfoliated, which gives an opportunity for early detection of 
CIS cells in semen of men at risk forTGCT. 
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INTRODUCTION 
Testicular germ cell tumors of adults (TGCTs), seminomas and nonseminomas (a lso known as 
type II GCTs)[98]. account for 1-2% of all malignancies in men. Although the disease is uncom-
mon an annual rise in incidence is observed in most Western countries [40, 72, 98, 99]. In the 
Netherlands a 5% annual increase was found between 1990 and 2005 [1 00]. Carcinoma in situ 
(CIS) is accepted as the precursor ofTGCT [5, 1 01]. CIS cells orig inate from primordial stem cells 
or gonocytes that escape normal development at an early point during intrauterine develop-
ment [1 02]. These CIS cells start to pro liferate during puberty, presumably after a raise in sex 
hormone levels. Patients with CIS of the testis wi ll develop testicular cancer within 5 years in 
50% and probably all patients w ill develop testicular cancer ultimately [4]. CIS is frequently 
found in the adjacent parenchyma ofTGCTs [10]. CIS cells are located inside the seminiferous 
tubules at the basal membrane, in the niche of the spermatogonia, but they can leave their 
original location and spill over into the lumen. in addition, CIS cells can show a pagetoid spread 
to neighbouring tubules, the rete testis [1 03] and even epididymus (see Figure 1 ). 
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Fig 1: Post orchidectomy specimen showing distinct OCT3/4 positive cells (stained red} in the 
epididymal lumen. 
In view of this, it is plausible that CIS cells are exfoliated in semen, as are spermatozoa. CIS is 
present in the testis long before a tumor develops and may be used for screening purposes in 
men at risk forTGCT, specifically in men with fertility problems (0.6%), testicular microlithiasis 
(20%) and men w ho were treated for TGCT, and those at risk for a contralatera l tumor (5%)[9, 
63, 77]. Type II TGCTs are highly sensitive to treatment, which is also true for CIS [4, 1 04]. This 
allows early local treatment, preserving hormonal function in most cases[81]. Ever since it was 
established that CIS is the precursor of TGCTs efforts have been made to detect CIS cells in 
semen. The use of semen for detection of neoplastic cells in patients with testicular cancer was 
already suggested by Czaplicki in 1987 [1 OS] and Giwercman in 1988 [1 06]. Different methods 
such as Fluorescent in situ hybridization [1 07]. immunohistochemistry using Ap-2 gamma and 
PLAP [7, 108, 109] and immunohistochemistry with magnetic beads using the M2A antibody 
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[11 0) proved to be unsuccessful or too laborious. In contrast t o t he markers mentioned above 
OCT3/4 is a very robust nuclear marker that has proven to be an absolute and specific marker 
for CIS, seminoma and embryonal carcinoma in test icular tissue and is now used as a standard 
marker in diagnosing CIS and TGCTs [12, 13, 74) (see Figure 2A). Our goal of this pilot study was 
to develop a reliable staining method. Moreover, we tried to evaluate t he use of the OCT3/ 4 
marker for early detection of CIS cells in semen of patients w ith known risk factors for CIS or 
TGCT. 
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Fig 2 (A): Seminifero us tubule w ith Carcinoma In Situ sta ined with the OCT3/4 marker (Brown).(B+C): 
Microscopic slides of semen showing spermatozoa and OCT3/4 positive cells from 2 patients diagnosed 
w ith a TGCT. 
PATIENTS AND METHODS 
Patient select ion 
The Institutional Ethics Committee approved t his study and all participant s gave written 
informed consent (code MEC-2005-282). 
In this pilot study we selected, based on ult rasound evaluation, pat ients who were at risk of 
harboring CIS in their testicles. Between January 2006 and January 2007 a total of 42 patients 
and 15 controls were included (see Table 1 for group characteristics). Fourteen patients were 
diagnosed with a testicular mass or ultrasound detected lesion suspect for malignancy; all 
except 1 underwent unilateral inguinal orchidectomy. This latter patient underwent an open 
testicular biopsy with frozen sect ion analysis. No malignancy was found on frozen section, 
and therefore no orchidectomy was performed. All orchidectomy patients were counseled 
for semen cryopreservation and were asked to donate a semen sample for t his study. In six 
of the 14 orchidectomy patients we were able to obtain a complete semen sample before 
orchidectomy. Eight out of the 14 orchidectomy patients only donated a residual part of at 
least 0,3 ml after the majority was cryopreserved for future fertility treat ments. Also, patient s 
who were diagnosed with testicular microcalcifications (TM), during analysis for male inferti lity, 
candidates for t esticular biopsies were asked to pa rticipate. A t ot al of 13 men w ith bilateral 
TM and bilateral testicular biopsy were included and all donated a complete semen sample. 
Fourteen post-orchidectomy patients were included. These patient s were either diagnosed 
with a marker relapse (n=12) during their active surveillance protocol or were informed about 
Table 1: Oct3/4 staining results listed by diagnosis. 
Group 
Suspect for having a 
TGCT 
Post -orchidectomy 
Bilateral testicular 
microcalcifications 
Control group 
Total 
Number Diagnosis 
14 4 seminoma~ 
14 
13 
15 
56 
4 nonseminomas3 
2 combined tumors3 
1 Leydig cell tumor 
2 testis containing CIS with a 
burned out tumor 
1 Sertoli cell only 
11 nonseminomas 
3 combined tumors 
3 CIS (2 bilateral) 
10 No malignancy 
Not available 
15 CIS containing testis 
a All testicular germ cell tumors had CIS in the adjacent parenchyma 
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Mean age at time OCT3/4 positive 
of diagnosis staining 
33.8 2/4 (SOo/o) 
23.7 4/4 (100%) 
26.6 2/2 (100%) 
26.0 0 
28.9 1/2 (SOo/o) 
28.0 0 
26.3 0 
24.8 0 
34.4 3 (100%) 
34.0 0 
0 
12/15 (80%) 
this study by their physician who requested participation (n=2). None of these patients had 
testicular abnormalities on clinical examination or ultrasound. Moreover, 15 normospermic 
patients from the Andrology clinic with no known risk factors forTGCT were used as negative 
controls. All semen samples were produced by masturbation. 
Methods 
The testicular biopsies and the orchidectomy specimens were examined using standard 
protocols for the detection of TGCT and CIS. The semen samples were aloud to liquefy after 
production and thereafter dissolved in 10% phosphate buffered formalin for one hour. In one 
patient who underwent a bilateral orchidectomy the left testicle showed a spermatocele, which 
content was aspirated and used for the detection of OCT3/4 positive cells. At least 0,3 ml semen 
was obtained if the patient participated. After fixation the samples were centrifuged for 20 
minutes with 1600 G where after the pellet is resuspended in phosphate buffered saline and 
vibrated, using an automatic shaker, to make a single eel! solution. Cytospins of this suspen-
sion were made on a strong adhesive microscope slide (Starfrost©) and were dried overnight. 
Immunohistochemistry with monoclonal anti-OCT3/4 (POU5Fl, Santa Cruz sc-1 0, sc-s279) anti-
bodies was performed on the formalin fixed semen samples as described earlier[13]. After the 
first 15 patients we modified our last staining step by converting from a 3-diaminobenzidine 
Tetrahydrochloride (DAB, brown) to a 3-amino-9-ethy!carbazole (AEC, red) reaction to increase 
the contrast between the OCT3/4 positive cells and the spermatozoa and lower the background 
staining. No differences in cell morphology were seen between these techniques. As a positive 
control microscope slides were used with OCT3/4 positive cells from an established TGCT cell 
line (NT2)[111]. The microscope slides were blinded and evaluated separately by two individu-
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als and were scored positive if a distinct nuclear staining was seen in large cells with large nuclei 
and clearly recognizable cytoplasm. Doubtful staining was scored negative. 
RESULTS 
Three out of the 13 men (23%) who underwent testicular biopsies forTM were diagnosed with 
CIS, which in 2oft he cases was bilateral. The 14 orchidectomy specimens showed a seminoma 
in 4 patients (of which 1 was bilateral), nonseminoma in 4 patients, a combined tumor {contain-
ing both a seminoma and a nonseminoma component in a single tumor) in 2 patients. In 2 
testicles CIS was found next to a burned out tumor. In one patient who had a suspicious intra-
testicular hypoechogenic lesion an open testicular biopsy was performed and immediately 
stained with a direct alkaline phosphatase staining method [112]. Histopathological evaluation 
of this sample showed a Sertoli cell only (SCO) pattern. No CIS or malignant component was 
found and therefore no orchidectomy was performed. One orchidectomy specimen showed a 
Leydig cell tumor. 
All orchidectomy specimens containing a TGCT showed CIS in the tissue adjacent to the 
tumor. In 12 out of the 15 patients (80%) harboring CIS at the time of semen donation OCT3/4 
positive cells were found in the semen sample (Table 1). Two out of the three negative patients 
were diagnosed with a seminoma. OCT3/4 positive cells were seen with distinct CIS morpho!~ 
ogy as shown in Figure 2B+C. 
The number of OCT3/4 positive cells ranged from 1 to > 10 per sample. No correlation 
was found between the extensiveness of CIS in the testis or ejaculate volume and number of 
exfoliated CIS cells. In patients with bilateral CIS who donated at least two total ejaculates 
OCT3/4 positive cells could be found in most successive samples. Patient characteristics, and a 
comparison between the OCT3/4 antibody staining of semen and the histopathological find-
ings are shown in Table 1. 
In the patient with the bilateral seminoma only OCT3/4 positive cells could be found in the 
aspirated spermatocele and not in the semen sample. No OCT3/4 positive cells were found in 
the patients who had no histological proven abnormalities of the testis nor did we find OCT3/4 
positive cells in the semen samples from the post orchidectomy group. Mean age of the three 
patients in which no OCT3/4 positive eel! were found in the semen although proven TGCT was 
higher compared to the patients in which OCT3/4 positive cells were seen, respectively 35.8 
versus 28.4 (p=0.067). Mean age in the seminoma patients with or without OCT3/4 positive 
cells were respectively 26.8 versus 40.9 years (P=0.12). 
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DISCUSSION 
CIS is an asymptomatic condition that can be found in testicular biopsies in infertile patient 
with risk factors forTGCT or in patients with abnormal findings on ultrasound examination [4]. 
A testicular biopsy is still the gold standard in diagnosing CIS with a false-negative percentage 
of O.So/o, and recently it is even suggested to take a two-site biopsy to increase the diagnostic 
yield [11]. Although it is a very sensitive diagnostic test, it is reported that CIS cells are not 
always randomly distributed, explaining false negative test-results in some cases [93]. Since 
the discovery of exfoliated CIS cells in semen in 1988 [1 06], a great deal of effort has been put 
in finding a method to detect these cells in patients at risk forTGCTs [11 0, 113]. A non-invasive 
detection method would be helpful to a certain extend [13]. 
In this study we were able to detect OCT3/4 positive cells in semen from all CIS bearing 
patients. This specific patient group may benefit from early detection. 
Although other studies as well as our own study have shown that CIS cells can be detected in 
semen there are still a number of pitfalls. Malignant cells from the invasive tumor are not likely 
to be exfoliated due to the predominant intact architecture of the seminiferous tubules. The pri-
mary location ofthe CIS cells beneath the tight junctions of the Sertoli cells may prevent spread 
in the first stage before proliferation has started. There is probably a time window between 
the early stage of CIS and the time the tumor obstructs the tubules in which the CIS cells are 
being exfoliated. Also the impact of the change in environment on cell morphology of CIS cells 
passing through the male genital tract may prevent proper detection. In the third place, with 
this technique the natural surrounding, in which the CIS cells are easily recognizable, is lacking 
making a positive identification more difficult and totally dependent of immunohistochemis-
try and cell morphology. In our study all patients showed recognizable CIS cells stained with 
the OCT3/4 marker (Figure 2B+C). The use of immunohistochemistry to detect the CIS cells, 
although it is highly specific, should be performed using a standardized method. Expertise 
to perform these staining techniques accurately to avoid false negative results is, therefore, of 
major importance. Moreover, the specificity of the antibodies used must be confirmed, and a 
standardized method for immunohistochemical detection must be applied, including proper 
positive and negative controls. Hoei-Hansen et al reported a diagnostic rate for the detection 
of CIS cells in semen from men diagnosed with CIS only of the testis, using AP2-gamma of 50% 
and Oo/o for OCT3/4 [7]. They were however not able to compare these techniques as they 
have not stained the same slides for AP2-gamma as well as OCT3/4. Also possible sub-optimal 
immunohistochemical detection of OCT3/4 might be related to the published limitation. They 
also described three false-positive results were seminal fluid showed borderline AP2-gamma 
stained cells. A subsequently performed testicular biopsy failed to confirm this diagnosis. We 
did not encounter any false-positive result using the OCT3/4 marker. Although we did not 
have pathological examination of the controls, no abnormalities were seen on ultrasound or 
clinical investigation, making the change of an existing TGCT very small [114]. AI! three cases, 
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in which no OCT3/4 cells were found in the ejaculate, showed severe fibrotic tubules paten~ 
tia!ly hampering exfoliation of CIS cells. The incidence of pagetoid spread of CIS cells in the 
rete testis differs between patients with seminoma and non~seminoma, with less pagetoid CIS 
involvement in the seminoma group [1 03]. Patients with a seminoma often have an extensive 
host response, less CIS and more atrophic tubules [1 0]. This lymphocytic infiltration may even 
result in a complete eradication of CIS in seminoma patients [1 0, 115]. Seminoma patients 
are in general older than non-seminoma patients and the risk of any of these factors inhibit-
ing exfoliation is increased. In our study semen from two patients (50%) with seminomas did 
not show any OCT3/4 positive cells in comparison in a!! patients with non seminomas OCT3/4 
positive cells were seen. A similar tendency was seen in the study of Hoei-Hansen et al in which 
they saw a significant difference in positive cells exfoliated between seminoma (17,4%) and 
non-seminoma patients {56,6%) [7]. Age (and histology of the tumor) might therefore play 
an important role in the exfoliation of CIS cells, with a higher change of finding these cells in 
patients at young age. 
The purpose of this study was to try to detect CIS cells in semen especially to diagnose CIS 
before an overt tumor has developed. Although TGCT is a highly curable disease the potential 
long-term side effects of the treatment protocols used are numerous and severe. Long-term 
side effects will occur in approximately 20-30% and consist mainly of nephrotoxicity, ototoxic-
ity, neurotoxicity and gonadal damage [1 1 6]. CIS can be treated with orchidectomy or local 
radiotherapy with a curability rate reaching 100%, thus preventing potential hazardous chemo-
therapy in case CIS is left untreated and a testicular tumor develops. In this study two patients 
had bilateral CIS and were advised to undergo bilateral radiation therapy. However, in case 
of infertility couples may choose to have artificial reproductive techniques performed before 
radiation treatment is performed. The third patient with unilateral CIS underwent an inguinal 
orchidectomy to prevent the potential scatter radiation on the contra lateral testicle in case of 
radiation therapy. 
The combination of the peak-incidence of TGCTs, the long-term presence and exfoliation 
of CIS cells and well known risk factors may provide a setting in which screening could be use-
ful. Also the relative high incidence (5%) of patients with TGCT occurring in the contralateral 
testis underscores the need for close follow-up and early detection in this specific group [117]. 
Patients visiting a fertility clinic have a 20-fold greater incidence of testicular germ cell cancer 
than fertile men and CIS is found in approximately 0.6% and could therefore be a population 
who could benefit from screening [64] .In addition, infertile males with bilateral TM, who have 
approximately a 20 percent chance of harboring CIS, might specifically profit from this tech-
nique [9]. Due to the relative low incidence, the high number of patients at risk and the overall 
good survival in case ofTGCTthis test should be easy to use, cheap, highly specific and sensitive 
to make it cost-effectiveness. We are aware that the numbers in our study are relative small 
en the results presented here are therefore preliminary. Future research will focus on a more 
specific enrichment of the CIS cells, integrating an automatic screening tool for the detection 
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of OCT3/4 positive cells, increasing the numbers to substantiate our results and make a cost-
benefit analysis and perhaps finding treatments that eradicate CIS while preserving remaining 
spermatogenesis. 
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ABSTRACT 
Male patients diagnosed with cancer are often referred for semen cryopreserva- tion before 
gonadotoxic treatment but often have low semen quality. The aim of this study was to evaluate 
which type of cancer affects gonadal function and proposes a risk factor for low pre-treatment 
semen quality. Between January 1983 and August 2006,764 male cancer patients were referred 
for semen cryo- preservation prior to chemotherapy and radiotherapy. We compared semen 
characteristics and reproductive hormones between different groups of cancer patients. In 
addition, we evaluated the role of tumour markers in patients with testicular germ-cell tumours 
(TGCT) on fertility. Abnormal semen parameters were found in 489 men (64%) before cancer 
treatment. Patients with TGCT and extragonadal germ-cell tumours had significantly lower 
sperm concentra-tions and inhibin B levels than all other patient groups. No semen could be 
banked in 93 patients (12.2%). Eight hundred and thirty-nine of 927 (90%) produced semen 
samples were adequate for cryopreservation. lnhibin B in all groups showed to be the best 
predictor of semen quality. Although pre-treat-ment raised tumour markers were associated 
with a decrease in inhibin Band increased follicle stimulating hormone, both predictive for low 
semen quality; no direct linear association could be found between raised beta-HCG, alfa-feto-
protein and semen quality. Only 1/3 of cancer patients had normal semen parameters prior to 
cancer treatment. Patients with TGCT and extragonadal GCT have the highest risk for impaired 
semen quality and gonadal dysfunction at the time of semen cryopreservation. 
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INTRODUCTION 
Survival rates of young male cancer patients have improved substantially during the last 
decades because of to improved anti~cancer treatment modalities and early detection. Post-
treatment quality of life has become an important issue in the management of men with, 
testicular cancer, Hodgkin's lymphoma and leukemia, the commonest malignancies in patients 
of reproductive age. Therapy for these malignancies may consists of aggressive chemotherapy 
and radiotherapy and is accompanied by unwanted side effects, such as infertility and sexual 
problems. Especially the potential sterilizing effects of these treatment regimes are of major 
concern for young patients. This depends on the type and amount of cytotoxic agents used. 
The only established method to secure the potential reproductive capacity is cryopreservation 
of sperm[118]. If the patient wants to father a child after surviving cancer and gonadotoxic 
treatment has resulted in spermatogenic failure, banked semen can be used for artificial repro-
ductive techniques (ART), usually in vitro fertilization (!VF) and intra cytoplasmatic sperm injec~ 
tion (ICSI). The number of pregnancies obtained with IVF and ICSI using cryopreserved semen 
average around 24% for IVF and 33%for ICSI [1 1 8, 119]. About 10% of the patients will eventu-
ally use their frozen semen [118]. Since the introduction of ICSI, even low numbers of motile 
spermatozoa may be sufficient for successful treatment and should be cryopreserved. It may 
be important to know in advance which cancer patients are at risk for impaired pre-treatment 
semen quality because defective spermatozoa are more vulnerable to the freezing process 
and this may negatively influence the outcome of ART in the future. So far, clinical diagnosis 
itself has not shown to be a predictor of the deleterious effects of the cryopreservation process 
on sperm quality [120]. In male cancer patients systemic and local effects of the cancer can 
influence the pre-treatment fertility, although the precise mechanism has not yet been totally 
clarified [121].1n this study, we evaluated semen parameters and reproductive hormones from 
male cancer patients referred for semen cryopreservation at our fertility clinic. Furthermore, 
we assessed if symptoms associated with advanced disease such as fever, night sweats, fatique 
and weight loss influences sperm quality. With this study, we aim to assess the potential fertility 
impairing effect of different types of cancer before cancer treatment and evaluate which cancer 
patients are at the highest risk of having diminished gonadal function prior to therapy. 
MATERIAL AND METHODS 
Between January 1983 and August 2006, 764 male cancer patients were referred to the 
Andrology clinic for semen cryopreservation. All patients were referred before receiving any 
gonadotoxic treatment. From all patients diagnosis was reported and a short history was 
taken concerning potential fertility impairing problems. Symptoms associated with advanced 
disease including weight loss, recent episodes of fever, night sweats or fatigue were recorded. 
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Semen was produced by masturbation in a private room and if desired visual erotic stimulation 
was available. Abstinence time was not standard noted in our patients. After collection of the 
semen sample volume, total sperm count (x1 06), sperm concentration (x1 06/ml), progres-
sive sperm motility (%) and morphology (% normal forms) were evaluated according to the 
guidelines of the World health Organization (WHO) laboratory manual for the examination of 
human semen valid at time of evaluation [122]. The protocols for sperm concentration and 
motility measurement are comparable for the different manuals. Reference values for sperm 
concentration are more than 20 x1 06/ml and for progressive motility more than 50% [122]. 
Semen samples were found suitable for cryopreservation if motile spermatozoa were present. 
A second semen collection and cryopreservation procedure was offered if time was available 
before cytotoxic treatment was started. Peripheral blood samples were obtained as part of the 
diagnostic procedures for analysis of reproductive hormones, including luteinizing hormone 
(LH), follicle stimulating hormone (FSH), inhibin Band testosterone [123]. All serum samples 
were collected within 3 months prior to the date of semen cryopreservation and before inva-
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Fig 1: Number of men referred for semen cryopreservation according to year of referral. 
sive gonadotoxic anticancer treatment Reference values were for LH 3-10 U/1, for FSH 3-8 U/1, 
for lnhibin B 150-400 ng/1 and for testosterone 10-30 nmol/1 [124]. In the patients diagnosed 
Table 1: Patient characteristics according to diagnosis. All numbers are given in median and range. 
Total number Age Volume Sperm Total Sperm Conc>20 Azoospermia !nhibin B FSH LH Testosterone 
of patients (Years) (mil Concentration number Motility million samples (ng//1) (U/1) (U/1) (nmol/11 
Endocrinologlcal (106/rnJ)* (10'1 (%)' (%) (%) 
data available 
in() 
Hematological 26.3 2.5 18 34.3 34 205 3.1 4.7 13.5 96 (22) 34 25 
malignancies 14.6-51.6 (0-9) (0-323) (0-581) (0-81) 33-304 0.4-31.7 1.8-9.6 4.5-24.9 
28.9 2.2 48.5 126 so 91* 3.2 2.3 10.5 
Brain tumors 21 (7) 61 13 
14.4-50.9 (0.2-7) (0-749) (0-1282) (5-89) 72-224 1-12.4 0.1-3.7 2.2-13.9 
3.7 
16.3 35.6 3.4 39 80 40 156 0.3 
3.8 
Carcinoma's 35 (14) 48 15 
15.3-56.9 (0.2-15) (0-135) (0-1080 (0-66) 64-308 1.8-11.4 10.9-21.1 
10.2 
Extra gonadal 1.8 12.3 1or 2.5 2.3 14.1 26.9 5.6* 23 
germ cell 17(7) (1-5) (0-94) 10 25 14.9-40.9 (0-36) (0-61) 33-236 0·10.0 1.2-8.2 5.0-42.6 
tumors 
Hodgkin 25.2 (13.8- 2.0 20 35 39 153 3.5 3.5 16.5 
173 (67) 38 23 
lymphoma 44.1) (0-11) (0-243) (0-899) (0-71) 61-324 1.5-18.2 0.8-11.1 3.4-32.0 
Non Hodgkin 29.4 (15.7- 2.4 33 64 30 162 3.9 3.7 14.1 
"' 
92 (38) 41 24 
Lymphoma's 51.2) (0-8) (0-387) (0-968) (0-66) 73-332 0.7-19.5 1.2-10.7 6.0-27.6 0 0 
• 0 
22.3 (13.9- 1.8 25 28.8 37 148 2.2 2.9 12.7 "-Sarcoma's 38 (9) 41 20 0 (0-1058) 0.6-13.7 ~ 38.3) (0.1-7) (0-260) (0-69) 69-351 1.0-5.2 6.9-26.8 2 
0 
27.1 (14.6- 2.6 9.9'* 25.5 41 73' 5.0 3.2 16.1 8. 
TGCT 292 (149) 28 18.6 0 
45.7) (0.2-9) (0-308) (0-766) (0-83) 1-312.0 0-128.0 0.1-23.8 0.6-63.5 0 5 
3.5 3 
26.9 (13.8- 2.3 17 35 38 117 3.9 15.0 . 
Total 764(313) 35 21 (0.1-
" 56.9) (0-15) (0-749) (0-1282) (0-89) (1-351) (0-128) (0.6-63.5) 0 23.8) • 0 
0 
ro 
*groups in which lnhibin B levels were significantly lower than all other groups without* (P<0.05). 1< g. 
§! 
-
~ 
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with TGCT levels of beta~HCG (ref o~ 1.91U/I), alfa~fetoprotein (AFP, ref 0~9microg/l) and Lactacte 
dehydrogenase (LDH, ref 0~449 U/1) were measured. 
For statistical analysis, SPSS 16.0 was used (SPSS inc, Chicago, Ill): p-values lower than 0.05 
were considered significant. Values are depicted as median to correct for the distorting effect of 
outliers in combination with the minimum and maximum level. Non-parametric analyses were 
used if the distribution was not normal and the Mann-Whitney-U-test was used to compare 
different groups. Correlations were calculated using the spearman's coefficient, due to the non-
normal distribution of the hormone values. 
RESULTS 
Seven hundred sixty-four male patients had a median age of 26.9 years, range 13.8-56.9. The 
number of patients referred substantially increased during the last years (Fig 1 ). The majority of 
patients were diagnosed with a testicular germ cell tumor (n=292, 38%) or Hodgkin lymphoma 
(n=173, 23%, Table 1). Semen characteristics for the complete group were as follows; median 
spermatozoa concentration 20x106/ml (range 0-749), total sperm count 39.6x106 (range 
0-1282), sperm volume 2.4 ml (range 0.1-10.8) and progressive motility 39.0% (range 0-80). 
Semen characteristics and hormone evaluation per diagnoses are listed in table I. Patients with 
testicular germ cell tumors (TGCT) and extragonadal-germ-cell tumors (extragonadal GCT) 
showed a significant lower sperm concentration than the other patients (p<0.05). Only 330 
(36%), of the 914 semen samples, showed sperm concentrations in the normal range (above 
20x106/m!). In the men diagnosed with TGCT and extragonadal GCT only 28 and 10 percent 
respectively had normal sperm concentrations. 
Seventy-four patients (9.7%) provided 78 semen samples, in which no spermatozoa could 
be found (n=61) or no motile spermatozoa were found (n= 13). In these patients cryopreserva-
tion was not possible. A total number of 19 patients (2.5%) failed to produce a semen sample 
due to severe illness or stress. The 671 patients who succeeded to provide a semen sample 
produced 839 semen samples. 
Seventy-four patients were diagnosed with an azoospermia of which 38.5 percent were 
diagnosed with a TGCT compared to 15.4 percent with Hodgkin Lymphoma (HL) 15.4 percent 
with non-Hodgkin-Lymphoma {NHL) and 14.1 percent with a hematological malignancy. Inter-
estingly, only one out of the 17 patients with an extragonada! germ-cell tumor was diagnosed 
with an azoospermia. 
Jn 313 patients a hormonal evaluation and semen preservation was performed, in 262 men 
(84%) this was done at the same day of semen cryopreservation. Median serum levels for the 
complete cohort were: FSH 3.9 U/1, lnhibin B 117 ng/1, LH 3.5 U/1 and testosterone 15 nmol/1 
(Table 1). One hundred ninety-four (61%) patients had lnhibin 8 levels below normal,65 patients 
(21%) had an increased FSH level.lnhibin 8 was the only marker, that significantly correlated 
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Fig 2:A) Spermatozoa concentration according to diagnosis. B)lnhibin B levels according to diagnosis. 
Horizontal dotted line represents low border of normal for lnhibin B (150ng/l, Pierik et al 2003) 
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Table 2: Tumour markers and fertility markers according to known or unknown pre~orchidectomy tumour 
markers. 
Group lnhibin B FSH (U/1) LH (U/1) Testosterone Semen Sperm Sperm 
(ng/11 (nmof/1) volume Concentration motility(% 
(mil (x106/ml) progressive) 
TGCT patients 74 3.2 3.0 17.8 2.9 13.5 42 
with known pre- {1-312} (0-51.8) (0.1-23.8) (1-63.5) (0.5-8.0) (0-124) (0-73) 
orchidectomy tumour 
markers 
TGCT patients with 73 7.3 3.4 15.1 2.4 21 42 
unknown pre- (8-248) (0-128) (0.1-17.5) {0.6-33.5) (0.4-7.2} (0.2-308) (8-82) 
arch id ectomy tumour 
markers 
Correlation of pre-
orchidectomy tumour 
markers 
Alfa-fetoprotein (AFP) -0.25 -0.44 .. -0.36'' 0.37" 0.22 -0.16 -0.23 
Beta-HCG -0.52'* -0.73~ -0.19 0.62" 0.15 0.03 -0.07 
Lactacte -0.29* -019 -0.02 0.27 0.13 -0.01 -0.02 
Dehydrogenase (LDH) 
'P<O.OS Values are depicted as median and lower and upper range. Correlations are 
"P<O.Ol depicted between the pre~orchidectomy tumour markers and fertility markers. 
with pre-treatment sperm concentration (r=0.428, p=0.00001 ), for FSH these values were non-
significant (r=-0.105, p=0.072). In 85 patients with spermatozoa concentrations below 10 mil-
lion/ml only 33 (38%) had abnormal FSH levels compared to 63 (74%) with decreased lnhibin B 
levels. Patients diagnosed with TGCTs, extragonadal GCTs and brain tumors showed significant 
lower median levels of tnhibin B compared to patients diagnosed with HL, NHL, leukemia and 
carcinomas (Fig 2). FSH was not statistically different between patient groups. In TGCT patients 
in whom inhibin B was measured, 119 out of 127 men (94%) had subnormal levels (<150ng/l). 
In the patients diagnosed with an extragonadal GCT no differences in fertility markers were 
seen between the patients diagnosed with intracranial GCTs and the patients diagnosed with 
retroperitoneal or mediastinal GCTs. 
Of the men diagnosed with TGCTs 73 had a nonseminoma (49%), 52 a seminoma (35%), 22 
a mixed germ cell tumor (15%) and two CIS only (1%). In 128 TGCT patients we were able to 
collect tumor markers and in 68 patients we were able to collect both pre-orchidectomy tumor 
marker and reproductive hormones (Table 2). Although high beta-HCG levels were correlated 
with a decrease in lnhibin B which is usually predictive for low semen quality, no correlation was 
found between beta-HCG and semen quality (Table 2). 
In 267 patients accompanying symptoms were noted at time of semen cryopreservation 
(SCP); 49 had febrile episodes before SCP, 48 stated to have night sweats, 61 complained of 
fatigue and 56 had weight loss. Although, no correlation was found between these symptoms 
and sperm concentration caution should be taken to interpretate these findings as these 
symptoms were only noted in a small cohort. However, out of20 patients in whom one of these 
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symptoms was documented and no sperm could be cryopreserved eight patients (40%) had 
febrile episodes compared to 38 out 242 (16%) in whom motile spermatozoa were seen. The 
same trend was seen for fatigue, weight-loss and night sweats. 
DISCUSSION 
We present a large study, which dearly demonstrates that most male cancer patients referred 
for semen cryopreservation are at increased risk for a diminished sperm quality. Almost two-
third of all semen samples were abnormal indicating that patients with cancer are at risk for an 
impaired semen quality. In approximately 11 percent of the males we were unable to cryopre-
serve semen before gonadotoxic therapy due to absence of motile spermatozoa or failure to 
produce and 64% of the semen samples were abnormal according to the reference values of the 
WHO guidelines for semen analysis. Only a minority of the men could not produce an ejaculate 
due to severe illness and stress. In these patients, the use of a penile vibrator or an electro-
ejaculation under general anesthesia could be considered. However, the low semen quality in 
male cancer patients should not withhold physicians to refer patients with cancer for SCP since 
in approximately 90 percent semen could be preserved. Fortu-nately, we also demonstrate a 
large increase in the num-ber of men referred in this time-period. As cancer diagnoses did not 
increase proportionally, the increase in referral can be attributed to an increase in SCP aware-
ness of the medical oncologists and probably also of the patients. The success of new assisted 
reproduction techniques, such as intracytoplasmic sperm injection, probably plays a major role 
in the referral pattern as only few motile spermatozoa are necessary for lCS! and success rates 
are reasonable good [118]. 
We have measured reproductive hormones, including lnhibin B, and demonstrated a correla-
tion with low semen quality in patients before cancer treatment. Combining semen analysis 
and hormonal evaluation, patients with TGCTs and extragonadal GCTs demonstrated signifi-
cantly decreased gonadal function as compared to the other patient groups. In contrast, to the 
significant differences in lnhibin B no significant difference in FSH levels was seen between 
TGCT patients and the patients diagnosed with other malignancies. Petersen already showed 
thatTGCT patients had lower lnhibin 8 levels than healthy controls but failed to show a differ-
ence between TGCT patients and HL patients in a smaller cohort [125]. Vigersky eta!. found a 
pituitary dysfunction in 11 HL patients, but we could not confirm these observations in a much 
larger cohort of HL patients[126]. 
Patients with TGCTs without pre-orchidectomy raised tumor markers were still diagnosed 
with lower levels of lnhibin 8 than the other patient groups. Jacobsen showed that declined 
pre-orchidectomy sperm quality can recover after orchidectomy[127]. However, if an increased 
FSH level was found before orchidectomy no recovery was noted. This indicates that not only 
the endocrine effect of the testicular tumor itself but also a pre-existing gonadal dysfunction 
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is present. An elevated FSH also indicates that the contralateral testicle has a diminished sper-
matogenesis. This was already histological demonstrated in testicular biopsies by Hoei-hansen 
et al:. they found one or more signs ofTDS ·mas much as 25.2% of the contralateral testkles in 
men with TGCTs [45]. 
In our study no significant differences in FSH levels were found between the patients diag-
nosed with germ cell tumors and those diagnosed with other forms of cancer in contrast with 
lnhibin B levels which were significantly lower in the TGCT group. lnhibin B might be a better 
marker to detect signs of testicular dysgenesis than FSH in male cancer patients. 
Jacobsen et al recently showed in a large cohort study of32.442 Danish men that low semen 
quality is a risk factor for extragonadai-GCTs [8]. We can confirm these observations by dearly 
showing an impaired gonadal function in this group. Patients diagnosed with extragonadai-
GCTs had lower sperm concentrations and lower lnhibin B levels than those patients with other 
malignancies as seen in the TGCT group. TGCTs and extragonadai-GCTs probably arise from the 
same primordial germ cell (PGC), which, if normally differentiated, provides the basis for normal 
spermatogenesis. A problem in normal differentiation might be the basis of extra-gonadal GCTs, 
which m'1ght also explain the h'1gher chance of diminished spermatogenesis in these patients. 
Beta-HCG has a LH-Iike effect and therefore interferes with pituitary function leading to an 
increase in testosterone (as shown in table 2} and estrogen levels which both have an inhibitory 
effect on pituitary function. Although the effect of elevated beta-HCG and AFP might play a 
partial role in the decline of sperm quality, these elevated markers do not totally explain the 
decrease in spermatogenesis and impaired semen quality is also found in patients with TGCT 
without increased tumor markers. 
Fever might be one of the causative factors resulting in decreased semen quality. Recently, 
Carlsen et al. demonstrated a decline in sperm concentration following fever [1 28]. Although 
males presenting with fever, night sweats, fatique and weight loss had a slightly higher chance 
of having azoospermia no statistically significant correlation could be found between these 
symptoms and neither sperm parameters nor reproductive hormones. 
CONCLUSIONS 
Semen cryopreservation is possible in approximately 90% of referred men with cancer. A clear 
decline in sperm quality is seen in most patients. Patients diagnosed with TGCTs and extrago-
nadai-GCTs are at increased risk of severe spermatogenic failure, which indicate a pre-existing 
gonadal dysfunction. Increased levels of beta-HCG and AFP have an impact on reproductive 
hormones, but the effect on spermatogenesis seems minimal. 
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ABSTRACT 
Study objective: To evaluate the feasibility of semen cryopreservation (SCP) in pubertal boys 
before receiving gonadotoxic therapy and to identify which pre-treatment parameters might 
predict successful cryopreservation. 
Design: retrospective data analysis 
Setting: Tertiary fertility centre/ Academic Children's hospital 
Patients: Between 1995 and 2005,80 boys (median age 16.6 year, range 13.7-18.9) consulted 
the outpatient clinic of Andrologyfor SCP before a potential gonadotoxic treatment 
Interventions: We assessed the pre-treatment semen parameters, hormone levels and patients 
characteristics. 
Main outcome measures: Measurement of the number of adolescents able to cryopreserve 
semen. 
Results: Thirteen boys failed to produce semen by masturbation. In 53 boys semen quality was 
adequate for cryopreservation. In fourteen patients semen analysis did not show motile sper-
matozoa and therefore SCP could not be performed. Although lnhibin B showed a strong cor-
relation wHh sperm count (p<O.Ol ), no significant difference was found in serum testosterone, 
inhibin B, LH and FSH levels in the patients with or without successful sperm yield. Moreover, 
median age was not different between patients with and without a successful sperm yield. 
Conclusions: Semen cryopreservation in boys is a feasible method to preserve spermatozoa 
before gonadotoxic therapy is started and should be offered to all pubertal boys despite their 
young age. Serum hormone levels do not predict sperm yield. 
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INTRODUCTION 
During the last decades, mainly as a consequence of improved treatment efficacy, the overall 
number of childhood cancer survivors has increased substantially[129]. Subsequently, long-
term sequelae after treatment of pediatric cancer have gained increasing interest. An impor-
tant potential long term side effect is infertility[130, 131]. Each type of cancer requires specific 
therapy protocols that may be associated with impairment of gonadal function. Previous stud-
ies have shown that patients receiving agents with alkylating properties, such as Procarbazine, 
Cyclophosphamide and Cisplatin and/or irradiation are at a high risk of fertility problems later 
in life [132-134]. !n general, rapidly dividing spermatogonia are most susceptible for the toxic 
effects of chemotherapy [133]. Moreover, immunosuppressive agents, used both in cancer 
and in the treatment of non-malignant systemic diseases, may reduce male fertility [135]. 
Cryopreservation of spermatozoa is the only established method to enable future assisted 
reproduction techniques (ART) if patients are rendered infertile after therapy. Currently, sperm 
banking is routinely offered to adults who are to receive potentially spermatotoxic therapy, 
whereas pubertal boys may not benefit from sperm banking due to uncertainties about their 
spermatogenesis and the ability to produce semen. However, cryopreservation of spermatozoa 
seems to be useful from the onset of sperm production (spermarche). In individual cases, the 
occurrence of spermarche, an mid-pubertal event, is difficult to predict due to a wide variety in 
testicular size and secondary sex characteristics [136]. So far only few studies have described 
semen cryopreservation in adolescents [137-141]. However, none of these studies examined 
the role of serum hormone levels in predicting sperm yield and successful sperm cryopreserva-
tion. We evaluated the feasibility of semen cryopreservation in pubertal boys before receiving 
gonadotoxic therapy and tried to identify whether serum hormone levels could predict a suc-
cessful sperm yield. 
PATIENTS AND METHODS 
We evaluated the results of semen analysis and endocrine serum markers in boys aged 13-18 
years who were referred by the department of pediatric oncology for cryopreservation before 
start of gonadotoxic therapy between December 1995 and December 2005. Information on age 
at semen analysis, endocrine serum markers, type of disease, patient characteristics, treatment 
regimes and follow-up data were obtained. Patients who previously received chemotherapy 
were excluded. Semen cryopreservation was rendered successful if motile spermatozoa could 
be banked potentially preserving the chance of fatherhood. The study protocol was approved 
by the hospital medical ethical board and was performed in accordance with the Helsinki 
agreement of 1975 on human experimentation. 
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Assessment of semen collection and semen analysis 
The pediatric oncologist provided information on the possibility to cryopreserve spermatozoa, 
before cytotoxk treatment was started. In principle, semen samples were collected by mastur-
bation and alternatively by urine collection after retrograde- or electro-ejaculation. A physician 
of the Andrology department counseled all patients and if desired, visual erotic stimulation 
was provided. Patients with a retrograde ejaculation were catheterized and a buffer medium 
was installed in the bladder for collection of retrograde ejaculated sperm. After masturbation 
urine was collected and motile spermatozoa, if present, were cryopreserved. After the collec-
tion of semen volume, sperm count (xl 06), sperm concentration (xl 06/ml), progressive sperm 
motility(%) and morphology(% normal forms) were evaluated according to the guidelines of 
the WHO laboratory manual for the examination of human semen.[142, 143] Semen samples 
were defined to be adequate for cryopreservation in any case where motile spermatozoa 
were found, independent of concentration. A second semen collection and cryopreservation 
procedure was offered if motile spermatozoa were found in the first semen sample if time was 
available before cytotoxic treatment was started. All patients, in whom semen could be banked, 
signed an informed consent form concerning ownership and destination of the banked semen 
in case of death. 
Evaluation of endocrine hormone levels. 
Peripheral blood samples were obtained as part of the diagnostic procedures for analysis of 
serum hormone levels, including luteinizing hormone (LH), follicle stimulating hormone (FSH), 
inhibin B, testosterone and sex hormone-binding globulin (SHBG) levels. Serum samples 
were stored at -30° Celsius until analysis. lnhibin B was measured using kits purchased from 
Serotec Ltd (Oxford, UK). Within-assay and between-assay coefficients of variation (CV) were 
less than 9%, and less than 15%, respectively. Serum FSH and LH were determined with the 
lmmulite assay (Diagnostic Products Corporation (DPC), Los Angeles, CA, USA). Within-assay 
and between-assay CV were less than 6% and 9%, and less than 5% and 1 1 o/o for FSH and LH, 
respectively. Serum testosterone levels were determined using coated tube radioimmunoas-
says (DPC).I ntra- and ·lnterassay variation coefficients were 3% and 4.5%. SHBG was determ·lned 
using an lmmulite assay (within and between-assay< 4% and< 7%). 
Statistical analysis 
For statistical analysis SPSS 11.5.0 was used (SPSS inc, Chicago, Ill). Correlations were assessed 
using Pearson correlation. For group differences the independent t-test or the Mann-Whitney 
U test was used according to the distribution of the variables according to the Kolmogorov-
Smirnov test. P values <0.05 were considered significant. 
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RESULTS 
Between 1995 and 2005 a total number of 80 boys (median age 16.6 year, range 13.7-18.9) were 
referred to the Andrology outpatient clinic for semen cryopreservation prior to a potential fertil-
ity impairing treatment. Patient characteristics, sperm concentration, sperm motility, volume and 
endocrinological evaluation at time of semen cryopreservation are listed by diagnosis in table 1. 
Table 1: Age, serum hormone levels and sperm characteristics listed by diagnosis. Values are given in 
median and standard error of the mean(). 
Disease n Age lnhibin FSH Testosterone LH Sperm Sperm Sperm CryOpreserved 
B U/1 nmol/1 U/1 cant motility volume (%of total) 
ng/L (106/ml) {%) (mil 
Ewings 6 15.7 120.5 5.7 10.6 3.2 9.2 29.0 1.8 4 
sarcoma (0.6) (38.3} (4.0} (3.4} (0.9} (3.9} (5.6} (0.8} (66.7%) 
Osteosarcoma 2 16.8 257.0 2.1 16.9 1.6 35.5 35.0 0.8 2 
(0.9} (2.5} (15.0} (0.4} (100%) 
Mesenchymal 6 15.6 91.5 5.9 13.4 3.2 2.4 24.5 1.4 4 
tumour (0.7} (12.1) (1.8} (1.6} (0.7} (3.4} (7.4} (0.3} (66.7%) 
Hodgkin's 20 16.3 141.0* 3.1 11.7 2.3 12.0 29.5 0.8 14 
Lymphoma (0.3} (22.3} (0.7} (1.8} (0.5} (5.1} (3.9} (0.2} (70.0%) 
NHL 8 17.4 152.0* 2.9 9.8 3.4 5.9 20.5 1.0 6 
(0.5} (26.9} (1.2} (2.2} (0.7} (26.0} (3.9} (0.4} (75.0%) 
ALL 7 17.2 171.0* 1.2 11.8 3.1 62.0 32.0 1.8 6 
(0.5} (20.4} (1.5} (1.3} (1.5} (60.0} (3.7} (0.2} (85.8%) 
AML 3 17.3 186.0* 4.0 12.8 3.8 12.5 33.0 2.3 1 
(0.4} (19.0} (1.9} (1.7} (12.5} (33.0} (0.1} (33.3%) 
AA!MDS 2 16.5 159.5 6.0 12.4 3.1 7.8 26.0 3.9 1 
(0.5} (119.5} (3.9} (6.1} (0.8} (5.2} (10.5} (1.2} (50.0%) 
Autoimmune 4 17.3 154.0* 1.4 6.6 5.2 2.2 2.0 0.8 
disease (0.7} (14.7) (3.5} (2.8} (3.8} (20.8} (3.5} (0.2} (25.0%) 
Testicular 15 17.0 85.o~· 0.2 19.5 1.7 12.5 29.0 1.7 11 
germ cell (0.2} (12.0} (1.6} (3.9} (2.5} (12.0} (5.2} (0.3} {73.3%) 
tumour 
Brain tumour 7 15.6 80.0 5.5 5.0 2.2 2.5 7.0 1.0 3 
(0.6} (29.6} (3.0} (1.3} (0.8} (4.8} (10.9} (0.2} (60.0%) 
Others 2 15.9 137.0 5.0 7.4 3.1 0.4 0 1.0 0 
(0.6} (0%) 
Total 80 16.9 130.0 2.9 12 2.8 9.1 26.0 1.0 53 
(0.1} (9.6} (0.6} (0.1} (0.5} (6.5 (2.1} (0.1} (66.3%) 
NHL =Non Hodgkin lymphoma, ALL =Acute lymphoblastic leukemia, AML =Acute myeloid leukemia, 
AA =Aplastic anemia, MDS = Myelodysplastic syndrome, Mesenchymal tumor group consist out of 
2 rhabdomyosarcoma's, 1 synovial sarcoma, 1 sarcoma like hamangioma and 1 nerve sheet tumor, 
Autoimmune disease group consists out of 2 wegener disease, 1 systemic lupus erythromatosus 
and 1 kidney transplant, brain tumors group consists out of 2 germinoma's, 2 pineal tumors, 2 
medul!obastoma's, 1 pylocytair astrocytoma the other group consists out of 1 carcinoma of the 
nasophanrynx and 1 desmoplastic round cell tumor * lnhibin 8 levels compared to the TGCT patients 
P<O.OS. 
00 
~ 
~ 
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Sixty-seven patients produced a total of 92 samples of which 91 were obtained by mastur-
bation. Forty-seven patients produced only one sample before starting therapy whereas 19 
paf1ents produced two and one patient three semen samples. Two patients had retrograde 
ejaculations and delivered in total three urine samples after masturbation, of which only in 
one the semen quality was sufficient for cryopreservation. In one patient electro-ejaculation, 
under general anesthesia, was performed because the patient was unable to produce a 
semen sample by masturbation due to a tumor related neurological disorder. Thirteen out of 
80 patients (16.3%), aged 13.9 to 18.7 years (median 16.7), initially failed to produce semen 
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Fig 1: Lines indicate median values. Mann-Whitney U test showed no significant difference between 
the two groups. Semen samples were defined to be adequate if motile spermatozoa were found and 
successively were banked. 
by masturbation. The main reason for not being able to produce was that they were either 
to ill or tired to produce a sperm sample. Only one patient returned three days after the first 
failed attempt and successfully produced an adequate semen sample (volume 0.4 ml, sperm 
concentration 174x106/ml and 2% progressive motility).ln the other 12 patients time did not 
allow a second attempt and an electro-ejaculation procedure was not offered. Age at time of 
masturbation of the patients who were capable or those who were incapable of producing a 
semen sample was 17.1 versus 16.5 years (NS, p=0.13). Fifty-three patients (66.7%) aged 13.7 
to 18.9 year (median 17.0) produced adequate semen samples. These boys produced 71 semen 
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Table 2: Serum hormone levels and sperm characteristics in different age groups. Values listed as median and 
standard error of the mean(). 
Age n % fnhibin B Testosterone FSH LH Sperm Sperm Sperm Production 
group ng/1 nmo!/1 U/1 U/1 concentration motility volume succeeded 
(years) 10'6/rnf {o/o) (ml) (%) 
13~14 3 3.8 205.0 5.6(0.9) 1.3 1.8 11 1 .0 (41.9) 59.0 (5.8) 1.7 2 (66.7%} 
(30.0) (0.3) (0.1) (0.3) 
14-15 7 8.8 112.0 4.4 (2.5) 4.5 2.2 7.4 (39.6) 12.5 (5.4) 1.0 6 (85.7%) 
(20.0) (1.9) (2.1) (0.2) 
15-16 15 18.8 137.0 13.5 (1.5} 2.7 2.6 2.1 (2.8) 13.0(4.1) 0.9 14 (93.3%) 
127.3) (1.0) (0.5) (0.2) 
16-17 19 23.8 102.0 13.3 (1.7) 2.9 2.2 3.6 (3.5) 19.5 (5.8) 1.2 13 (68.4°/o} 
(20.1) (1.3) (1.6) (0.3) 
17-18 26 32.5 136.0 11.5(1.7} 2.9 4.0 25.0 (15.4) 27.0 (3.6) 1.0 19 (73.1%} 
(13.6) (1.4) (1.0) (0.3) 
18-19 10 12.5 113.0 13.3(4.9) 2.3 4.2 9.7 (1.5} 33.0 (4.0) 1.8 9 (90%} 
(28.4) (1.7) (0.7) (0.3) 
Total 80 100.0 130.0 (9.6) 12.0(1.0) 2.9 2.8 9.1 (6.5) 26.0(2.1) 1.0 67 (83.7%} 
(0.6) (0.5) (0.1) 
samples, which were subsequently cryopreserved. Fourteen patients (1 7.5%), aged 14.4 to 1 7.8 
year (median 1 5.8), produced 21 insufficient semen samples of which 15 (71.4%) showed no 
spermatozoa at all and 6 (28.6%) showed immotile spermatozoa only. 
Endocrinological evaluation at time of cryopreservation was performed in 61 patients. 
lnhibin B was strongly correlated with sperm concentration (R=0.360, p<0.01 ). None of the 
serum markers levels (lnhibin B, LH, FSH, testosterone) was different between patients with 
and without adequate sperm yield (Fig !). Because Tanner stage at time of diagnosis was only 
documented in 16 patients no correlations about semen quality could be made. Testicular 
volume was not measured at time of diagnosis. 
Patients with acute lymphoblastic leukemia (ALL) produced higher sperm concentrations, as 
compared to patients with solid tumors, brain tumors, Hodgkin lymphoma (HL), acute myeloid 
leukemia (AML) and autoimmune diseases p<O.OS (table1 ), Testicular germ cell tumor (TGCT) 
patients had significantly lower levels of inhibin B than patients with HL, ALL, AML and auto-
immune diseases (table 1 ). Median age at diagnosis was not different between the different 
diagnosis groups (table 1 ). 
Median follow-up time of the complete group was 3.4 years (range 0.8- 14.0) and median 
age at follow-up was 20.7 years (range 1 6.2-32.3). Twelve out of the 80 patients (15%) died 
during this follow-up after a median time spam of 1.3 years (range 0.4-7.2). Ofthese 12 patients 
only five had banked semen successfully. Until time of evaluation none of the patients applied 
for an assisted reproduction technique (ART) with the cryopreserved semen. Ten boys returned 
to the andrology clinic after a median follow-up time of 1.1 year (range 0.4~2.9) to evaluate 
their post treatment semen quality. Semen analysis in four of them (2 with sarcoma, 2 with 
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HL) showed an azoospermia whereas in the others (2 with HL, 1 with AML, 3 with TGCT) motile 
spermatozoa were found. 
DISCUSSION 
Our study indicates that semen cryopreservation is feasible to secure the potential to father 
a child in two-third of these pubertal boys, in the age range from 13 years on. Reproductive 
potential may not be the major concern for young boys with cancer or a systemic disease. Usu-
ally, there is not much time to discuss sperm banking because treatment needs to be started 
soon after diagnosis. However, cryopreservation is currently the only established method 
allowing the possibility to produce offspring should they survive their disease and remain 
infertile after therapy [144]. Therefore, raising the issue of potential infertility and possibility of 
semen cryopreservation, with the purpose to preserve fertility in later life should be part of the 
information given by the pediatric oncologist/hematologist to teenagers at diagnosis. Gins-
berg et al. showed in a somewhat older adolescent patient population that d·1scussing semen 
cryopreservation within 1 week of diagnosis was accepted by the majority of patients[141 ]. 
In this cohort of boys no semen could be cryopreserved due to failure to masturbate in 13 
out of 80 patients and the absence of motile spermatozoa in 14. The cause of pre-treatment oli-
gospermia is not always clear, but a direct tumor effect, congenital predisposition or endocrine 
disruption may be factors involved [145]. The high level of distress during disease and the stress 
of producing semen in a hospital may also cause an impairment of semen quality, as well as 
ejaculatory problems [146, 147]. If it is oncological safe to postpone treatment clinician's should 
attempt to obtain multiple semen samples to preserve sufficient spermatozoa for future use. 
The assistance of a trained oncology nurse or nurse-practitioner in explaining the procedure 
and accompanying the patient to the Andrology clinic, to diminish the stress of talking about 
masturbation in presence of the parents, should therefore be considered [148]. Edge et al. 
investigated the level of understanding the need for banking sperm in young boys and found 
that th ·Is level to be high with an average score of 7.2 out of 1 0 [149]. 
In our study patients with ALL had significant better sperm concentrations as compared to 
the other patient groups (fig 1!). This finding was not reported in other studies reporting pre-
treatment semen quality [19, 137, 150]. These differences might be explained by symptoms, 
such as fever or weight loss, which accompany malignant disease. Also the inter-individual dif-
ferences in pubertal stage and age can cause differences in sperm quality between these patient 
groups. Compared to the study of Bahadur et al. we did not find a significant difference in sperm 
concentration between AML patients as compared to patients with other malignancies. This 
discordance might be explained by the difference in patient age between these our study and 
theirs (respectively 17.2 versus 14.3 years. However it should be stressed that in both studies the 
number of AML patients was small and these results should be confirmed in larger series. 
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lnhibin 8 is currently the best marker for spermatogenesis and can be used to assess gonadal 
function [123, 151]. Although inhibin 8 levels showed a significantly positive correlation with 
sperm concentration a cut off point for successful semen cryopreservation could not be found. 
Although patients with TGCT had significantly lower levels of inhibin B than the patients with 
other malignancies, the sperm concentrations did not differ significantly. It is not known what 
could explain the lower pre-treatment levels of lnhibin B. In this cohort it is unknown in what 
proportion the testicular dysgenesis syndrome, which in severe cases predisposes to TGCT, and 
in which the gonadal function and fertility is already diminished before diagnosis [51] plays a role. 
The youngest boy who produced an adequate semen sample was 13 years of age. Age is 
not a predictive factor for successful spermatogenesis, but there is a trend towards a relation 
with successful semen cryopreservation (p=0.06). We advocate that all boys from 12-13 years of 
age, who are about to undergo gonadotoxic treatment, should be offered semen cryopreserva-
tion whenever they have at least entered the first phases of pubertal development. The group 
aged 13 to 14 years had low Testosterone levels but normal to high !nhibin 8 levels. This can be 
explained by the fact that lnhibin B levels increase after Tanner stage Gl Pl and testosterone 
levels start to increase after Tanner stage G2P2 [152]. These boys might therefore just have 
entered the early phases of pubertal development. 
Sexual activity should be discussed before referring boys for cryopreservation to assess the 
possibility of collection of semen through masturbation. If the patient is unable or sexually 
immature or when attempts to produce semen by masturbation have failed other options 
should be discussed[153]. Vibratory stimulation and electroejaculation (EEJ), under total 
anesthesia, have proven to be a successful technique to collect semen in patients with ejacula-
tion disorders due to various etiologies [153]. Two studies reported the use of penile vibratory 
stimulation or EEJ in adolescents before anti cancer therapy [153, 154]. So far, a total of 8 pedi-
atric patients have been reported in which semen could be collected which contained motile 
spermatozoa and in which cryopreservation was feasible. EEJ seems to be an adequate option 
if masturbation fails. Recently, it became clear from questionnaires that the motivation from 
parents and patients for this procedure in these circumstances is very high. [155]. Recently, we 
performed our first electro-ejaculation in a 13 year old boy whit Hodgkin Lymphoma, who was 
not sexually mature enough to masturbate. We obtained motile spermatozoa and were able to 
freeze 2 straws. This data was not included in this study. In our study 13 (16.3%) patients were 
unable to produce semen by masturbation, mainly due to their medical condition. From other 
studies we know that masturbation failure rates in adolescents is as high as 8.9-13.9 o/o which 
is similar to our results (16.3%) [137, 138, 149].1t should be underscored that the number of 
boys being unable to produce semen is probably underestimated since a number of patients 
decline from being referred for semen cryopreservation through masturbation. This indicates 
that the proportion of boys that might benefit of EEJ may even be higher. The possible role of 
performing a testicular sperm extraction (TESE) or freezing non-motile spermatozoa still is a 
point of discussion. 
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Intra-cytoplasmic sperm injection (ICSI) allows couples to achieve pregnancy even with very 
low numbers of motile spermatozoa and therefore cryopreservation of any amount of motile 
spermatozoa is indicated [156]. As ICSI is also being performed with non-motile spermatozoa 
the clinical availability and outcome of this invasive techniques in these young patients 
should be investigated[157]. In our clinic the use of banked semen for ART is around the 9 
percent (unpublished data). Pregnancy rates after ICSI treatment with cryopreserved semen 
are reported to be as high as 34.7 percent per cycle [158]. Due to the young age and the relative 
short follow-up period so far, none of the included patients in this study requested the use 
of the banked semen for ART as yet. In the near future long term follow up data of ART after 
cryopreservation will become available in these childhood cancer survivors. 
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ABSTRACT 
Objective: To assess the utilization rate and ART outcome of cryopreserved semen of cancer 
patients with an average follow-up of 7 year {range 2-23). 
Design: retrospective data analysis. 
Setting: University-affiliated Andrology and Reproduction center. 
Patients: 629 male cancer patients who were referred for SCP between 1983 and 2004. 
Interventions: Review of patient characteristics and ART outcome. 
Main outcome measures: Utilization rate and live births using cryopreserved semen. 
Results: A total of749 semen samples from 557 men were preserved. Ninety-one patients died 
during follow-up and another 29 requested disposal. Forty-two patients requested the use of 
their banked semen. ART data were available in 37 patients. A total of 101 ART cycles (32 IVF, 
53 ICSI, 9 cryo-ET, 7 lUI) were performed resulting in respectively 8, 16, 2 and 1 pregnancies. 
Pregnancies rates for IVF and ICSI were significantly higher than those for !Ul. 
Conclusion: So far, 7.5 percent of the cancer survivors have used his banked semen, which led 
to life births in 49 o/o of the couples. Semen cryopreservation is a reliable method to preserve 
the fertility potential and gives couples a reasonable change of achieving parenthood. 
Utilization rate of cryopreserved semen 179 
INTRODUCTION 
Survival rates for patients with malignancies have steadily increased during the last decades, 
due to the use of multi-drug regimens. These treatment protocols may have deleterious effects 
on testicular and ovarian function. Male and female cancer patients are at risk of becoming 
infertile from cancer therapy [132]. The chance for reproduction after chemotherapy is difficult 
to predict, due to many contributing factors and wide inter-individual variance [145]. The only 
established method to secure fertility in male cancer patients before gonadotoxic therapy is 
semen cryopreservation (SCP), which in time can be used for assisted reproduction techniques 
(ART). Before the "IVF/ intracytoplasmatic sperm injection (ICS!) era'; cryopreserved semen 
was only used for intra-uterine inseminations (lUI) and the first successful human pregnancy 
using banked semen was achieved in 1953 [159}. However, because of the deleterious effects 
of the freezing and thawing of the semen, the post-thaw quality was often not good enough 
for lUI [160]. The introduction of new sophisticated ART during the last decades such as in vitro 
fertilization (IVF) and ICS! overcame these severe sperm concentration and motility problems 
[156, 161]. These techniques provided patients, who banked semen and were infertile after 
treatment, with a reasonable chance of conception [162]. 
Although the total number of patients referred to our clinic for sperm banking is steadily 
increasing, the awareness of most oncologists of this subject is still insufficient. Several reports 
described the lacking knowledge of oncologists about assisted reproduction techniques [163-
165]. The success rates of IVF and ICSI treatments using cryopreserved semen are currently 
almost as high as using fresh semen [166, 167]. The use rate of cryopreserved semen differs 
widely between the different studies. Only few studies reported on the utilization rate of 
cryopreserved semen in combination with ART outcome of large oncological patient cohorts 
using these new techniques (Table 1). In this retrospective study, we report the use rates of 
cryopreserved semen and subsequent ART outcome from a large cohort of 629 male cancer 
patients presenting for SCP in a university Hospital. With this study, we intend to inform medical 
specialists about the utilization and success rates and convince them to discuss SCP with all of 
their patients that are at risk of becoming infertile. 
MATERIAL AND METHODS 
We evaluated patient characteristics, type of cancer, use of the cryopreserved semen and ART 
outcome of all male cancer patients, who banked semen between 1983 and December 2004 at 
the Erasmus Medical Center, Rotterdam, the Netherlands. From a total of 907 patients counseled 
for SCP, 629 were referred for sperm banking prior to receiving a potential gonadotoxic therapy. 
After producing their semen sample, all male patients were counseled by a physician of the 
department of Andrology. Semen samples were cryopreserved if motile spermatozoa were 
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table 1: Overview of recent studies describing use rate of cryopreserved semen and outcome. 
Total number Discontinuation Disease Duration Number of IUJCycli IVFCycli JCSI Frozen embryo Number of Percentage Live births 
of patients who group of the patients who (pregnancies) (pregnancies) Ccyli transfer pregnancies of couples 
banked semen program used their (pregnancies) (pregnancies) with ART achieving 
banked semen parenthood 
(percentage) 
Revel et al. Diverse 1~18year+ 21 62 18 26 12/21 23 
2005. (Revel et ,,, (57.0%) (5twins) 
al2005) treatment 
between 
1999·2002 
Chung et al. 164 37 Diverse 10 years 6/164 10 5 3 2 2/6 
2004 2. (Chung 92 prior to 1993-2003 (3.7%) (0) [1) (1) (33.3%) 
et al2004) therapy 3ICI 
Magel sen 422 TGCT 1983·2002 29/422 16 14/29 15 
et aL 2005 (6.9%) (48.3%) 1 twice 
(Magelssen et pregant 
al2005) 1 triple 
pragnacies 
Ragni et al 686 124 Diverse 1986-2001 36/686 40 6 42 14 12/28 12 
2003. (Ragni et (5.2%) (3) (0) {11) (43%) 2 ongoing 
al2003) 81ost to 
follow-up 
Mesequer 184 16 Diverse 1991-2004 30/184 5 25 5 16 12/30 12 
et al. 2006. (16.3%) (1) (14) (1) (40.0%) 3 ongoing 
(Meseguer et 
al2006) 
Agarwal et al. 316 Diverse 1982-2001 29/316 42 26 19 15 11/29 19 
2004. (Agarwal (9.2%) (3) (6) (7) (37.9%) 3 twins 
etal2004) 2 triplets 
Kelleher et al. 833 191 Diverse 1980-2002 64/833 35 22 22 20 29 39 
2001. (Kelleher (7.7%) (11) (6) (12) (45.3%) 
et al2001) 
Lass et al. 306 Diverse 11 years 11/306 12 14 6 7 9 8/11 9 
2001. (Lass et (3.6%) (3) (2) (4) (0) (72.3) 1 Twin 
al2001) 
Our results 557 120 Diverse 1983-2004 42/557 7 32 53 9 27 18/37 25 
(7.5%) (1) (8) (16) (2) (46.8%) 3twins 
2ongoing 
ICI= Intracervical inseminations;TGCT"" Testicular germ eel! tumors 
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found. Simultaneously, type of disease and a short history was noted. When a gonadotoxic 
treatment could be delayed, patients were advised to return for subsequent donations. Patients 
were advised to return to our andrology clinic at least 6 months after treatment to evaluate 
sperm production. Spermatogenesis recovery was scored positive if motile spermatozoa were 
seen in a post treatment sperm analysis. If patients were at least two years in remission and 
proven to be infertile sperm could be used for ART in our fertility clinic. 
Cryopreservation 
Semen was obtained by masturbation and was evaluated according to the WHO guidelines for 
semen analysis valid at that time [142]. The ejaculate was cryopreserved if motile spermatozoa 
were seen independent of concentration. After diluting the semen sample with cryoprotectant 
(Orange Medical, Ti!burg, the Netherlands) the samples were cooled and stored in aliquots in 
liquid nitrogen vapour. All paf1ents signed an informed consent form concerning ownership 
and destination of the banked semen in case of death. 
Assisted reproduction techniques 
Couples requesting fertility treatment were evaluated regarding a nationally approved fertil-
ity protocol, in which menstrual cycle abnormalities and tubal patency were included for the 
woman. Depending on the amount and quality of the semen cryopreserved, lUI, IVF or IVF-ICSI 
was considered. Beside the semen amount available, regular criteria were used (female age, 
cycle abnormality, tubal patency) to decide which form of ART was appropriate. 
Intrauterine inseminations were performed in the natural menstrual cycle. Detection of 
ovulation was established by a LH-urine test (Ovulady, Clindia bv., Leusden, The Netherlands). A 
single insemination was performed the day after a positive test. 
IVF, whether or not combined with ICSI, was initiated using a standard long agonist sup-
pression protocol with 150 IU recombinant follicle-stimulating hormone (FSH; Gonai-F, Serono 
Benelux bv, Amsterdam, The Netherlands or Puregon, NV. Organon, Oss, The Netherlands), 
after Gonadotropin Releasing Hormone (GnRH)-agonist (Decapeptyl, Ferring bv, Hoofddorp, 
The Netherlands) down-regulation. When at least 3 follicles> 16 mm were present, 10.000 IU 
of human chorionic gonadotropin (hCG, Pregnyl, Organon, Oss, The Netherlands) was injected 
subcutaneously. Ovum pick-up was performed 36 hours later. Embryos were transferred 3 days 
after oocyte pick-up. Luteal phase support was started on the day of oocyte pick up. 
Statistical analysis 
Data concerning the partner, oocyt retrieval, oocyt implantation and pregnancy outcome 
were recovered from the electronic database from the department of Reproduction Medicine. 
Patient and sperm characteristics are expressed as mean and standard error of the mean (SEM) 
or median and range if there was a non normal distribution. Statistical analysis was performed 
using the statistical package for the social sciences (SPSS 11.5, Chicago). 
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RESULTS 
Six-hundred and twenty-nine patients were referred for sperm banking before gonadotoxic 
therapy. Referrals greatly increased after 1993 from 15 patients to more than 80 per year in 
2004. Median age was 27 years (range 14-57 years). The median follow-up time after semen 
cryopreservation was 7 years (range 2-24 years), at which the median age was 34 years {range 
18-66 years). Patients were diagnosed with testicular germ cell tumors (TGCT, n=236), Hodgkin 
lymphomas (HL, n=143lr non Hodgkin lymphomas (NHL, n=81), sarcomas (n=31), carcinomas 
(n=28), acute myeloid leukemias (AML, N=26), acute lymphoid leukemias (ALL, n=30), brain 
tumors (n=18) , chronic lymphoid leukemia (n=4), chronic myeloid leukemia (n=l 0), hema-
tological malignancies other than mentioned above (n=11), extragonadal germ cell tumors 
(n=8) one melanoma and two schwannomas. A total of 749 semen samples were produced 
ranging from 1-5 samples per patient. Seventeen patients (2.7%) were unable to produce a 
semen sample and in 55 (8.7%) paf1ents the semen sample provided, did not contain motile 
spermatozoa and therefore was not suitable for cryopreservation. We were able to preserve 
semen in 557 patients (88.6%). Semen characteristics at time of semen cryopreservation for 
the complete group were; median concentration 17.5 million/ml (range 0-749 million/ml); 
median progressive motility 38.5 o/o (range 0-89%); median volume 2.4 ml (range 0- 10.8 ml). 
Men diagnosed with testicular cancer or extragonadal germ eel! tumors had significantly less 
spermatozoa per semen sample compared to other patients (p<O.Ol, table 2). 
Table 2. Semen characteristics by diagnosis 
Hematological malignancies 
Brain tumors 
Carcinoma's 
Extragonadal germ cell tumors 
Hodgkin lymphoma's 
Non Hodgkin lymphoma's 
Sarcoma's 
Testicular germ cell tumors 
Total 
* p<O.Ol 
Values are median (sd). 
Use rate 
Ageattimeof 
SCP 
23,9 (8.6) 
28,9 (10.1) 
36,0 (11.2) 
30,3 (6.4) 
25,5 (6.2) 
28,4 (7.8) 
22,3 (6.6) 
27,3 (5.5) 
26,8 (7.4} 
Volume Concentration Progressive 
(ml) (106/ml) motility(%) 
2,2 (1.7) 17,0 (53.0) 34 (20) 
2,2 (1.8) 42,0 (181.4) 60 (27) 
2,9 (1.9) 42,0 (38.8) 39 (20) 
2,4 (1.3) 13,0 (13.8) 17 (25) 
2,0 (1.7) 20,0 (44.6) 37 (20) 
2,S (1.7) 36,0 (64.5) 32 (16) 
1,9 (1.4) 30,0 (58.2) 39 (16) 
2,6 (1.7) 9,0 (34.4)* 41 (20) 
2,3 (1.7) 17,0 (56.4) 38 (20) 
Out of the total group of 557 men with cryopreserved semen 218 (39%) returned for semen 
analysis after cancer treatment. Motile spermatozoa were found in 155 (71.1 %) out of the 21 8 
men, of which 20 men reported a spontaneous pregnancy. Data on post treatment spontane-
ous pregnancies was not structurally obtained from the complete group. During follow-up 91 
(14.3%) patients died from recurrent or persistent malignancy or therapy related complications 
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without using their banked semen. The median time span between cryopreservation and 
death was 1.3 years (range 0-14 years, median 1.3). Twenty-nine patients requested disposal of 
their cryopreserved semen. Within this group eight did so, after returning for semen analysis, 
which showed motile spermatozoa in seven and azoospermia in one. Three out of the 29 men 
reported a spontaneous pregnancy. 
Of the 557 patients who banked semen 42 (7.5%) patients requested the use of the banked 
sperm after a mean time of 57 months (range 15-130 months). Post treatment semen analysis 
showed an azoospermia in all42 men. Nine patients requested to take their banked semen to 
another fertility clinic of which five were lost to follow-up. 
Assisted reproduction outcome 
The remaining 37 patients all underwent ART, of which, 33 patients were treated in our hospital. 
The mean age of the female partners at time of the assisted reproduction technique was 32 
years (range 21-40 years). These 37 couples had a total of 101 ART cycles; 7 lUI cycles, which 
resulted in one pregnancy (14.3%); 321VF cycles, resulting in 8 pregnancies (25.0%), 53 cycles 
of ICSI, resulting in 16 pregnancies (30.1 %) and 9 cryopreserved embryo transfers (ET) result-
ing in 2 pregnancies (22.2%; table 3). A total of 25 children were born: 19 singletons, 3 twins. 
Two couples are currently awaiting a child. Mean age between the females who did or did not 
achieve a pregnancy was not significantly different, respectively 32.1 versus 32.3 years (p==0.86). 
Table 3. ART characteristics per treatment. 
Treatment IVF ICSI Frozen ET lUI 
No. of cycles 32 53 9 7 
Age female years 30.5 + 3 .. 9 34.0+4.1 28.1 +4.5 
No. of oocytes 342 395 
(mean, range) (10.7, 1-26) (7.6, 0-25} 
No. 2-pronuclear oocytes 128 236 
(mean fertilization rate) (42.4%) (57.8%) 
No. fertilisation failures 9 (28.1%) 5 (9.4%) 3 (33.3%) (cycles) 
Embryo transfers 0 10 6 3 
6 20 2 
2 16 27 4 
(Mean +sd) 1.2 +0.9 1.4+0.7 1.1 +0.9 
No. transferred embryos 37 74 10 
No. clinical pregnancies 8/32 (25.0%) 16/53 (30.1%) 2(22.2%) 1 (14.3%) 
No. Live births (total) 8 15 
Singletons 8 9 1 
Twins 0 3 0 0 
EUG 0 0 0 
Early abortion 0 0 
Active Pregnancies 0 2 0 0 
Pregnancies per number of 3 (60%) 5 (25%) 0(0%) 
embryo's transferred 2 5 (31%) 11 (40.7%) 2(50%) 
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All eight pregnancies resulting from !VF treatments, four cycles in which two embryos 
were transferred, were singletons. Three out of the 27 ICSI cycles, in which 2 embryos were 
transferred, resulted in twin pregnancies. One ICSI treatment resulted in an ectopic pregnancy. 
Eighteen out of the 37 partners achieved at least one live birth with the use of cryopreserved 
semen and two patients are currently awaiting a child. Thus, resulting in a success percentage, 
with two couples currently awaiting a child, of at least 54%. Four patients had two successive 
pregnancies using banked semen. In a total of 20 cycles (11 IVF, six ICSI and three cryotransfers) 
we were unable to transfer an embryo. In only one case this was due to the absence of motile 
spermatozoa after thawing. The other failures were either due to fertilisation failures, ovarian 
stimulation failures or bacterial infection of the culture dish. Three cryopreserved embryos did 
not survive freezing and were not transferred after thawing. Thirty-three patients out of the 37 
patients still have semen banked, which can be used for future treatment. Mean storage time 
between the couples who did achieve pregnancy and those who did not was respectively 4.7 
and 4.8 years (p=0.87). No correlation was found between the storage time and pregnancy rate. 
DISCUSSION 
This study reports on the utilization rate of cryopreserved semen and ART outcome of a large 
cohort of cancer patients from one semen bank in an university Hospital. To our knowledge 
this is one of the largest studies and the longest follow-up reported on the use and outcome 
of cryopreserved semen. Few single centre studies have reported on utilization rates as well as 
ART outcome using sophisticated techniques, such as IVF and ICSt, using cryopreserved semen 
{See table 1 ). Schmidt et al. recently reported the ART outcome of a large cohort of men with 
malignant disease, however, they also included men in which spermatogenesis was recovered 
and ART was performed using fresh semen[158]. 
In our opinion the usefulness of sperm banking is primarl!y measured by analyzing the 
number of children born and number of males achieving fatherhood using the banked semen. 
These are in essence the main goals for which men bank their semen. During the last years new 
assisted reproduction techniques have substantially increased chances of becoming father 
using cryopreserved semen [156, 175, 176]. Male cancer patients might have an impaired pre-
treatment semen quality but this certainly should not rule out sperm banking, since with ICSI 
only a few motile spermatozoa are needed [162, 177]. Our study reports on an average success 
rate of achieving parenthood using cryopreserved semen of at least 54% (Table 1 ). This success 
rate differs widely between studies ranging from 33 to 73 percent (Table 1 ). Failure to achieve a 
pregnancy using the cryopreserved semen after treatment is a devastating outcome and must 
therefore be discussed prior to the SCP procedure. Patients have to be informed that post-thaw 
quality cannot be predicted and usually 50-75% of the spermatozoa will not survive freezing. 
In our study longer storage time did not correlate with lower pregnancy rates. Secondly the 
Utilization rate of cryopreserved semen Iss 
female partner may have fertility problems leading to a poor response when stimulated. Freez-
ing of spermatozoa may also affect fertilization potential. In our study fertilization fa.1lures were 
more often seen in IVF cycles. Two females did not respond to the hormonal treatments, which 
resulted in an early discontinuation of IVF procedure. 
Post-cancer quality of life studies revealed male infertility as one of the most devastating 
long-term side effects of anticancer therapy [132]. As cancer survival has increased largely dur-
ing the last decades, oncologists are more aware now of the long-term quality of life. It is our 
responsibility to inform the oncologist about the new possibilities in fertility treatment and 
relative good pregnancy outcome using the cryopreserved semen. In the past patients with 
low quality semen were often rejected from SCP due to disappointing results of lUI and IVF 
[178]. In our clinic each year more male cancer patients are referred for elective sperm cryo-
preservation. During the last decade we have actively informed the oncologists about semen 
cryopreservation using the region wide Comprehensive Cancer Centre Rotterdam (CCHR). This 
is a knowledge centre, which maintains an extensive network and fulfils a coordinating func-
tion within the field of oncology in the southwestern part of the Netherlands. 
The use rate in our cohort is comparable with the other large studies. We calculated the use 
rate with the total number of patients who actively had semen preserved in our sperm bank. 
Although the use rate of 7 .So/o may seem low, these men could not have fathered their own 
child if their sperm had not been banked. If we only include cancer survivors use rate increases 
to 9.6o/o. We did not include the post mortem use of cryopreserved semen, which in our clinic 
sporadically occurred. The use rate will increase in time as some of the men who banked 
their semen will not be ready to procreate or have a stable relationship in which children are 
desired. We also have to keep in mind that a number of patients already have fathered a child 
before gonadotoxic treatment and their wish to undergo assisted reproduction treatment 
may be low. Studies evaluat'mg the reason of sperm disposal showed that most requests were 
obtained from men who regained fertility or had improved semen quality aftertreatment[179]. 
Furthermore, the patients were not actively followed to assess spontaneous pregnancies. 
Seventy-one percent of the men returning for semen analysis showed at least some recovery of 
spermatogenesis and may potentially achieve a spontaneous pregnancy. Men who did achieve 
a spontaneous pregnancy will most likely not attend our clinic to use the banked semen. 
In conclusion: We strongly recommend discussing SCP with all men at risk of becoming 
infertile after receiving gonadotoxic treatment. Semen cryopreservation is at this moment the 
only established and reliable method to preserve fertility. Semen can be stored for a reasonable 
long time without affecting pregnancy rates. The use of cryopreserved semen will lead to suc-
cessful pregnancies in more than half of the couples. 
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ABSTRACT 
Background: Although it is accepted that pediatric-cancer treatment harbors a risk of gonadal 
damage large cohort studies using up-to-date fertility markers are lacking. 
Procedure: The aim of our study was to evaluate the gonadal toxicity of childhood cancer 
treatment using fertility markers. We included 248 adult male long-term survivors of childhood 
cancer. Median age at diagnosis: 5 years, median age at follow-up: 24 years, median follow-
up time 18 years. We evaluated patient characteristics, treatment modalities, testicular size, 
endocrinological parameters including lnhibin B, luteinizing hormone (LH), follicle-stimulating 
hormone (FSH) and testosterone. 
Results: The median value of lnhibin Bin the cancer survivor group was 126 ng/1 versus 177 
ng/1 in the control group (P<0.001 ). In the survivors, 67% had lnhibin B levels below the normal 
reference value of 150 ng/1 compared with 26% in the control group (p<O.OS).Inhibin B was the 
most sensitive discriminator between survivors and controls. Significantly decreased lnhibin B 
levels and increased FSH levels were found in men treated for Hodgkin and non-Hodgkin lym-
phoma, acute-myeloid leukemia, neuroblastoma and sarcoma as compared to other malignan-
cies. Cumulative dosages of procarbazine and cyclophosphamide were the only independent 
chemotherapy-related predictors for decrease of lnhibin B levels and increase of FSH. Age at 
time of treatment did not influence post-treatment lnhibin B or FSH levels. 
Conclusions: Severe gonadal impairment is a risk in a considerable subgroup of childhood 
cancer survivors based on current fertility markers, like inhibin B. Boys receiving gonadotoxic 
treatment before puberty are not protected from post treatment gonadal dysfunction. 
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INTRODUCTION 
In the past decades survival of childhood cancer improved significantly following optimized 
treatment modalities [180]. Therefore, the number of survivors of childhood cancer in the 
general population is estimated to increase [181, 182]. Several studies have shown an impaired 
gonadal function in adult male survivors of childhood cancer [183, 184]. Post-treatment 
gonadal damage showed to be depending on the type of used agents and cumulative dosages 
administered during childhood [185-187]. Usually, studies were based on one type of malig-
nancy and treatment protocol and had limited number of survivors included [185-187]. Age 
at time of treatment was suggested to give some protection against chemotherapy induced 
gonadal damage due to quiescent stage of the testis in the pre-pubertal age [188]. At present, 
semen analysis serves as the gold standard for predicting the reproductive capacity of men in 
their reproductive age. However, young adults treated for childhood cancer are reluctant to 
provide a semen sample for analysis. Therefore, reliable serum markers that reflect gonadal 
function in men may serve as a more convenient screening tool in determining reproductive 
function in male cancer survivors at least to start with. In recent studies we and others have 
shown that lnhibin B is the best serum marker for spermatogenesis [123, 124, 151, 189-191]. 
lnhibin B values after puberty depend on FSH secretion and are associated with sperm concen-
tration and testicular volume not only in healthy individuals but also after chemotherapy and/ 
or radiotherapy [192, 193]. However, studies in large cohorts of adults treated for childhood 
cancer describing the role of !nhibin Bas male fertility marker are not available as yet. The aim 
of this study was to evaluate gonadal damage in a large single center cohort of male childhood 
cancer survivors using modern fertility markers. 
PATIENT AND METHODS 
Between January 2003 and September 2006, 291 male survivors of childhood cancer were 
recruited to our late effects outpatient clinic. All had been treated in our centre. Of them 30 did 
not respond and thirteen survivors were not included in the analysis because they did not receive 
chemotherapy or radiotherapy during their childhood treatment. Written informed consent was 
obtained from all participants, according to protocols approved by the ethical review board of 
the Erasmus MC. The distribution by diagnosis is given in Table I. Of the Hodgkin Lymphoma (Hl) 
group, 22 included survivors have been described in a previous larger series [19l].ln order to 
describe the complete cohort of survivors these patients were included in the study. 
At the time of the study, all survivors were at least 18 years of age and at least five years after 
cessation of treatment. Median age at initial diagnosis was 5 years {range 0-15 years). Median 
age at follow-up was 23 years (range 18-41 years) with a median follow-up time of 18 years 
(range 5-39 years, Table l). Complete physical examination including measurement of testicular 
90 
volume and serum hormone analysis consisting of LH, FSH, testosterone and lnhibin B was per-
formed. Testicular volume was measured by Prader Orchidometer. Sperm analysis performed in 
a subset of cancer surv·lvors was performed according to the 1999 WHO laboratory manual for 
the examination of human semen and sperm-cervical mucus interaction [142]. 
The control group consisted of74 normospermic men, with a sperm concentration >20xl06/ 
ml and progressive motility >50%, aged median 33.4 years (range 23-51 year). Peripheral blood 
samples in survivors and controls were taken at time of their visit. The normospermic men were 
recruited from the fertility clinic. During andrological work-up they were found to be normo-
spermic. The reference values of LH, FSH, lnhibin Band testosterone values for male adults in 
our institute are 1.5-8.0 U/1, 2.0-7.0 U/1, 150-400 ng/1, 10.0-30.0 nmo!/1, respectively. Within-assay 
and between-assay coefficients of variation (CV) for lnhibin B were 9% and 15%, LH 6% and 9%, 
FSH 5% and 11%, testosterone 3% and 4.5%, respectively[194]. The cut-off value of 150 ng/1 for 
lnhibin B is taken as it has been shown that this provided the highest sensitivity and specificity 
in identifying low semen quality[124]. 
Statistical Analyses: The computer program Statistical Package for Social Science (SPSS inc., 
Chicago, Illinois, version 11.1) was used for data analysis. Non-parametrk analyses were done 
as a non-normal distribution if the distribution was not normal. P-values <0.05 were considered 
significant. Survivor characteristics are expressed as median with range. 
RESULTS 
The range of serum hormone values of the complete survivor group and the control group are 
depicted in Table I. In general, the survivors had higher FSH and LH levels and lower testosterone 
and lnhibin B levels than the controls (Tables! and ll).lnhibin B was the strongest discriminator 
between the survivors (median of 123.0 ng/1, range 0-393) and the controls (median 176.5 ng/1, 
range 60-556; p<0.0001, Fig. 1 ). 
One hundred forty-five of the 221 survivors (65%) in whom lnhibin B was measured had 
values below 150 ng/1 in contrast to 19 (26%) ofthe 74 controls (Fig. 1 ). When analysed by type 
of cancer, survivors of Hodgkin's lymphoma, non-Hodgkins lymphoma, malignant mesenchy-
mal tumors, acute myeloid leukemias, sarcoma's and neuroblastomas showed median lnhibin 
B levels below 100 ng/1 suggestive for severe gonadal dysfunction (Table I, Fig. 2). Survivors of 
acute lymphoblastic leukemia and renal tumors had relative normal median lnhibin B levels of 
respectively, 140 ng/1 and 146 ng/1 (Table I, Fig. 2). 
We compared sperm analysis with endocrinological parameters in a subgroup of21 patients; 
nine had an azoospermia with a median inhibin B level of median 39 ng/1 (range0-79). Two 
patients were diagnosed with an oligospermia (sperm concentration between 5 and 20 million/ 
ml), sperm concentrations of 13x106 and 15x106 spermatozoa/ml, and had lnhibin B levels of 
67ng/l and 72 ng/1. F1ve patients who had severe oligo-asthenospermia (sperm concentrations 
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Figure 1: lnhibin B values of controls and childhood cancer survivors. Each dot represents one person. 
The horizontal lines represent the median values of inhibin Bin the normospermic controls (176.5 ng/1) 
and in the survivors (123.0 ng/1, p<O.OOOl ). 
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Figure 2: Median lnhibin B values and quartile ranges per diagnosis. The horizontal dotted line represents 
the lower threshold of normal (150 ng/!) 
below Sxl 06/ml) and lnhibin 8 levels of median 25 ng/1 (range 2~39). Two of them had severe 
oligospermia and with only a few immotile spermatozoa in their semen, with lnhibin B levels of 
2 ng/1 and 19 ng/1. The five survivors with a normospermia had median lnhibin B levels of ng/1 
(range 125-234).1nhibin B levels showed a significant correlation with sperm concentration in 
both survivors (r: 0.671, p:O.Ol) and controls (r: 0.345, p:0.03). 
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Using a linear regress'1on model, treatment determinants for low lnhibin B levels (lnhibin 8 
<150 ng/1) were calculated. Only regimens containing cyclophosphamide or procarbazine but 
not any other drugs, were independent determinants for low !nhibin B levels '1n the patients 
treated with chemotherapy (p<O.Ol). None of the other chemotherapeutic agents was inde-
pendently associated with altered lnhibin B levels. Cyclophosphamide was part of the treat~ 
ment protocol in 131 of the 248 survivors with a median dosage of 4.8 gram/m2 (range 0.25~32 
gram/m2). lnhibin B levels showed a significant negative correlation with total cumulative 
dosage (TCD) of cyclophosphamide (r~-0.531, p<0.001) (Fig. 3).1nhibin B levels were abnormal 
in all but one survivor receiving a TCD of more than 10 gram/m2 (Fig. 3). 
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Figure 3: Dose-effect of cyclophosphamide (gram/m2) on lnhibin B levels. The horizontal line shows the 
lower threshold of normal for lnhibin B (150 ng/1) the other line shows the linear regression (Rsq "'0.201, 
correlation coefficient R=-0.531, p>O.OOl) 
HL survivors treated with MOPP had lower lnhibin B levels, median 15 ng/1 vs 143 ng/1, 
p<O.OOl) smaller testis volumes, i.e. 12.7 ml versus 17.8 ml (P <0.01), higher FSH levels (median 
22.6 U/1 versus 4.7 U/1, p <0.001) and higher LH levels (5.9 U/1 versus 2.4 U/1, p< 0.001) than the 
HL survivors who did not receive procarbazine. These values indicate a severe gonadal dysfunc-
tion in the 15 HL patients treated with procarbazine. 
Age at which cyclophosphamide and procarbazine were administered showed no correla-
tion with lnhibin 8 levels (r=-0.06, p=O.S26 and r=0.182, p=0.516, respectively). Young age at 
time of cyclophosphamide administration did not show a protective effect on gonadal function 
whether they received low or high TCD of cyclophosphamide (Fig 4A and 48). This was even 
more obvious when we evaluated patients younger and older than 10 years with a relatively 
low (TCD < 10 gram/m2) dosage of cyclophosphamide. Median lnhibin 8 level in the patients 
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Figure 4: Distribution of lnhibin Bin survivors treated with cumulative doses of cyclophosphamide of 
0.25- 10 gram/m 2, correlation coefficient R=-0.097, p=0.371 (A) and 10-30 gram/m2 correlation coefficient 
R=-0.052, p=O.SO (B) according to the age at time of treatment. 
younger than 10 years (n=58) was 138 ng/1 compared to 127 ng/1 in the older group (n=29) 
(p=0.402). Although the groups were smaller, no age-effect was seen in the patients receiving 
cyclophosphamide in higher concentrations (TCD > 10 gram/m2). The survivors treated before 
the age of 10 (n=28, inhibin B available in 22) had median lnhibin B level of 21 ng/1 (range 
0-218) compared to 10 ng/1 (range 5-78) in the older group (n=S) (p=0.845). 
The 10 survivors (1 HL, 4 AML, 4 ALL, 1 NHL). who received total body irradiation (TBI 7.5 
or 12 Gy) as part of myelo-ablative therapy, had extremely low lnhibin B levels (median 1 0.0, 
range 0.0-62.0 ng/1). Of those, only two survivors had low testosterone levels (7.6 and 8.6 
nmol/1) whereas the others had normal testosterone levels (>=1 0 nmol/1). No impairment in 
gonadotrophins was found in the subgroups. Additionally, four survivors (3 ALL, 1 AML) had 
received testicular irradiation (24 Gy) on both testes. One survivor with a MMT was treated with 
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pelvic radiotherapy (45 Gy), which included the scrotum. Testicular volume was evaluated in 
three as one had testicular implants (lnhibin B == 0 ng/1) and in one patient it was unfortunately 
not documented. These three survivors showed severe impairment of testicular growth (testis 
volume median 2.0 ml, range 1 to 3 ml). Median lnhibin B level available in the four survivors, in 
whom the testicles were not removed, was 1 0 ng/1, range 0-13). 
Testicularvolume did not differ between the controls and the survivors in the total group nor 
in one of the subgroups by diagnosis (p=0.391 ). This is reflected by the fact that only 18 males 
(7.3%) of the cancer survivors had subnormal levels oftestosterone (<10 nmol/1) compared to 
eight men (10.8%) in the control group. AI! but three men out the patient group fully completed 
pubertal development compared to all in the control group. 
DISCUSSION 
Although several studies have shown the value of modern fertility markers for prediction of 
spermatogenesis, studies on gonadal function after chemotherapy and irradiation in large 
series of adult male cancer survivors, using lnhibin Bas a novel serum markers are lacking [130, 
184, 191, 195, 196]. Therefore, we performed a study in a full single centre cohort of male child-
hood cancer survivors (n=248). 
We found a significant difference in reproductive hormone levels between survivors and 
controls, of which lnhibin B proved to be a better discriminator than FSH for the assessment 
of spermatogenesis between the two groups (table II). This was already known in healthy 
individuals but this study shows that this is also the case in cohorts of male long-term survivors 
of childhood cancer. We used a cut-off value of 150 ng/1. We acknowledge that this cut-off 
value is arbitrary and therefore performed the same analyses with a cut-off value of 80 ng/1 and 
also found that cyclophosphamide and procarbazine were the only independent treatment 
determinants for impaired gonadal function. 
Patients with Hodgkin lymphoma, non-Hodgkin lymphoma, malignant mesenchymal 
tumors, acute myeloid leukemia, Ewing sarcoma and neuroblastoma have a relative high risk of 
subfertility after treatment. This is in line with the review article by Brougham and Wallace, who 
divided childhood cancer types into three subgroups according to risk of subfertility [1 97]. Our 
study confirms that diagnostic subgroups are indicative for post treatment gonadal function, 
but mainly explained by the different treatment regimes accompanying these diagnoses. 
In our study, cyclophosphamide and procarbazine containing regimens, both compounds 
with alkylating properties were the most deleterious drugs for the gonadal function. This 
finding supports earlier studies in which these drugs were associated with severe gonadal 
dysfunction[198, 199]. Cyclophosphamide showed a negative dose correlation with lnhibin B 
levels. Almost all survivors who received a cyclophosphamide TCD of 1 0 gram/m2 or more were 
at risk for severe spermatogenic dysfunction. These findings support the earlier observations 
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in which a dose-dependent effect of cyclophosphamide was found [130, 198]. This dose effect 
was not found for procarbazine containing regimens, which indicates that this agent might 
already be gonadotoxic in low concentrations in males. Our study confirms that not only the 
type of agent used but also the cumulative dosage is important in predicting post-treatment 
gonadal function[200, 201]. 
Total body- and testicular irradiation causes severe gonadal dysfunction[202-204], which is 
illustrated by the fact that 8 out of 10 survivors treated with TB! had almost undetectable lnhibin 
B levels (<=26 ng/l).ln addition, local radiotherapy to the testis was administered in 5 men who 
all showed extremely low lnhibin B levels. Although semen analyses were not available of these 
men, the previous published correlations between lnhibin B levels and sperm count indicates 
that these survivors probably have a severely impaired spermatogenesis [123, 191 ]. 
This study illustrates that young age at time of childhood cancer treatment does not prevent 
post-treatment gonadal damage. Although such protection at very young age has been sug-
gested in the past, our findings confirm those of Thomson et al. who observed severe gonadal 
dysfunction in male survivors even if treated in pre-pubertal life [196]. Pre-pubertal age has 
been classically characterized as a quiescent period potentially providing some kind of protec-
tion against chemotherapy [188]. However, during this period there is active proliferation of 
Sertoli and Leydig cells which might explain the damage after cytotoxic treatment [205-208]. 
Childhood cancer patients and/or their parents should therefore be informed about the risk of 
infertility after chemotherapy independent of age and pubertal stage. Therefore, sperm pres-
ervation should be considered for risk groups as young as possible, and if necessary assisted by 
artificial procedures like electro-ejaculation methods [154, 194]. 
The question whether lnhibin B can replace semen analysis as a gold-standard remains 
unanswered. Although lnhibin B is highly specific, it still is an indirect marker and controversies 
exist. Sperm analysis remains the gold-standard especially as with modern assisted reproduc-
tion techniques, like intra-cytoplasmic sperm injection, only a few normal spermatozoa are 
needed for conception. Therefore, we propose to encourage survivors to have lnhibin B levels 
measured after chemotherapy as a first step to assess gonadal damage in order to identify 
survivors at risk for impaired spermatogenesis. 
In the total group treated with chemotherapy, testosterone levels were slightly lower than 
the controls, however; only 7 o/o of the survivors had low testosterone values. This might indi-
cate that the Leydig cells are more resistant to gonadotoxic treatment than the germinal cells. 
The minimal dysfunction of Leydig cells is supported by the observation that all except three 
survivors, of which two received testicular radiotherapy, fully completed pubertal develop-
ment, which is mainly dependent on testosterone production.lt is conceivable that most boys 
will complete their pubertal development possibly by an increase in LH levels, which occurred 
in our cancer survivors i.e. significant higher levels of LH were found in the survivors compared 
to in the normospermic men. This might indicate that in some survivors (10 percent in this 
study) a Leydig cell dysfunction exists, which can be compensated by elevated LH levels. This 
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underscores that the assessment of reproductive capacity in childhood cancer survivors by 
solely evaluating secondary sexual characteristics or testosterone is insufficient. 
This study demonstrates the importance of fertility counselling and pre~treatment semen 
cryopreservation in male survivors of childhood cancer. Moreover, the results of this study 
show the ongoing need to consider the risk of gonadal toxicity of certain agents in the design 
of new protocols for newly diagnosed children with cancer. lnhibin B levels may be helpful to 
assess the gonadal function. Determination of lnhibin B levels, being the best marker for assess-
ing gonadal function and recovery, is a relative easy and quick non-invasive method to assess 
gonadal function. Although it can be used to identify patients at risk with impaired reproduc-
tive capacity, combination with sperm analysis remains mandatory to evaluate reproductive 
options when there is an active child wish. Our results emphasize the need for gonadal function 
assessment and fertility counselling in long-term survivors of childhood cancer. 
I 
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Table 1: Patient characteristics per diagnosis group. 
Diagnosis Nr Age at Age at lilhibin B FSH lH Testosterone Testis diagnosis visit volume 
23.0 3.5 20.0 
All 5.0 (18.0- 140 3.6 (0.1- 15.5 (2.0-88 (0.3-15.0) (0-393) (0.5-58.7) (3.7-27.3) 
40.0) 14.9) 25.0) 
21.0 3.2 15.0 
3.0 (18.0- 68 3.9 (0.1- 12.8 (10.0-AML 11 (0.5-14.0) (10-195) (0.3-15.0) 
33.0} 8.9) {8.5-45.1) 20.0) 
24.0 3.6 15.0 
Hl 28 11.0 (18.0- 54 9.2 (1.2- 13.2 (8.0-(2.0-1 5.0) 
41.0) (0-274) (1.7-51.0} 10.9) (8.8-32.7) 22.5) 
23.0 4.0 15.0 
NHl 42 8.0 (18.0- 88 5.5 (0.9- 15.5 (9.0-(2.0-14.0) 
36.0) (5-232) {0.9-31.7) 11.5) (7.6-27.9) 22.5) 
23.0 
4.0 
3.3 17.5 
Renal tumors 27 
3.0 (18.0- 146 (0.1- 14.5 (10.0-(0.7-11.0) 
39.0) (13-244) (0.5-47.4) 16.3) (4.5-28.9) 25.0) 
25.0 4.7 15.0 
MMT 18 5.5 (18.0- 55 14.4 (0.1- 14.6 (4.0-(1.0-14.0) 
36.0) (0-226) (0.5-65.8) 12.9} (2.8-28.9) 16.5} 
23.0 3.6 20.0 
Osteosarcoma 12.0 (18.0- 146 6.0 (2.0- 14.8 (11.0-9 (1.0-15.0) (38.-339) (0.7-17.3) 
37.0) 8.5) (9.7-23.2) 25.0) 
25.5 3.6 16.3 
8.0 (18.0- 36 8.6 (1.1- 16.1 (15.0-Ewing Sarcoma 6 (5.0-15.0) (15-299} (1.7-15.8) 
36.0) 8.1) (9.7-20.2) 20.0) 
Neuroblastoma 
24.0 3.9 15.0 
0.1 (18.0- 79 6.3 (1.3- 15.0 (12.0-
+Gang I ioneu ro blastoma 
11 (0.1-1.0) 
30.0) (21-212) (3.3-20.6) 7.5) (7.6-20.4) 20.0) 
20.0 3.7 22.5 
Others 
1.5 (18.0- 114 3.6 14.4 (15-8 (0.3-9.0) (10-295) (1.4-21.4) (1.4-
30.0) 7.2) (12.5-24.7) 25.0) 
33.4 
3.6 
2.7 16.5 
Controls (23.3- 176.5 16.8 74 (60-556) (0.6-18.0) (0.3- (11.0-
50.6) 19.2) (4.7-27.7) 30.0) 
ALL= Acute lymphoblastic leukemia, AML= acute myeloid leukemia, Hl= Hodgkin lymphoma, NHL= 
Non-Hodgkin lymphoma, MMT =Malignant mesenchymal tumor. Others consist out of 1 embryonal 
adenocarcinoma, 1 Langerhans histiocytosis, 2 hepatoblastomas, 1 malignant schwannoma, 1 nasopharynx 
carcinoma, 2 yolk sac tumors, 1 Grawitz tumor. Values given as median and range. 
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Table 2: Comparison of serum hormone levels between survivors and controls. Values are indicated as 
median and range. Percentages of abnormal levels for each serum marker and sperm concentration are 
given. 
Survivors (n-248) Percentage Controls Percentage P-value 
of abnormal (n=74) of abnormal 
levels levels 
lnhibin B {ng/1) 123.0(0-393)1 65% 176.5 (60- 25% < 0.0001 
556) 
Testosterone (nmol/1) 14.7 (2.8-45.1)2 8% 16.8 (4.7- 10% 0.05 
27.7) 
FSH (U/1) 4.6 (0.3-65.8) 2 32% 3.6 (0.6-18.0) 17% 0.01 
LH (U/11 3.6 (0.1-16.3)2 10% 2.7 (0.3-19.2) 2% <0.0001 
Sperm concentration 0.01 (0.0-158.0)3 76% 52.5 (21.1- 0% <0.0001 
(106/m!) 234.0) 
Testicular volume {ml) 17.5 (2-35)4 17% 16.5(11-30) 14% 0.391 
1 (n=221) 2 (n=244) 
3(n=21) 4 (n=233) 
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ABSTRACT 
Introduction: One of the risks of childhood cancer treatment is fertility impairment later in life. 
In the past a large proportion of children with acute lymphoblastic leukemia (ALL) has received 
cranial irradiation as part of their treatment. The aim of this study was to evaluate whether 
cranial irradiation negatively affects pituitary regulated gonadal function in male survivors of 
childhood ALL 
Procedure: We examined gonadal function, including lnhibin B, LH, FSH, testosterone, and 
pituitary axis function bymeasuringTSH, Free-T4 and IGF-IIevels in 891ong-term male survivors 
of childhood ALL after a median follow-up time of 19 year (range 7-34 years). 
Results: Twenty-nine out of 89 male ALL survivors received cranial irradiation. lnhibin, FSH, 
LH, Testosterone, testicular volume as well as TSH and Free-T41evels were not different in the 
cranial irradiated group as compared to the non-irradiated group.IGF-IIevels were significantly 
lower in the cranial irradiated group. Survivors treated with total body irradiation or testicular 
irradiation had significantly decreased gonadal function based on hormone levels. 
Conclusion: These data show that, in contrast to the negative influence on the growth hor-
mone axis, cranial radiotherapy as part of ALL treatment does not have a deleterious long-term 
effect on the hypothalamic~pituitary-gonadal axis or pituitary-thyroid axis. 
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INTRODUCTION 
Currently, more than 75% of all pediatric acute lymphoblastic leukemia (ALL) patients survive 
and reach adulthood [209]. Successful treatment of children with ALL involves administration 
of multi-agent chemotherapy and includes central nervous system (CNS) prophylaxis. In the 
past, CNS prophylaxis consisted of cranial irradiation, which has been replaced by intrathecal 
chemotherapy in most of the current treatment protocols. An increasing cohort of childhood 
ALL survivors who have been treated with cranial radiotherapy in the past has now reached 
reproductive age. It has been reported that cranial irradiation can influence the hypothalamic-
pituitary-gonadal axis and potentially lead to impaired endocrine function resulting in growth 
disturbances and impaired fertility[21 0, 211 ]. In addition, it has been suggested that young 
patients treated before 10 year of age are at increased risk for gonadal dysfunction after treat-
ment[212-215]. 
Earlier fertility studies in pediatric ALL survivors were mainly based on pituitary hormone 
level measurement or on registration of life birth rates and did not include novel markers like 
lnhibin 8[213]. lnhibin B is produced by the Sertoli cells and is strongly correlated with sperm 
characteristics and fertility capacity in men and also correlates with spermatogenic status in 
testicular biopsies [124, 151]. lnhibin 8 has a negative feedback mechanism with follicle stimu-
lating hormone (FSH) and it has been shown to be a good marker for testicular damage after 
chemotherapy [195, 216, 217]. 
In the present study, we evaluated the impact of childhood cranial radiotherapy on pituitary 
regulated gonadal function in a large single center cohort of male long-term survivors of child-
hood ALL including novel markers like lnhibin B. 
Patients and Methods 
Patients 
Out of a total of 500 survivors of childhood cancer 99 registered adult male survivors of 
childhood ALL, diagnosed and treated in our hospital between 1973 and 1998, were identi-
fied. Seven survivors refused participation and three were lost to follow-up. A!l 89 survivors 
who participated in this cross-sectional study were in continuous complete remission and at 
least five years after completion of therapy. Written informed consent was obtained from all 
participants, according to protocols approved by the ethical review board of the Erasmus MC. 
General fertility characteristics of these survivors have been reported previously[217]. The pres-
ent study focuses on the differences of endocrine late effects between patients treated with or 
without cranial radiotherapy. Median age at time of diagnosis was five years (range 0-15 years) 
and median age at follow-up was 25 years (range 18-40 years), with a median follow-up time 
of 19 year (range 7-34 years). Data concerning treatment protocols, disease and patient char-
acteristics were retrieved from the medical records. All 89 survivors were treated according to 
::: 
102 
the national ALL protocols at time of diagnosis, including the ALL-2,3,5,6,7,8,9 protocols of the 
Dutch Childhood Oncology Group (DCOG)[218-224]. Thirteen survivors had been diagnosed 
with a relapse and were treated accordingly. Twenty-five male survivors (28%) received cranial 
irradiation with a median cranial irradiation dosage of 25 Gy (range 15-30 Gy) (Fig 1). Twenty 
patients were treated with 25 Gy, 1 with 30 Gy, 1 with 15 Gy, 1 with 20.4 and 2 with 18 Gy. None 
of the survivors had been treated with cranio-spinal irradiation. 
The survivors who received total body irradiation (TBI), testicular irradiation, mediastinal 
irradiation or orbital irradiation with or without cranial radiotherapy were evaluated separately 
(n=9). The patient with orbital irradiation and the patient with mediastinal irradiation were 
excluded from the main analysis of endocrine side-effects. 
99 childhood ALL survivors l diagnosed between 1973-1998 J 
were eligble for inclusion 
isg were included] 
Therapy I 
I 
I I I I 
w 
Chemotherapy ' 1 Chemotherapy + Chemotherapy + Chemotherapy+ 
ithout Irradiation J Cranial Irradiation branial Irradiation (25Gy) Other Irradiation 
N=55 N=25 (25Gy) Additional Irradiation N=5 
N=4 
I I 
r l I I I I 
Testicular ' Total Body 1( Mediastinal I Testicular '1( Total Body Orbital Cavity I 
Irradiation I lrradiaton I' Irradiation 1 Irradiation J I lrradiaton Irradiation N=2 (24Gy) ' N=l (12Gy) N=l (24Gy) ) ( N=3 (12Gy) N=l (24Gy) l /l N=l (20Gy) ) 
Fig 1: Flowdiagram showing the radiotherapy and chemotherapy modalities of the treated ALL patients. 
Median irradiation dosages are given between brackets. 
Endocrinological evaluation 
A complete physical examination and serum hormone analysis from peripheral blood samples 
were taken at time of the visit at our outpatient clinic for childhood cancer survivorsthe. 
Samples were obtained by vena puncture, processed within 2 hours after withdrawal and 
stored at -21 'C. Gonadal function was evaluated by lnhibin-B, Luteinizing hormone (LH), 
Follicle-stimulating Hormone (FSH), testosterone and Sex hormone binding globulin (SHBG). 
In addition, thyroid-stimulating hormone (TSH), Free T4 (FT4) and Insulin-like Growth Factor 
(!GF-1) were also measured to determine the broader effect of cranial irradiation on the pituitary 
axis. Levels of IGF-1 between the subgroups were compared with reference values by using 
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SDS scores (Z scores), which express the difference between the measurement of an individual 
and the median value of the reference population [225]. The thresholds for normal values of 
hormone levels are indicated in Table 1. 
Statistics 
Statistical analysis was performed using SPSS 16.0 software (SPSS, Chicago, IL). Differences 
between treatment groups were tested using the student t-test and correlations were tested 
using Pearson's correlation. P values are all measured in the two-way classification with p<0.05 
considered statistically significant. 
RESULTS 
Hormone levels from the pituitary-gonadal axis and survivor characteristics were available for 
all survivors with the exception of one missing value of lnhibin B (Table 1). 41 Forty-one of the 
male survivors (47%) had decreased (<150ng/!) levels of lnhibin B of which 19 had lnhibin B 
levels below 1 OOng/l.lnhibin B levels strongly correlated with FSH (r=-0.559, p<0.00001), LH (R= 
-0.423, p<0.0001) and testicular volume (r=0.505, p<O.OOOOl ). 
Neither the cumulative dosage of cyclophosphamide nor any of the other chemotherapeu-
tic agents were significantly different between the survivors with low or normallnhibin B levels 
independent of the threshold level of 150ng/l or 1 OOng/1. FSH and LH levels were increased in 
respectively 14 (16%) and 8 (9%) patients. Of the survivors who had both an increase in FSH 
and LH, 3 patients were treated with testis irradiation and 4 with total body irradiation. Only 3 
patients were diagnosed with low levels of testosterone of which 1 was treated with testicular 
irradiation (9 nmol/!) whereas two received chemotherapy only (both 7.7 nmol/1). All patients 
(n=7) treated with total body or testicular irradiation showed signs of testicular damage illus-
trated by high levels of LH, FSH and low levels of lnhibin 8 (Fig 2). Age at time of treatment did 
not correlate with levels of lnhibin 8, FSH, LH, or testosterone in the long-term survivors. 
The additional negative impact of cranial irradiation on testicular function is minimal as no 
differences in lnhibin 8, FSH, LH and testosterone levels were found between survivors treated 
with chemotherapy in combination with cranial irradiation (n=25) and survivors treated with 
chemotherapy alone (n=SS) (Table 1 ). Median testicular volumes in both groups were not dif-
ferent (median 20 ml, range 10-25, p=0.54). In addition, no difference in pituitary or testicular 
hormone levels were found between those patients treated with ;:::25 Gy (n=21) and those 
treated with <25 Gy (n=4). 
TSH and FT4 levels were available in 38 survivors, of whom all except one had FT41evels 
within the normal range. TSH levels were normal in all except two survivors of which one 
received chemotherapy only and one chemotherapy with TBI. Both had borderline abnormal 
TSH levels (0.36 and 0.37 mUll) but normal FT41evels. No difference inTSH and FT41evels were 
Table 1: Hormone levels according to treatment modality. The two patients treated with orbital 
irradiation and mediastinal irradiation are not shown. Normal range is given for each hormone. Values 
given as median and range. Z-scores are given as mean and standard deviation. 
Table 1 Complete No Cranial P-value11 Total body P-value't Testicular P-va]ue¥ 
group radiotherapy irradiation irradfation irradiation 
(med 25 Gy, 
rangelS-30) 
Number of 87 55 25 4 3 
patients 
Age at 5.0 (0-15) 6.0(1-15) 4.2 (0.1-14) 0.02 4{4-12) 0.70 5 {2-5) 0.27 
diagnosis 
(yrs) 
Age at 25 (18- 24 (18-34) 29 (23-40) <0.0001 25 (22-35) 0.25 30 (21-33) 0.11 
follow-up 40) 
(yrs) 
Follow-up 19 (7-34) 18 (7-24) 26 (16-34) <0.0001 18 (15-31) 0.13 25 (16-31) 0.01 
time (yrs) 
lnhibin-B 155 155.5 (67- 177.0 (35- 0.85 15 (10-20) <0.0001 10(0-10) <0.0001 
(150-400 {0-393) 392) il 393) 
ng/1) 
Testosterone 16.2 16.6 (7.7- 16.4 (11.1- 0.21 12.2 {11.8- 0.09 11.9 (9.0- 0.14 
(10.0-30.0 (7.7-29.4) 29.4) 20.9) 16.0) 17.0) 
nmol/1) 
SHBG(l 0-70 28.9 26.2 (10.6- 31.6 (15.1- 0.03 22.8 (15.0- 0.80 47.8 (42.7- <0.0001 
t nmol/1) (10.6- 51.4) 51.3) 40.2) 67.7) 
0 67.7) ~ 
u 
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LH (1.5-8.0 4.0 (0.1- 3.4(0.1-8.1) 3.1 (1.3-5.3) 0.38 10.8 (7.7- <0.0001 13.9 (8.2- 0.08 
U/1) 18.9) 13.9) 18.9) 
F5H (2.0-7.0 4.0 3.4(1.3-14.1) 4.3 (1.1-15.7) 0.14 23.7 (15.9- 0.01 48.2 (42.8- 0.01 
U/1) (1.1-58.7) 31.4) 58.7) 
Testicular 20 (2-25) 20.0 (13-25) 20.0 (10-25) 0.79 12.5 (4- 0.02 2.5 (2-3)* <0.0001 
volume 13)* 
(>15ml} 
FreeT4(11- 14.8 15.1 (11.6- 15.0 (11.8- 0.69 12.5 (12.3- 0.06 14.8i 0.79 
25 pmol/1) (11.8- 30.1 )b 22.7)' 12.6) 
22.7) 
TSH (0.4-4.3 1.3 (0.36- 1.14(0.37- 1.2 (0.46- 0.42 1.9 (0.36- 0.19 0.79i 0.61 
mU/1} 3.43) 2.48)d 2.76)e 3.43) 
Height {em) 178 (163- 182 (165- 175 {163- 0.006 169(167- 0.035 170 (165- 0.13 
192) 192) 189) 184) 186) 
Body Mass 24.1 23.9 (17.9- 25.4 (19.2- 0.04 19.5 (18- 0.06 20.7 (19.6- 0.13 
Index {17.9- 39.6) 33.8) 24.2) 21.4) 
39.6) 
IGF-1 (15-47 24.3 27.4(13.1- 17.3 (12.8- 0.003 20.6 (11.5- 0.17 7.8 (6.5- 0.02 
nmol/1) (6.5-54.2) 54.2)h 47.5)' 32.3) 23.0) 
IGF-1 -0.49 (1.3) -0.11 (1.1) -0.82 (1.1) 0.02 -0.82 (1.3) 0.24 -2.2 (1.6) 0.01 
{z-scores) 
v p-values as compared to the non-irradiated group 
a n""54, b n""l o,c n=21, d n=11 ,e n=21/ n=1,9 n=21 ,n no:=38, i n=21) n=l 
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Fig 2: Median lnhibin B values and quartile ranges according to treatment and location of irradiation. One 
patient in the TBI group and two survivors in the testicular radiated group also received cranial irradiation. 
The horizontal line represents the lower threshold level for lnhibin B (150ng/l). 
found between the patients treated with or without cranial irradiation. The patient treated with 
orbital, mediastinal or testicular irradiation were also excluded from this analysis. 
Of the patients treated with or without cranial irradiation IGF-1 was measured in respectively, 
38 and 21 survivors. Males who received cranial irradiation had significantly lower IGF-IIevels 
(p~ 0.0031, lower Z-scores (p~0.02) , shorter stature (p~0.006) and a higher body mass index 
(p~0.04) than those treated with chemotherapy alone (Table 1 ). Total body height was signifi-
cantly lower in the cranial irradiated and TBI group compared to the non-irradiated group (table 
2). The survivors treated with TB! had a significant higher BMI compared to the non-irradiated 
group (Table 1). 
Discussion 
This is the first study that evaluated the long-term effect of cranial irradiation in very long term 
male survivors of childhood ALL on fertility using novel gonadal markers. We found no deleteri-
ous effect of cranial irradiation on gonadal function thereby providing important information 
forb adult survivors of childhood ALL treated in the past, as well for the small subgroup of ALL 
patients that still benefits from cranial irradiation in current treatment protocols [218, 226]. 
Our study does not confirm the results reported by Siimes et at. They reported an increased 
risk on testicular damage in a group of 41 childhood ALL survivors treated with cranial irradia-
tion by measuring LH, FSH, testosterone testicular size and pubertal stage.ln their study 17 out 
of 41 survivors were irradiated with a median dose of 20-24 Gy. In the current study, we show 
in a larger single center cohort (n=80, of which 25 subjects received cranial irradiation), with a 
Table 2 nog ni 
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longer follow-up time (19 years), including novel fertility markers, that cranial irradiation does 
not determine the risk of gonadal damage. 
Moreover we studied the different'1al influence of cranial irradiation on gonadal the thyroid 
and growth hormone axes, which indicates that the negative effect of cranial irradiation on 
growth hormone production, which has previously been reported in other studies, is selec-
tive[211,227].1n addition, it suggests that impairment of height in the cranial irradiated group 
is due to growth hormone deficiency, as illustrated by low IGFl levels, and not by thyroid hor-
mone depletion, although we realize that growth hormone function tests would be required to 
confirm these results in these individual survivors[211, 228, 229]. 
Interestingly, the study by Siimes eta/ reported a difference in testicular volume between 
cranial irradiated and non-irradiated cases. Our study in a larger cohort and with a longer fol-
low-up time, shows no difference in testosterone, lnhibin 8 values nor testicular sizes between 
the survivors treated with or without cranial irradiation. It is feasible that an interobserver 
variability in the study by Siimes eta/. may have played a role, as survivors were evaluated in 4 
different cancer centers. In our study we had the opportunity to determine testicle size in all 
survivors by one and the same clinician. 
Quigley eta!. reported elevated gonadotrophin levels in childhood ALL patients treated 
with 24Gy cranial radiotherapy and chemotherapy and confirmed gonadal damage by testicu-
lar biopsies showing an absence of germ cells[21 0). Their analysis was performed immediately 
after cessation of treatment and not repeated after a long-term follow-up. This suggests that 
recovery of gonadal function takes occurs[230). 
Another method to study male fertility after childhood ALL is to investigate the number 
of !ife births in male and female ALL survivors and compare this with an age matched control 
group, which was done by a Norwegian group[214]. Only four out 131 male adult ALL survivors 
fathered children of which three received cranial irradiation. The conclusion of their study was 
that their data were probably incomplete and therefore statements concerning the detrimental 
effect of cranial irradiation as component of ALL treatment on male gonadal function could not 
be made.ln our study we did not include semen analysis or life births as end points. However, it 
'1s questionable whether proven fatherhood can be used as a marker for gonadal damage after 
chemotherapy, as achieving a pregnancy is not solely dependent of sperm quality. Comparing 
gonadal markers is more suitable for the assessment of treatment induced male gonadotoxic-
ity, as reflected by strongly correlated lnhibin Band FSH values [195]. 
Interviews are another way to get insight in to fertitlity rate in childhood cancer survivors. 
Byrne et al performed telephone interviews and assessed life births in 213 men treated for ALL 
before age 18 on protocols of the Children's Cancer Group and compared these results with 145 
male siblings. They found a decreased number of life births in childhood ALL survivors treated 
with cranial radiotherapy before the age of 10 years at diagnosis, their fertility was only 9o/o (RF 
0.09, 95o/o Cl 0.01-0.82) compared to controls [213]. However, this study did not include female 
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fertility information as a determinator for a couples fertility potential. Therefore life births do 
not accurately reflect male gonadal function. 
In our complete ALL survivor group cancer younger age attime oftreatment was not associ-
ated with a higher risk of impaired gonadal function. It is not possible to conclude whether cra-
nial irradiation after the age of 10 years induces a lower risk for pituitary and gonadal damage 
from our analysis as the group of survivors who were treated after the age of 10 was too small. 
Our study suggests that previously applied treatment protocols for ALL are not highly 
gonadotoxic. Except for cyclophosphamide, most chemotherapeutic agents administered in 
ALL treatment have a relatively mild gonadotoxicity, which is underscored by the current study 
[217]. In our cohort, the total cumulative dosage of cyclophosphamide did not exceed 1 Omg/ 
m2, which is considered to be the threshold level for its gonadotoxic effect. This made it pos~ 
sib!e to evaluate the effect of cranial radiotherapy as independent variable[217]. Furthermore 
this study shows that it remains important to refer all patients for semen cryopreservation 
before treatment[231 ]. 
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GENERAL DISCUSSION 
Since the discovery of Carcinoma in Situ as the precursor of testicular germ cell cancer, research 
on the origin and possible causes of testicular maldevelopment has increased. The hypothesis 
that several diseases of the male reproductive system share a common environmental cause 
was first postulated in the early 1990s, with reports on endocrine disruption causing genital 
malformations and reproductive disorders in animal wildlife. Parallel to these observations 
temporal trends in testicular cancer and other male reproductive disorders were observed in 
humans [235]. More recently, it was reported that men with prenatal exposure to estrogen 
diethylstilbestrol (DES) or phtalates had an excess risk for undescended testis, hypospadia and 
testicular cancer [236]. 
Development of CIS seems dependent on the micro-environment created by Sertoli cells 
in the testis and by Granulosa cells, being ther female counterpart of Sertoli cells, in the dys-
genetic gonad. These Sertoli cells are also involved in the development ofTM.It has been sug-
gested that these calcified concretions within the lumen of seminiferous tubules originate from 
sloughing of degenerated intra-tubular cells and from failure of the Serto!i cells to phagocyte 
the debris [36-38]. The occurrence ofTM in patients who are at risk for developing testicular 
cancer stresses both the importance of the Sertoli eel! function for correct development of 
the testis, and the role of the Sertoli cell malfunction in TDS. Future research should focus on 
potential disrupters of Sertoli-cell development and function during the neonatal period. 
Althogh the role of Anti-Mullerian Hormone (AMH) levels during postnatal gonadal matu-
ration and after puberty remains vague, it was recently suggested that they are involved in 
germ-cell development, and also that they affect the differentiation and function of Leydig cells 
[237, 238]. Their role of AMH as a potential marker for testicular dysgenesis should therefore 
be further investigated. 
As stated in this thesis, we recommend an active approach should be taken in men with TM 
and additional risk factors forTGCT. This approach should include testicular biopsies. The physi-
cal and social impacts of such an active approach should be explored in a prospective study. To 
evaluate the testis, regular ultrasonography is advised in most of the follow-up protocols ofTM. 
Indicators for TDS and CIS of the testis are gonadal dysfunction and ultrasonic features as TM, 
an in homogenous parenchyma of the testis and testicular atrophy [47]. 
In the United States the economic burden of evaluating and following men with TM when 
they are at risk for testicular cancer was estimated by Peterson et al. to be greater than $18 
billion and therefore not cost-effective [35].!t might therefore be better to perform highly 
accurate testkular biopsies in men with TM and associated risk factors for TGCT. Stoehr et al. 
showed recently that the only benefit of scrotal ultrasonography lies in the detection of asyn-
chronous tumors, not of ClS[239]. The use of other imaging methods such as CT-scanning or 
MRI to evaluate the testicular parenchyma is also not likely to help the detection of CIS, which 
these imaging techniques cannot detect. 
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If CIS is detected before it progresses to an invasive tumour stage and subsequentely treated 
this may result in a significant reduction ofTGCT and the consequences of its treayment [5). It 
is therefore important to identify high risk-groups forTGCT in whom diagnostic testicular biop-
sies can be performed, as this invasive procedure is unsuitable for large population screening 
programs. This will probably include men with cryptorchidism, gonadal dysfunction (impaired 
fertility and hypogonadism) and ultrasonographic features such as TM. A prospective case find-
ing study should be performed to evaluate this early detection program of CIS. 
We have shown that the detection of CIS in testicular biopsies is hampered by various factors 
which can be partially overcome if immunohistochemistry is performed on all testicular biop-
sies. As shown in chapter 5, few CIS cells can be present within the biopsy specimen. Recently, 
OCT3/4, a reliable new diagnostic marker has been added to the palette of markers. Although 
it has proven to be highly specific and sensitive, it is not yet used widely. In a specific highly 
selected population, we demonstrated that immunohistochemistry can produce an additional 
diagnostic yield of 20 percent in detecting malignant disease. While the additional value of 
performing immunohistochemistry in a non-selected population has yet to be examined, its 
advantages ·In detecting CIS orTGCTs are unlikely to differ. 
Schulze et al. performed histological analyses on Testicular Sperm Extraction (TESE) material 
and found CIS in 0.7% of the biopsies [240]. As the testicular biopsies were not stained with 
specific CIS orTGCT markers, the actual prevalence of CIS in the above mentioned study might 
even be higher. We therefore stress that in all testicular biopsies for TESE and for assessing 
spermatogenic status should use immunohistochemistry should be used specifically to test for 
the presence of CIS. Also, two-sited biopsy has already been shown to produce an additional 
diagnostic yield of 18% [13]. If CIS is highly suspected, a two-sited biopsy should therefore be 
performed in all testicular biopsies in addition to immunohistochemistry. 
We demonstrated that even without immunohistochemistry, an experienced pathologist is 
able to find more cancer in testicular biopsies. This means that testicular biopsies should ideally 
be evaluated in a referral centre by an experienced pathologist. This will reduce the number of 
false-negative diagnoses and improve diagnostic outcome. As this thesis has already pointed 
out, there are obviously many advantages to detecting CIS before it has advanced to an inva-
sive cancer. Although many advantages detecting CIS does not eliminate the need to perform 
an orchidectomy or to irradiate both the testis in men diagnosed with CIS. This will result in 
sterility and hypogonadism. 
It is becoming increasingly clear that CIS originates from primordial germ cells/gonocytes. 
Gene-mapping studies of CIS cells showed that CIS is not a malignant cell in a classic sense, but 
is an arrested polyploid gonocyte: oncogenes are not overrepresented, while tumor suppressor 
genes are not underrepresented [238]. However, it is still uncertain what triggers the CIS cell 
to evolve into an intratubular seminoma or embryonal carcinoma, and, as often occurs after 
puberty, eventually into an invasive cancer. If this transition is understood, it might be possible 
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to develop treatment options that can prevent CIS from developing and progressing to an 
invasive cancer. 
In this thesis we have shown that CIS can also be detected in testicular biopsies, but another 
opportunity for detecting it is presented by new non-invasive techniques that use exfoliated 
CIS cells in semen. Potentially, this non-invasive detection method may provide an extra diag-
nostic tool for detecting CIS in patients at risk, or even for the male population as a whole in a 
screening-based setting. While many methods of detecting exfoliated CIS cells have been tried 
with discouraging results [1 07, 110, 113, 239], Hoei-Hansen and coworkers were recently the 
first to diagnose CIS in an infertile patient by detecting exfoliated CIS cells [1 08]. We confirmed 
the strength of the method using a novel method, which detects CIS before the patient pres-
ents with symptoms. 
Unlike many other diseases, such as bladder carcinoma or prostate cancer, screening forTGCT 
is based on the detection of the pre-invasive stage, and thus on preventing the development 
of malignancy. In 2006,605 young males in the Netherlands were diagnosed with a TGCT, most 
of them of a reproductive age. The incidence ofTGCT in males aged 15-34 was 12 per 100,000 
(Dutch Cancer Society/Koningin Wilhelmina Fonds KWF data). Due to an annual increase in 
TGCT of approximately 5%, it has been calculated that 728 young males in the Netherlands will 
be diagnosed with a TGCT in 2010. Because the overall 5-year survival is approximately 95%, 
most men wil! survive [87]. This also means that they will live with the consequences of the 
treatment ofTGCT for a substantial part of their lives [240]. 
The detection and treatment of CIS would prevent many of the sequelae seen when a 
patient is treated for TGCT. Potentially, this new non-invasive method may provide clinicians 
with an extra diagnostic tool. Although it should still be tested in larger populations, the idea of 
exfoliating CIS cells offers new diagnostic opportunities. We acknowledge that a screening pro-
gramme with the current non-invasive test is not yet ap!icable in general practise. The current 
test should first be validated in a large multi-centre study, and the method of detecting CIS cells 
in semen must be optimised before it can be used on a large scale. Such studies should also 
show whether all young men should be screened, or that screening should be performed only 
in high-risk populations. HoweverTGCT proves to be a disease which is an seriuos candidate for 
developing a screening strategy. 
FERTILITY AND GONADAL FUNCTION BEFORE AND AFTER CYTOTOXIC 
TREATMENT. 
Male spermatogenesis is a complicated process that starts with the division of stem cells and 
ends with the formation of mature spermatozoa. Many factors can influence male fertility, 
including the presence of malignant disease [241]. In 2005, 40,684 males in the Netherlands 
were diagnosed with cancer, 869 of whom were in the 15-34 age group (Dutch Cancer Society 
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data). The impact of being diagnosed with cancer in this specific age group, when most men 
are in their reproductive period, is very high. While most of them are concerned about their 
fertinty after treatment, they are not aware of the possibility of impaired fertility before cancer 
treatment has started. We showed that fertility was reduced in two-thirds of the male cancer 
patients at diagnosis, which is far more than in a general population. 
The etiology of diminished spermatogenesis before treatment is probably multifacto-
rial. Disease-related factors may be involved, such as endocrine disturbances, stress and an 
increased catabolic state that can accompany cancer, especially in an advanced stage [12 1, 145, 
162]. These factors are difficult to overcome in order to optimize pre~treatment semen quality. 
In a study of young cancer patients, we showed that men with TGCT have a lower semen 
quality and lower lnhibin B levels compared to patients diagnosed with other malignancies. In 
contrast to men with testicular dysgenesis syndrome, patients first diagnosed with germ-cell 
tumors often showed to have normal FSH levels. This may be explained by the negative effect 
on FSH secretion of beta-HCG, which is produced by some testicular tumors. 
On the basis of the 20-year prevalence period, the number of cancer survivors in the Neth-
erlands is expected to increase from 366,000 in 2000 to 692,000 to 2015 (Dutch Cancer Society 
data). This means that the number of cancer survivors will almost have doubled over a 15-year 
period, producing an annual increase in prevalence of almost 6% (Dutch Cancer Society data). 
Although, due to the use of new treatment protocols, children diagnosed with cancer nowedays 
have a very good chance of surviving their disease, most treatment protocols unfortunately 
have long-term sequalae. Approximately two-third of all childhood cancer survivors will suffer 
from adverse treatment-induced side effects, one-third of which will are severe, and sometimes 
even life threatening [242]. Because childhood cancer therapy continues to be refined, the 
study of late effects is also an ongoing process. 
In this thesis, we have focused on fertility and endocrine disturbances caused by treatment-
induced toxicity. One of the most commonly used alkylating agents in paediatric cancer treat-
ment is cyclophosphamide, which has a dose-dependent effect of induced infertility. Patients 
receiving a total cumulative dose of more than 10 grams/m2 are at risk of severe gonadal 
damage. We found no similar dose-dependent effect in patients treated with procarbazine. 
However, all these patients had very low lnhibin B levels, suggesting severe gonadal dysfunc-
tion independent of the total cumulative dose of the drug. We conclude that, procarbazine is 
extremely mutagenic to germ cells, and causes irreversible damage [243]. 
Although the total study group consists of 261 survivors, we acknowledge that our results 
may have been influenced by the wide diversity of different cancers and treatment protocols. 
Even so, this is the largest single-centre long-term follow-up study to date. Ideally, future stud~ 
ies may come to more definitive conclusions, although, treatment protocols are constantly 
changing, making it difficult to obtain large patient populations with comparable treatment 
protocols. This problem could partially be overcome by the introduction of a nation-wide 
database, which has already been initiated by the Dutch Childhood Cancer Workgroup. 
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In our study, the age at time of treatment did not correlate with post-treatment gonadal 
function. Previous studies claimed that, due to the lack of activity, pre-pubertal testes have a 
lower risk of gonadal damage due to cancer treatment [212]. The pre-pubertal period, however, 
is not a quiescent time for the testis[188], and it seems that chemotherapy before puberty 
also can impair gonadal function. Besides its harmful effect on the spermatogonial stem cells, 
chemotherapy in childhood can also damage Sertoli cells and Leydig cells, which proliferate in 
this period [244]. A decline in Sertoli cell numbers affects spermatogenesis later in life. Because 
pre-pubertal boys are also at risk for impaired fertility later in life, options to preserve fertility in 
these boys should be developed. 
There are different methods of measuring the detrimental effect of cancer treatment proto-
cols on gonadal function: by evaluating the total number of live births after cancer treatment, 
and by measuring reproductive hormones and semen quality, which reflect gonadal function. 
In our opinion, live births rates are not a good marker of gonadal damage after gonadotoxic 
treatment.This also depends on the fecundity of the partner. Even, if the patient is diagnosed 
with a reduced sperm quality, he may still be able to induce pregnancy in a fertile partner. 
We found that most cancer survivors were reluctant to provide a semen sample for analy-
sis and used serum lnhibin B as an alternative method of determing gonadal damage after 
gonadotoxic treatment [124]. However, while low lnhibin B indicates that spermatogenesis is 
impaired, it does not indicate the extent of impairment. A clear cut-off value for the presence of 
spermatozoa is not found. Fertility markers are not a good substitute for semen analyses in the 
assessment of future treatment options for ART. 
The direct gonadotoxic effect of radiation and chemotherapy treatment can also influence 
gonadal function by disrupting the hypothalamic-pituitary-gonadal axis. We investigated the 
specific effect on gonadal function of cranial radiotherapy in children with Acute Lympho-
blastic Leukaemia (ALL). It has been reported that a radiation dose of> 18 Gy can disrupt the 
hypothalamic-pituitary-gonadal axis, potentially resulting in impaired endocrine function and 
growth disturbances[21 0, 211]. 
It has been suggested that the future fertility of these children may be impaired, and that 
low age at time of treatment (<1 0 years) is a risk factor for post-treatment gonadal dysfunction 
[212-215]. However, in a cohort of 89 male childhood ALL survivors with a very long follow-
up, we found no deleterious effect of cranial irradiation additional to the gonadotoxic effect 
of chemotherapy on pituitary-gonadal function. Although the treatment protocols differed 
slightly, these findings are reassuring with regard to the fertility of men who have received 
cranial irradiation for ALL. Although it was not the primary objective, our study demonstrated 
an impact of cranial rad·1otherapy on the growth hormone and thyroid axis. This emphasizes the 
need for long-term follow-up in these patients. To ensure timely diagnosis and early hormone 
replacement therapy, regular testing is recommended. 
The risk of infertility after treatment is a major concern for cancer survivors (245, 246]. The 
only established method for preserving fertility is semen cryopreservation (SCP). Surprisingly, 
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desp"ite the fact that that it is a simple procedure, Schover et al. demonstrated that only 27% of 
men in a cohort in the United States diagnosed with cancer was referred for semen cryopreser-
vation [245]. Lack of information was usually the reason that sperm banking in these patients 
was not performed. 
For the various reasons described in this thesis , not many young boys with cancer are 
referred for sperm banking, despite the fact, as we have demonstrated, that it is successful in 
the majority of pubertal boys. Although it may be a difficult subject to discuss, young boys in 
whom spermatogenesis may have started should be informed about the possibility of cryopre-
serving their sperm. Edge eta!. investigated the level of understanding the need for banking 
sperm in young boys and found it to be high, with an average score of 7.2 out of 10 [149]. 
Unlike our study, they also found a significant difference in successful sperm banking between 
younger and older patients. 
Edge et al. also clearly demonstrated that male patients who had less understanding of 
sperm bankmg and who had more difficulty discussing sperm banking were at risk for unsuc~ 
cessful sperm banking. Similarly, Schover et al. demonstrated that men who chose to bank 
sperm scored significantly higher on knowledge tests concerning cancer-related infertility than 
those who did not bank semen [245]. These findings suggest that discussing sperm banking is 
of utmost importance, and should be performed by an experienced physician or nurse practi-
tioner. 
Semen analysis showed that 14 pubertal patients from our cohort of 80 adolescents had no 
motile spermatozoa and the samples in question were not cryopreserved, as our clinic performs 
in-vitro fertilization only with motile spermatozoa. Perhaps non-motile spermatozoa should be 
frozen, as they might be used for future assisted-reproduction techniques. Although immature 
spermatids and secondary spermatocytes are currently used for Intracytoplasmic Sperm Injec-
tion (ICSI), success rates are still very low [247-249].1n TESE, non-motile testicular spermatozoa 
are sometimes used, which sometimes results in fertilization. However, the fertilization rate is 
lower than compared to the rate when motHe testicular spermatozoa are injected [250]. Suc-
cessful pregnancies have also occurred with the use ofiCSI in men with immotile cilia syndrome 
in whom only non-motile spermatozoa were present [251 ]. These data suggest that we should 
consider altering our pre-freeze requirements. If non-motile spermatozoa are cryopreserved, 
patients should be properly informed of the limited results that have been achieved with 
them. It should also be noted that these cells are currently not used for assisted reproduction 
techniques in the Netherlands and that techniques using fresh non-motile spermatozoa are 
associated with a very low chance of pregnancy. 
Due to the absence of spermatozoa or of motile spermatozoa, semen cryopreservation was 
not feasible in 14 patients in our cohort of 80 pubertal boys~ a specific but diverse group in 
whom pre-treatment endocrinological evaluation does not predict sperm yield. This makes it 
difficult to identify patients who might benefit from semen cryopreservation. We nonetheless 
advocate that all boys with cancer who have reached Tanner stage G2 should be referred for SCP. 
General Discussion 1115 
In boys who are unable to produce a semen sample, the use of electro-ejaculation techniques 
should also be considered. This minimally invasive procedure can be performed in combination 
with other procedures for which general anaesthesia is required, such as bone-marrow biopsies 
or port-a-cath placements. Electro-ejaculation in children is still not widely used. Hovay et al. 
published results on its successful use in a group of six adolescents aged 18 +/- 3 [153]. Large 
studies of the use and success rates of electro-ejaculation in pubertal boys with cancer are not yet 
available. Since attempts to produce semen may cause anxiety, distress and failure to produce 
sperm, there may be good arguments for making electro-ejaculation the standard procedure for 
all young boys referred for SCP. These topics should be evaluated in a prospective study. 
In boys in whom spermarche has not yet started, there are no good options for securing 
future fertility. As the inability to become a father in the future can have a high impact on 
a patient's psychological wellbeing in later adulthood, further research should focus on 
alternative methods for preserving fertility in prepubertal children [155]. Fertility-preservation 
techniques might focus on culturing and transplanting spermatogonial stem cells, which can 
be harvested from testicular biopsies. Spermatogonial Stem Cell Transplantation (SSCT) was 
first introduced in a rodent model by Brinster and Avarbock [252], when insertion of a germ-cell 
suspension into an infertile rodent resulted in the restoration of the spermatogenic process. 
The use of testicular allografting has also been investigated. Mice-donor testicular tissue 
was retrieved from cloned mice and transplanted into the testes of recipient nude mice. After 
three months, the donor testicular tissue had grown into the host testicle and colonized the 
seminferous tubules, in some cases inducing spermatogenesis [253]. As testicular tissue should 
be harvested for these techniques, a surgical procedure is needed in young cancer patients. 
Although this is an invasive procedure, Van den Berg et al. demonstrated that the majority of 
parents accept the use of biopsy to collect spermatogonial stem cells [155]. 
Van den Berget a!. also reported that hemicastration was accepted by as many as one-third 
of the parents of childhood-cancer patients. Although the idea is promising, this technique has 
some major drawbacks. The major limitation of autologous reimplantation is the re-introduction 
of the malignant disease [254], especially in haematological cancers. Most cancers in childhood 
are capable of penetrating the testicular tissue, increasing the risk of reintroduction [255]. This 
might be overcome by selecting the germ cells by fluorescence-activated cell-sorting. While 
Fujita et al. had promising results in transplanting testicular tissue from leukemic mice to 
recipient mice without inducing leukemia [256], it should be mentioned that recurrence can be 
caused by as few as five reintroduced leukemia cells [257]. The sorting method should therefore 
be 1 OOo/o secure. Other options such as in-vitro maturation of spermatogonia or xenografting 
should also be investigated. 
Although cryopreservation causes sperm quality to decline by approximately 50%, the 
introduction over recent decades of sophisticated new assisted-reproduction techniques such 
as in-vitro fertilization (!VF) and intra cytopalsmatic sperm injection (lCS!) have given men a fair 
chance of future paternity [156, 161 ]. Currently, the success rates of IVF and ICSI treatments 
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using cryopreserved semen are almost as high as those using fresh semen [1 67, 258]. We dem-
onstrated that approximately 7.5% of all referred men and approximately 1 0% of survivors, all 
of whom had been rendered infertile by treatment, used their cryopreserved semen. Using 
this semen, 49% of couples achieved a pregnancy and life birth. 
Our data also illustrates the relatively low success rate of Intra Uterine Insemination (lUI) 
using cryopreserved semen over IVF. The use of cryopreserved semen for lUI should thus be 
discouraged in certain cases, especially those in which few straws of semen can be stored. With 
the new ICSI technique, thawing one straw of banked sperm is often sufficient for IVF treatment. 
This allows the couple to undergo several treatments if necessary. Although lVF treatment is 
more invasive than lUI, the higher success rate and the lower quantity of motile sperm required 
favour the use of cryopreserved semen for IVF. Physicians treating male cancer patients should 
thus be encouraged to discuss the topic of semen cryopreservation with all of these patients. 

118 
CONCLUSIONS 
This thesis clearly demonstrates that the infertile patient is at risk for developing testicular 
cancer especially if he is diagnosed with TM. As illustrated in this thesis we advocate an active 
approach in men with TM and risk factors forTGCT, which includes performing testicular biop-
sies. The health- and social impact of such an active approach should be further investigated. 
Future research should also focus on the aetiology behind these microliths: the role of the 
Sertoli cell and potential disrupters of gonadal development in the origin of TM should be 
examined. Also efforts should be made to evaluate to which hormonal disrupters pregnant 
women are exposed to during early pregnancy. In this stage, male gonadal development is at 
increased risk. 
CIS is sometimes difficult to diagnose in testicular biopsies. Efforts have been made to 
decrease the number of false negative results for CIS. This thesis demonstrates a reliable 
method to evaluate testicular biopsies. On all testicular biopsies immunohistochemistry using 
specific markers, such as OCT3/4, should be performed. This will increase the diagnostic yield 
of testicular biopsies and decreases the number offalse negative results. 
We demonstrate that CIS cells are exfoliated in semen which can de visualized using OCT3/4. 
These findings give new insights for a screening programme for men at risk for testicular cancer 
which might result in higher cure rates and less treatment related sequelae. Further research 
should focus on examining novel non-invasive diagnostic methods. Potential diagnostic mark-
ers could possibly be found in the semen of TGCT patients. If these diagnostic markers are 
reliable a screening programme for testicular cancer is possible and should be investigated in 
a prospective multicenter study. 
Adult male cancer patients are often referred for semen cryopreservation before gonadotoxic 
treatment to secure their future fertility potential. Unfortunately pre-treatment sperm quality 
can already be impaired before cancer treatment has started. We demonstrate that only 7.5% 
will use their cryopreserved semen which is successful in 50% of the cases. This thesis presents 
pre-treatment sperm quality in male cancer patients and illustrates that especially patients with 
TGCTs and extra-gonadal GCTs are at increased risk for diminished pre-treatment fertility. 
We demonstrate that treatment protocols for childhood cancer which contains procarbazine, 
high doses of cyclophosphamide, testicular and total body irradiation can cause severe post 
treatment gonadal damage independent on the age at which this treatment is given. Patients 
treated with cranial irradiation did not have pituitary-gonadal-axis dysfunction, which offers 
some hope regarding fertility for childhood ALL survivors. This thesis also clearly illustrates 
that semen cryopreservation is feasible in pubertal boys with cancer and should therefore be 
discussed with the patient and his parents. Nor age at time of diagnosis or fertility markers can 
predict successful semen cryopreservation in this specific group of patients. 
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SUMMARY 
Approximately 15% of all couples are affected by subfertility defined as the inability to con-
ceive after one year of unprotected intercourse. In approximately 20 percent of the couples 
with fertility problems, a disturbance in male reproductive capacity is the sole cause. In the 
introduction, an update is given on the interaction between testicular development, infertility 
and testicular cancer. 
Testicular development is an early embryonic process and disturbances, either through 
internal or external factors, may have major consequences resulting in the so-called testicular 
dysgenesis syndrome. This syndrome has a variety of clinical symptoms ranging from minor 
spermatogenic disturbances, cryptorchidism, hypospadia, infertility and even testicular 
cancer. It is shown by several large studies that patients who have an impaired fertility are at 
increased risk for the development of a testicular germ cell tumour (TGCT}. Testicular cancer 
is the most common cancer of young men in their 20s and 30s and the incidence of testicular 
cancer is growing. Carcinoma In Situ (CIS} is currently accepted as the precursor of all TGCTs of 
adolescents and young adults (TGCTs), i.e., the seminomas and nonseminomas. CIS develops 
in the testis after birth and will progress to cancer after puberty. This offers an opportunity for 
screening as outlined in the introduction. The second part in the introduction elaborates on the 
detrimental effects of cancer and its treatment on gonadal function. 
In Chapter 4 we discuss the relevance of Testicular microlithiasis (TM). TM has been associ-
ated with testicular germ cell tumors in adolescents and adults (TGCTs} and with its precursor 
carcinoma in situ (CIS). A clear definition and a consensus concerning the malignant potential 
ofTM and the need for further diagnostics and follow-up are lacking. We reviewed the literature 
ofTM and its association with TGCT/C!S and current follow-up advises. A wide variety in preva-
lence of TM is described in different populations due to different sample size, composition, 
ultrasound and screening criteria. TM consists of a large heterogeneous group and must be 
considered in essence a benign condition. Stilt its association with TGCT is remarkable, and 
may be very useful when screening for TGCTs, especially in its pre-invasive stage, in specific 
risk groups. In view of its association with cancer, we propose to perform testicular biopsies 
in selected high-risk groups consisting of those males with additional risk factors for TGCT 
development. 
In Chapter 5 and 6 we describe the importance of proper evaluation of testicular biopsies. 
As mentioned CIS can be found in the testis before a testicular tumour has developed. The 
gold-standard for detecting CIS is to perform a random surgical biopsy as CIS is often spread 
throughout the testis. However false-negative biopsy results do occur as shown in Chapter 
5. We show that there are multiple causes for false-negative biopsy results including non-
heterogeneous distribution and the presence of only few malignant cells in the complete 
biopsy. We demonstrated that in a selected patient population of men whom were diagnosed 
with an invasive TGCT, while a matched previously obtained testicular biopsy was diagnosed 
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as non-malignant, immunohistochemistry was able to prevent 20% false negative diagnosis. 
Furthermore, we performed a simplified calculation to calculate the cost-effect'1veness of 
performing immunohistochemistry on a!! testicular biopsies. In these two chapters evidence is 
provided that the implementation of immunohistochemistry is most-likely cost effective, and 
improves quality of patient care, and should therefore be used as standard diagnostic practice. 
Two of the major characteristics of CIS including the presence of CIS before tumor develop-
ment and secondly the low number of false negative biopsy results make CIS a target for early 
detection and treatment. However, a testicular biopsy is an invasive procedure not suitable for 
large scale screening. In chapter 7 we elaborate on an alternative method to detect CIS. CIS 
cells lie in the semiferous tubules and are exfoliated with the spermatozoa. We performed a 
pilot study in which we were able to detect these exfoliated cells in patients with CIS and TGCTS 
using immunohistochemical markers. These findings advocate a large multicenter research 
to evaluate the specificity and sensitivity of this test and should evaluate the potential for a 
screening program forTGCTs. This potential screening program could than be used in selected 
high risk populations such as infertile men or men with undescended testes. 
In chapter 8 we analyzed semen and endocrinological hormone profiles of a large cohort of 
male cancer patients presenting for semen cryopreservation. Male cancer patients are referred 
for semen cryopreservation as the upcoming treatment is often gonadotoxic. We show an 
increase in referral and demonstrate that approximately 90% of a!! men are able to secure their 
fertility potential by freezing motile spermatozoa. Furthermore, we demonstrate that patients 
diagnosed with TGCTs or extragonadal germ cell tumors have a more impaired gonadal 
function than those diagnosed with other forms of cancer. This is in line with the testicular 
dysgenesis syndrome in which an impairment of testicular development leads to a variety of 
problems as described above. 
In chapter 9 we describe the success rate of semen cryopreservation in young pubertal boys. 
During the last decades, mainly as a consequence of improved treatment efficacy, the overall 
number of childhood cancer survivors has increased substantially. As a result the number of 
young boys referred is also steadily increasing. Semen cryopreservaf1on in this specific sub-
group is a stressful procedure. We analyzed if hormone profile could predict sperm quality in this 
diverse group. Unfortunately no predictors were found which could indicate successful sperm 
yield. However, we advocate that young boys diagnosed with cancer should be referred to a 
sperm banking clinic to assess if semen cryopreservation is possible. If the patient is unable or 
unwilling to masturbate electro-ejaculation could be an option to obtain motile spermatozoa. 
These spermatozoa can than be preserved until the patient has reached adulthood and wants 
to use his semen to conceive. To determine the usefulness of semen cryorpreservation we 
have evaluated the total number of men who used their cryopreserved semen. Approximately 
1 Oo/o of the cancer survivors have claimed their semen for an assisted reproduction technique 
(ART). A total of 101 ART cycles were performed resulting in 251ife births. In fifty o/o of the men 
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who used their cryopreserved semen at least one ART resulted in a life birth. These numbers 
illustrate the importance of semen cryopreservation in male cancer patients. 
To assess which patient groups are at increased risk of gonadal damage after cancer treatment 
we analyzed long-term survivors of childhood cancer. In chapter 10 we determined pituitary 
and gonadal hormones including lnhibin B, which is a good marker to assess spermatogenesis, 
to assess their gonadal function. Specific risk groups were found including those receiving 
either procarbazine or high dosages of cyclophosphamide. Furthermore patients treated with 
total body irradiation were at increased risk for gonadal dysfunction. We demonstrated that 
young age at time of cryopreservation did not protect the gonads from the detrimental effects 
of chemotherapy. With this data we are able to inform young patients concerning their risk on 
gonadal dysfunction and might indicate which patients might benefit from more aggressive 
fertility preserving techniques. In chapter 11 we focus on patients treated for childhood Acute 
Lymfoblastic Leukaemia (ALL) to assess if cranial irradiation has an additional detrimental effect 
on fertility in ALL treatment regimens. Therefore we compared two cohorts of childhood ALL 
survivors of which one was treated with cranial irradiation. We demonstrated that cranial irradia-
tion (median 24 Gy) had an effect on pituitary function including the growth hormone axis but 
did not have an additional effect on gonadal function. 
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SAMENVATTING 
Verminderde vruchtbaarheid (subferti!iteit) wordt gedefinieerd als het uitblijven van een 
zwangerschap binnen 1 jaar bij onbeschermde geslachtsgemeenschap. Bij ongeveer 
15% van aile paren is er nog geen zwangerschap opgetreden na 1 jaar en zij worden 
beschouwd als subfertiel. In ongeveer 20 procent van deze paren is een stoornis van de 
mannelijke vruchtbaarheid de enige oorzaak. Een ontwikkelingsstoornis van de zaadbal~ 
len (testes) is een belangrijke oorzaak van mannelijk onvruchtbaarheid. In de inleiding 
van dit proefschrift wordt de relatie tussen een ontwikkelingsstoornis van de zaadbal-
len en mannelijke onvruchtbaarheid besproken, evenals de relatie met zaadbalkanker. 
De ontwikkeling van de testes is een vroeg embryonaal proces en verstoringen, hetzij via 
interne of externe factoren, kunnen grote gevolgen hebben die uiteindelijk kunnen leiden 
tot het zogenaamd "testicular dysgenesis" syndroom. Dit syndroom heeft meerdere klinische 
uitingen, varierend van een gestoorde spermaproductie, indalingstoornissen van de testes 
(cryptorchisme), afwijkende ontwikkeling van de plasbuis (hypospadie), onvruchtbaarheid en 
zelfs zaadbalkanker. In verschillende grote studies is aangetoond dat mannen met een ver-
minderde vruchtbaarheid een verhoogd risico hebben op de ontwikkeling van kiemceltumor 
van de zaadbal. Zaadbalkanker is de meest voorkomende kwaadaardige aandoening bij jonge 
mannen in hun 20e en 30e levensjaar. De incidentie van zaadbalkanker neemt jaarlijks toe, de 
oorzaak hiervan is nog onbekend. 
Carcinoma In Situ (CIS) is het voorloperstadium van zaadbalkanker. CIS kan ontstaan in dysge~ 
netische testes en is dan al aanwezig na de geboorte. Uiteindelijk zal CIS uitgroeien tot zaadbal~ 
kanker na de puberteit, als hormonen de groei van de zaadballen stimuleren. De aanwezigheid 
van CIS biedt een kans voor vroegdetectie van zaadbalkanker, zoals geschetst in de inleiding 
van dit proefschrift. 
Na de eerste 2 inleidende hoofdstukken beschrijft hoofdstuk 3 van dit proefschrift de 
relevantie van kleine verkalkingen in de zaadbal!en, de zogenaamde "Testicular Microlithiasis" 
(TM) voor de diagnostiek van zaadbalkanker. Uit diverse studies komt naar voren datTM geas~ 
socieerd is met CIS en kiemceltumoren van de testes (TGCTs). Een duidelijke definitie van TM 
ontbreekt nog in de literatuur. Ook bestaat er geen consensus over de relatie tussen kiemcel~ 
tumoren en TM en de noodzaak van verdere diagnostiek en follow~up. Een overzicht van de 
literatuur die de associatie tussen TM en TGCT /CIS onderzocht hebben wordt verricht. Vervol-
gens worden adviezen geformuleerd over de manier waarop mannen die gediagnosticeerd 
zijn met TM verder onderzocht en gecontroleerd moeten worden. Een grote verscheidenheid 
in de prevalentie van TM is beschreven wat mede te wijten is a an het bestaan van verschi!lende 
steekproefgrootte, gebruik van verschillende echografische apparatuur en selectiecriteria voor 
kandidaten in de verschillende studies. Onze condusie is datTM moet worden beschouwd als 
een in essentie goedaardige aandoening, maar dater een associatie is met zaadbalkanker, 
vooral bij mannen met risicofactoren op zaadbalkanker. TM zou een zeer nuttig hulpmiddel 
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kunnen zijn bij het vroegtijdig ontdekken van zaadbalkanker, in een fase dater nag geen 
sprake is van CIS. In verband met de verhoogde kans op zaadbalkanker bij mannen met TM 
, wordt voorgesteld om weefselbiopsien te nemen van beide testes in mannen met tevens 
een verhoogd risico op zaadbalkanker. Dit wordt in hoofdstuk 4 verder geillustreerd middels 
een case report waarin enkele valkuilen van het nemen en beoordelen van een testis biopsie 
besproken worden. Hoofdstuk 5 en 6 beschrijven het belang van een correcte evaluatie van 
testisbiopsien. Zoals vermeld kan CIS in de testis worden gevonden voordat een tumor zich 
heeft ontwikkeld. Voor het stellen van de diagnose CIS is het nemen van een chirurgisch weef-
selbiopsie van de testis nodig. Oeze biopsie kan op een relatief willekeurige plaats genomen 
worden omdat CIS meestal verspreid voorkomt in de aangedane testis. Echter fout-negatieve 
resultaten doen zich voor, zoals oak wordt aangegeven in hoofdstuk 4. Een niet heterogene 
verspreiding van CIS in de testis en de aanwezigheid van slechts enkele kwaadaardige cellen 
in het volledige biopsie weefsel zijn enkele van de in dit proefschrift aangetoonde oorzaken. 
lmmunohistochemie was, in een geselecteerde patientenpopulatie van mannen die werden 
gediagnosticeerd met een invasieve vorm van TGCT, in 20% van de gevallen in staat om 
fout-negatieve uitslagen te voorkomen. Dit terwijl een eerder verkregen testisbiopsie als niet-
kwaadaardig was afgegeven. Tevens werd een berekening verricht van de kosteneffectiviteit 
van de uitvoering van immunohistochemie op aile testis biopsien. In deze twee hoofdstuk-
ken wordt bewijs geleverd dat de uitvoering van immunohistochemie kosteneffectief is, de 
kwaliteit van de patientenzorg verbetert, en daarom altijd verricht zou moeten worden. 
Twee belangrijke kenmerken van CIS, zoals de aanwezigheid van CIS v66r de ontwikkeling van 
zaadbalkanker en het I age aantal fout-negatieve biopsien geeft de mogelijkheid voor vroegtij-
dige opsporing van zaadbalkanker. Het verkrijgen van testes weefsel voor onderzoek is echter 
een invasieve procedure en daarmee ongeschikt voor grootschalige screeningsdoeleinden. 
In hoofdstuk 7 wordt een alternatieve methode beschreven om CIS te detecteren. CIS cellen 
liggen in de zaadbuizen van de testis en worden uitgescheiden met het sperma tijdens een 
zaadlozing. In een studie werd door ons aangetoond dat deze cellen bij patienten met CIS en 
zaadbalkanker in het sperma met behulp van immunohistochemische markers opgespoord 
kan worden. Deze bevinding pleit voor een grater onderzoek om de specificiteit en sensitiviteit 
van deze diagnostische test te evalueren. Deze test zou mogelijk in de toekomst gebruikt 
kunnen worden om zaadbal- kanker vroegtijdig op te sporen in een geselecteerde groep man-
nen met een hoog risico, zoals onvruchtbare mannen of mannen met niet ingedaalde testes. 
Hoofdstuk 8 beschrijft een groat cohort van mannelijke patienten met verschi!lende vormen 
van kanker. Deze mannen werden, voorafgaand aan hun behande!ing, verwezen voor het 
invriezen van semen (cryopreservatie). Zij worden doorgaans verwezen omdat een behandel-
ing met chemotherapie of bestraling de functie van de testes kunnen verminderen. In deze 
studie blijkt dat bij ongeveer 90% van aile mannen het sperma van voldoende kwaliteit is om 
in te vriezen. Bovendien blijkt dat patienten met zaadbalkanker een verminderde testisfunctie 
hebben vergeleken met mannen die met andere vormen van kanker zijn gediagnosticeerd. 
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Dit ondersteunt de "testiculaire dysgenesie" hypothese waarbij een stoornis van testiculaire 
ontwikkeling leidt tot diverse problemen, waaronder onvruchtbaarheid en zaadbalkanker. 
Hoofdstuk 9 beschrijft het nut van cryopreservatie van sperma bij jongens vanaf de 
puberteit, die gediagnosticeerd worden met een kwaadaardige ziekte. Gedurende de laatste 
decennia zijn de overlevingskansen voor deze jongens sterk toegenomen, vooral door een ver~ 
beterde werkzaamheid van de behandelingen. Hierdoor neemt het aantal jongens dat wordt 
verwezen voor cryopreservatie oak toe. Cryopreservatie kan om verschillende redenen voor 
deze jongens een stressvolle procedure zijn en het lukt niet altijd om sperma te produceren. 
In onze studie werden geen indicatoren gevonden die het succes van semen cryopreservatie 
kunnen voorspellen, zeals het stadium van de ontwikkeling van de geslachtsorganen of de hor-
moonspiegels. Dit betekend dat aile jonge jongens die gediagnosticeerd worden met kanker 
en waarvan aangenomen kan worden dat de spermaproductie begonnen is, verwezen moeten 
worden naar een semen bank om te beoordelen of cryopreservatie moge!ijk is. Als de patient 
niet in staat is te masturberen of hier bezwaar tegen heeft, zou elektro-ejaculatie een optie 
kunnen zijn om zaadcellen te verkrijgen: in narcose wordt dan een zaadlozingsreflex opgewekt 
door stimulatie van de betreffende zenuw. Deze zaadcellen moeten bewaard worden totdat 
de patient volwassen is en zijn semen wil gebruiken voor voortplanting. Om het nut van cryo-
preservatie van semen vast te stellen is het gebruik hiervan geevalueerd. Ongeveer 10% van 
de mannen die hun ziekte heeft overleeft maakt gebruik van het ingevroren semen voor een 
geassisteerde voortplantingstechniek. Een totaal van 101 cycli van geassisteerde voortplant-
ing werd uitgevoerd en dit resulteerde in 25 kinderen. Deze cijfers i!lustreren het belang voor 
mannen van het invriezen van sperma voorafgaande aan een vruchtbaarheids beperkende 
behandeling van kanker. 
In hoofdstuk 10 wordt getracht antwoord te geven op de vraag welke groepen patienten 
een verhoogd risico !open op schade aan de testes door een behandeling van kanker op 
kinderleeftijd. Hiervoor werden hypofysaire en gonadale hormonen bepaald, waaronder 
inhibine B wat een goede marker is voor de productie van zaadcellen. De kinderen die het 
chemotherapeuticum procarbazine of hoge doseringen cyclofosfamide hadden gekregen 
danwel behandeld waren met totale lichaamsbestraling hadden een hoog risico op ernst'1ge 
testes schade. Het krijgen van chemotherapie op jonge leeftijd leeftijd, waarin ogenschijnlijk 
de testes in een latente peri ode lijken te verkeren, beschermt niet tegen de schadelijke effecten 
van chemotherapie. Met deze gegevens kunnen de ouders van kinderen ge'informeerd worden 
over hun risico op testis schade als gevolg van de behandeling: deze is afhankelijk van het 
gebruikte geneesmiddel en de totale dosis die nodig is om het kind te genezen van kanker. 
Hiermee kunnen patienten geselecteerd worden die baat zouden kunnen hebben bij meer 
invasieve technieken voor het behoud van de vruchtbaarheid. 
In hoofdstuk 11 wordt een onderzoek verricht naar de geslachtshormonen van pati€nten die 
als kind behandeld werden voor Acute Lymfoblastische Leukemie (ALL). Hierin wordt onder-
zocht of een bestraling van de hersenen een extra negatief effect heeft op de vruchtbaarheid 
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bij de andere behandelingen voor ALL. Gekeken is naar een mogelijke verstoring van de 
hypofysefunctie. Daartoe werden de kinderen vergeleken die behandeld waren zonder of met 
hersenbestraling. Hieruit blijkt dat de bestrallng (medlaan 24 Gy) inderdaad een effect had op 
de hypofysefunctie, inclusief de groeihormoon-as, maar geen additloneel effect had op de 
functie van de testis. 
Oit proefschrift had als doe I de relatie tussen de ontwlkkeling van de testes, zaadbalkanker 
en verminderde vruchtbaarheid weer te geven. Hlervoor zijn diverse studies verricht waarin 
aangetoond werd dat het hebben van testiculaire microlithias, wat een teken is van een ontwik-
kelingsstoornis van de testis, een risico factor is voor het krijgen vaan zaadbal kanker. Tevens 
werd aangetoond dat de voorloper van zaadbalkanker op te sporen is via een niet invasieve 
methode wat wei Iicht in de toekomst de mogelijkheid geeft tot preventief onderzoek. Hierna 
werd toege!icht dat het opslaan van semen voorafgaand aan schadelijke chemotherapie 
belangrijk is bij zowel adolescenten als volwassen mannen. Oit omdat uit dit onderzoek bleek 
dat chemotherapie op kinderleeftijd zeer schadelijk kan zijn voorde nog ontwikkelende testes. 
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